17512723	CHEMICAL	GENE	T1	T7	True	0	What is [Drugprot] between @CHEMICALSrc$ androstanediol @/CHEMICALSrc$ and @GENETgt$ human RDH13 @/GENETgt$ ? [SEP] We show that murine Rdh12 and @GENETgt$ human RDH13 @/GENETgt$ do not reveal activity towards the checked steroids , but that human type 12 RDH reduces dihydrotestosterone to @CHEMICALSrc$ androstanediol @/CHEMICALSrc$ , and is thus also involved in steroid metabolism .	2 2 12 5 12 5 5|6|7 5|6|7 5|7 5|6|7 12 12 2 12 17 17 17 12 12 12 25 24 24 24 25 12 25 28 25 25 25 25 25 35 35 35 25 38 38 35 2	None-BC7
17512723	CHEMICAL	GENE	T1	T9	True	0	What is [Drugprot] between @CHEMICALSrc$ androstanediol @/CHEMICALSrc$ and @GENETgt$ human type 12 RDH @/GENETgt$ ? [SEP] We show that murine Rdh12 and human RDH13 do not reveal activity towards the checked steroids , but that @GENETgt$ human type 12 RDH @/GENETgt$ reduces dihydrotestosterone to @CHEMICALSrc$ androstanediol @/CHEMICALSrc$ , and is thus also involved in steroid metabolism .	2 2 11 5 11 5 8 5 11 11 2 11 16 16 16 11 11 11 25 25|19|20 25|19|20 25|19|20 25|19|20 25|20 25|19|20 11 25 28 25|23 25 25|23 25 25 35 35 35 25 38 38 35 2	PRODUCT-OF
17512723	CHEMICAL	GENE	T1	T6	True	0	What is [Drugprot] between @CHEMICALSrc$ androstanediol @/CHEMICALSrc$ and @GENETgt$ murine Rdh12 @/GENETgt$ ? [SEP] We show that @GENETgt$ murine Rdh12 @/GENETgt$ and human RDH13 do not reveal activity towards the checked steroids , but that human type 12 RDH reduces dihydrotestosterone to @CHEMICALSrc$ androstanediol @/CHEMICALSrc$ , and is thus also involved in steroid metabolism .	2 2 12 3|12|4 3|12|4 12|4 3|12|4 4 9 4 12 12 2 12 17 17 17 12 12 12 25 24 24 24 25 12 25 28 25 25 25 25 25 35 35 35 25 38 38 35 2	None-BC7
17512723	CHEMICAL	GENE	T2	T8	True	0	What is [Drugprot] between @CHEMICALSrc$ retinol @/CHEMICALSrc$ and @GENETgt$ RDHs @/GENETgt$ ? [SEP] Three @CHEMICALSrc$ retinol @/CHEMICALSrc$ dehydrogenases ( @GENETgt$ RDHs @/GENETgt$ ) were tested for steroid converting abilities : human and murine RDH 12 and human RDH13 .	4 1|4 4 1|4 10 6 4 4 4 6 10 10 14 14 14 10 10 19 16 16 10 19 19 23 19 10	None-BC7
17512723	CHEMICAL	GENE	T3	T12	True	0	What is [Drugprot] between @CHEMICALSrc$ retinol @/CHEMICALSrc$ and @GENETgt$ RDH12 @/GENETgt$ ? [SEP] @GENETgt$ RDH12 @/GENETgt$ , a @CHEMICALSrc$ retinol @/CHEMICALSrc$ dehydrogenase causing Leber 's congenital amaurosis , is also involved in steroid metabolism .	0|16 16 0|16 1 7 3|7 7 3|7 1 7 12 9 12 8 1 16 16 16 19 19 16 16	None-BC7
17512723	CHEMICAL	GENE	T2	T11	True	0	What is [Drugprot] between @CHEMICALSrc$ retinol @/CHEMICALSrc$ and @GENETgt$ human and murine RDH 12 @/GENETgt$ ? [SEP] Three @CHEMICALSrc$ retinol @/CHEMICALSrc$ dehydrogenases ( RDHs ) were tested for steroid converting abilities : @GENETgt$ human and murine RDH 12 @/GENETgt$ and human RDH13 .	4 1|4 4 1|4 9 6 4 6 9 9 13 13 13 9 9 9|13|15 9|13|15 9|13|15 9|13|15 9|13|15 9|15 9|13|15 15 23 15 9	None-BC7
17512723	CHEMICAL	GENE	T2	T4	True	0	What is [Drugprot] between @CHEMICALSrc$ retinol @/CHEMICALSrc$ and @GENETgt$ human RDH13 @/GENETgt$ ? [SEP] Three @CHEMICALSrc$ retinol @/CHEMICALSrc$ dehydrogenases ( RDHs ) were tested for steroid converting abilities : human and murine RDH 12 and @GENETgt$ human RDH13 @/GENETgt$ .	4 1|4 4 1|4 9 6 4 6 9 9 13 13 13 9 9 18 15 15 9 18 18 18|19|21 18|19|21 18|21 18|19|21 9	None-BC7
23557993	CHEMICAL	GENE	T5	T28	True	0	What is [Drugprot] between @CHEMICALSrc$ DPHD @/CHEMICALSrc$ and @GENETgt$ osteocalcin @/GENETgt$ ? [SEP] Subsequently , @CHEMICALSrc$ DPHD @/CHEMICALSrc$ accelerated production of bone structural genes , including COL1A1 and @GENETgt$ osteocalcin @/GENETgt$ comparably to 17β-estradiol .	5 5 2|5 5 2|5 5 5 10 10 10 6 10 13 10 13 13 13 13 19 19 5 5	INDIRECT-UPREGULATOR
23557993	CHEMICAL	GENE	T17	T31	True	0	What is [Drugprot] between @CHEMICALSrc$ DPHD @/CHEMICALSrc$ and @GENETgt$ MAP kinase @/GENETgt$ ? [SEP] The h-OB were 10 - 100 fold more sensitive to @CHEMICALSrc$ DPHD @/CHEMICALSrc$ than transformed osteoblasts : DPHD increased h-OB proliferation at 10nM and , at 100nM , activated @GENETgt$ MAP kinase @/GENETgt$ signaling within 30min .	2 9 9 6 6 7 8 9 9 11 9|10 9 9|10 15 15 9 9 18 9 20 18 22 18 18 18 26 18 26 32 32|27 32|27 32 32|27 18 34 32 9	None-BC7
23557993	CHEMICAL	GENE	T8	T29	True	0	What is [Drugprot] between @CHEMICALSrc$ 17β-estradiol @/CHEMICALSrc$ and @GENETgt$ osteoprotegerin @/GENETgt$ ? [SEP] In h-OB , DPHD increased the @GENETgt$ osteoprotegerin @/GENETgt$ to RANKL ratio and supported mineralization more efficiently than 10nM @CHEMICALSrc$ 17β-estradiol @/CHEMICALSrc$ .	2 5 5 5 5 7 5|6 5 5|6 11 11 5 5 5 13 16 13 19 19 17|13 13 17|13 5	None-BC7
23557993	CHEMICAL	GENE	T6	T28	True	0	What is [Drugprot] between @CHEMICALSrc$ 17β-estradiol @/CHEMICALSrc$ and @GENETgt$ osteocalcin @/GENETgt$ ? [SEP] Subsequently , DPHD accelerated production of bone structural genes , including COL1A1 and @GENETgt$ osteocalcin @/GENETgt$ comparably to @CHEMICALSrc$ 17β-estradiol @/CHEMICALSrc$ .	4 4 4 4 4 9 9 9 5 9 12 9 12 12|13 12 12|13 18 18 16|4 4 16|4 4	None-BC7
23557993	CHEMICAL	GENE	T7	T29	True	0	What is [Drugprot] between @CHEMICALSrc$ DPHD @/CHEMICALSrc$ and @GENETgt$ osteoprotegerin @/GENETgt$ ? [SEP] In h-OB , @CHEMICALSrc$ DPHD @/CHEMICALSrc$ increased the @GENETgt$ osteoprotegerin @/GENETgt$ to RANKL ratio and supported mineralization more efficiently than 10nM 17β-estradiol .	2 6 6 3|6 6 3|6 6 8 6 6 6 12 12 6 6 6 14 17 14 20 20 14 6	None-BC7
23557993	CHEMICAL	GENE	T8	T30	True	0	What is [Drugprot] between @CHEMICALSrc$ 17β-estradiol @/CHEMICALSrc$ and @GENETgt$ RANKL @/GENETgt$ ? [SEP] In h-OB , DPHD increased the osteoprotegerin to @GENETgt$ RANKL @/GENETgt$ ratio and supported mineralization more efficiently than 10nM @CHEMICALSrc$ 17β-estradiol @/CHEMICALSrc$ .	2 5 5 5 5 7 5 11 8|11 11 8|11 5 5 5 13 16 13 19 19 17|13 13 17|13 5	None-BC7
23557993	CHEMICAL	GENE	T1	T24	True	0	What is [Drugprot] between @CHEMICALSrc$ DPHD @/CHEMICALSrc$ and @GENETgt$ estrogen receptor @/GENETgt$ ? [SEP] Effects of @CHEMICALSrc$ DPHD @/CHEMICALSrc$ were eliminated by the @GENETgt$ estrogen receptor @/GENETgt$ antagonist ICI182780 .	6 3 1|2 1 1|2 6 6 13 13 13|7 13|7 13 13|7 13 6 6	ACTIVATOR
23557993	CHEMICAL	GENE	T18	T31	True	0	What is [Drugprot] between @CHEMICALSrc$ DPHD @/CHEMICALSrc$ and @GENETgt$ MAP kinase @/GENETgt$ ? [SEP] The h-OB were 10 - 100 fold more sensitive to DPHD than transformed osteoblasts : @CHEMICALSrc$ DPHD @/CHEMICALSrc$ increased h-OB proliferation at 10nM and , at 100nM , activated @GENETgt$ MAP kinase @/GENETgt$ signaling within 30min .	2 9 9 6 6 7 8 9 9 11 9 14 14 9 9 18|15 18 18|15 9 20 18 22 18 18 18 26 18 26 32 32|27 32|27 32 32|27 18 34 32 9	ACTIVATOR
23557993	CHEMICAL	GENE	T4	T25	True	0	What is [Drugprot] between @CHEMICALSrc$ DPHD @/CHEMICALSrc$ and @GENETgt$ RUNX2 @/GENETgt$ ? [SEP] During differentiation , @CHEMICALSrc$ DPHD @/CHEMICALSrc$ promoted early expression of osteoblast transcription factors , @GENETgt$ RUNX2 @/GENETgt$ and osterix .	2 6 6 3|6 6 3|6 6 8 6 12 12 12 8 12 12 12 12 14 14 6	INDIRECT-UPREGULATOR
23557993	CHEMICAL	GENE	T5	T27	True	0	What is [Drugprot] between @CHEMICALSrc$ DPHD @/CHEMICALSrc$ and @GENETgt$ COL1A1 @/GENETgt$ ? [SEP] Subsequently , @CHEMICALSrc$ DPHD @/CHEMICALSrc$ accelerated production of bone structural genes , including @GENETgt$ COL1A1 @/GENETgt$ and osteocalcin comparably to 17β-estradiol .	5 5 2|5 5 2|5 5 5 10 10 10 6 10 13 10|11 10 10|11 13 13 19 19 5 5	INDIRECT-UPREGULATOR
23557993	CHEMICAL	GENE	T3	T24	True	0	What is [Drugprot] between @CHEMICALSrc$ ICI182780 @/CHEMICALSrc$ and @GENETgt$ estrogen receptor @/GENETgt$ ? [SEP] Effects of DPHD were eliminated by the @GENETgt$ estrogen receptor @/GENETgt$ antagonist @CHEMICALSrc$ ICI182780 @/CHEMICALSrc$ .	5 3 1 5 5 12 12 12|7 12|7 12 12|7 12 9|5 5 9|5 5	ANTAGONIST
23557993	CHEMICAL	GENE	T6	T27	True	0	What is [Drugprot] between @CHEMICALSrc$ 17β-estradiol @/CHEMICALSrc$ and @GENETgt$ COL1A1 @/GENETgt$ ? [SEP] Subsequently , DPHD accelerated production of bone structural genes , including @GENETgt$ COL1A1 @/GENETgt$ and osteocalcin comparably to @CHEMICALSrc$ 17β-estradiol @/CHEMICALSrc$ .	4 4 4 4 4 9 9 9 5 9 12 9|11 9 9|11 12 12 18 18 16|4 4 16|4 4	None-BC7
23557993	CHEMICAL	GENE	T4	T26	True	0	What is [Drugprot] between @CHEMICALSrc$ DPHD @/CHEMICALSrc$ and @GENETgt$ osterix @/GENETgt$ ? [SEP] During differentiation , @CHEMICALSrc$ DPHD @/CHEMICALSrc$ promoted early expression of osteoblast transcription factors , RUNX2 and @GENETgt$ osterix @/GENETgt$ .	2 6 6 3|6 6 3|6 6 8 6 12 12 12 8 12 12 14 14 14 14 6	INDIRECT-UPREGULATOR
23557993	CHEMICAL	GENE	T20	T23	True	0	What is [Drugprot] between @CHEMICALSrc$ DPHD @/CHEMICALSrc$ and @GENETgt$ alkaline phosphatase @/GENETgt$ ? [SEP] In long-term differentiation assays , responses of h-OB to DPHD were significant at 10nM , and optimal response in most cases was at 100nM. At 7 - 21 days , @CHEMICALSrc$ DPHD @/CHEMICALSrc$ accelerated osteoblast differentiation , indicated by @GENETgt$ alkaline phosphatase @/GENETgt$ activity and osteoblast-specific mRNA production .	4 4 4 12 12 12 8 6 10 6 12 33 14 12 12 12 18 24 21 21 18 24 24 12 29 28 28 29 24 33 33|30 33 33|30 33 35 33 33 33 42 42|37 42|37 42 42|37 37 42 46 46 42 33	None-BC7
23557993	CHEMICAL	GENE	T7	T30	True	0	What is [Drugprot] between @CHEMICALSrc$ DPHD @/CHEMICALSrc$ and @GENETgt$ RANKL @/GENETgt$ ? [SEP] In h-OB , @CHEMICALSrc$ DPHD @/CHEMICALSrc$ increased the osteoprotegerin to @GENETgt$ RANKL @/GENETgt$ ratio and supported mineralization more efficiently than 10nM 17β-estradiol .	2 6 6 3|6 6 3|6 6 8 6 12 8|12 12 8|12 6 6 6 14 17 14 20 20 14 6	None-BC7
23557993	CHEMICAL	GENE	T19	T23	True	0	What is [Drugprot] between @CHEMICALSrc$ DPHD @/CHEMICALSrc$ and @GENETgt$ alkaline phosphatase @/GENETgt$ ? [SEP] In long-term differentiation assays , responses of h-OB to @CHEMICALSrc$ DPHD @/CHEMICALSrc$ were significant at 10nM , and optimal response in most cases was at 100nM. At 7 - 21 days , DPHD accelerated osteoblast differentiation , indicated by @GENETgt$ alkaline phosphatase @/GENETgt$ activity and osteoblast-specific mRNA production .	4 4 4 13 13 13 8 6 10 9|6 6 9|6 13 33 15 13 13 13 19 25 22 22 19 25 25 13 30 29 29 30 25 33 33 33 35 33 33 33 42 42|37 42|37 42 42|37 37 42 46 46 42 33	None-BC7
23161873	CHEMICAL	GENE	T15	T33	True	0	What is [Drugprot] between @CHEMICALSrc$ triglyceride @/CHEMICALSrc$ and @GENETgt$ ACC2 @/GENETgt$ ? [SEP] The reduction was more pronounced in the fructose-fed group and attributed to decreased hepatic expression of @GENETgt$ ACC2 @/GENETgt$ , FAS , SCD1 , and MTTP and a decrease in the rate of hepatic @CHEMICALSrc$ triglyceride @/CHEMICALSrc$ secretion .	2 5 5 5 5 9 9 9 5 5 5 15 15 15 11 17 16|15 15 16|15 17 17 17 17 17 17 17 15 28 15 31 31 28 36 36 32|36 36 32|36 31 5	None-BC7
23161873	CHEMICAL	GENE	T5	T21	True	0	What is [Drugprot] between @CHEMICALSrc$ aspartate @/CHEMICALSrc$ and @GENETgt$ ChREBP @/GENETgt$ ? [SEP] Interestingly , fructose-fed rats treated with @GENETgt$ ChREBP @/GENETgt$ ASO had increased plasma uric acid , alanine transaminase , and @CHEMICALSrc$ aspartate @/CHEMICALSrc$ aminotransferase concentrations .	11 11 4 11 4 9 9|6 9 9|6 5 11 14 14 14 14 14 17 14 14 14 18|23 23 18|23 23 14 14	None-BC7
23161873	CHEMICAL	GENE	T3	T22	True	0	What is [Drugprot] between @CHEMICALSrc$ uric acid @/CHEMICALSrc$ and @GENETgt$ alanine transaminase @/GENETgt$ ? [SEP] Interestingly , fructose-fed rats treated with ChREBP ASO had increased plasma @CHEMICALSrc$ uric acid @/CHEMICALSrc$ , @GENETgt$ alanine transaminase @/GENETgt$ , and aspartate aminotransferase concentrations .	10 10 4 10 4 8 8 5 10 12 12 11|12 11|12 12 11|12 12 16|12|13 16|12|13 16|12 16|12|13 12 12 23 23 12 12	None-BC7
23161873	CHEMICAL	GENE	T10	T28	True	0	What is [Drugprot] between @CHEMICALSrc$ monosaccharides @/CHEMICALSrc$ and @GENETgt$ carbohydrate response element-binding protein @/GENETgt$ ? [SEP] In addition to serving as substrates , @CHEMICALSrc$ monosaccharides @/CHEMICALSrc$ also increase the expression of key enzymes involved in de novo lipogenesis via the @GENETgt$ carbohydrate response element-binding protein @/GENETgt$ ( ChREBP ) .	2 11 4 2 6 4 11 11|7 11 11|7 11 11 13 11 16 16 13 16 21 21 19 17 24 24 24|17|22 24|17|22 24|17|22 24|17|22 24|17 24|17|22 30 24 30 11	None-BC7
23161873	CHEMICAL	GENE	T5	T22	True	0	What is [Drugprot] between @CHEMICALSrc$ aspartate @/CHEMICALSrc$ and @GENETgt$ alanine transaminase @/GENETgt$ ? [SEP] Interestingly , fructose-fed rats treated with ChREBP ASO had increased plasma uric acid , @GENETgt$ alanine transaminase @/GENETgt$ , and @CHEMICALSrc$ aspartate @/CHEMICALSrc$ aminotransferase concentrations .	10 10 4 10 4 8 8 5 10 13 13 13 13 13 13|14|15 13|14|15 13|15 13|14|15 13 13 17|23 23 17|23 23 13 13	None-BC7
23161873	CHEMICAL	GENE	T12	T30	True	0	What is [Drugprot] between @CHEMICALSrc$ fructose @/CHEMICALSrc$ and @GENETgt$ ChREBP @/GENETgt$ ? [SEP] To determine whether @GENETgt$ ChREBP @/GENETgt$ is a potential therapeutic target , we decreased hepatic expression of ChREBP with a specific antisense oligonucleotide ( ASO ) in male Sprague-Dawley rats fed either a @CHEMICALSrc$ high-fructose @/CHEMICALSrc$ or high-fat diet .	2 13 10 10|3 10 10|3 10 10 10 10 2 13 13 13 15 13 17 15 22 22 22 22 13 24 22 24 29 29 29 22 13 33 33 30|31 30 30|31 33 33 30 13	None-BC7
23161873	CHEMICAL	GENE	T3	T23	True	0	What is [Drugprot] between @CHEMICALSrc$ uric acid @/CHEMICALSrc$ and @GENETgt$ aspartate aminotransferase @/GENETgt$ ? [SEP] Interestingly , fructose-fed rats treated with ChREBP ASO had increased plasma @CHEMICALSrc$ uric acid @/CHEMICALSrc$ , alanine transaminase , and @GENETgt$ aspartate aminotransferase @/GENETgt$ concentrations .	10 10 4 10 4 8 8 5 10 12 12 11|12 11|12 12 11|12 12 17 12 12 12 17|23 17|23 23 17|23 12 12	None-BC7
23161873	CHEMICAL	GENE	T4	T23	True	0	What is [Drugprot] between @CHEMICALSrc$ alanine @/CHEMICALSrc$ and @GENETgt$ aspartate aminotransferase @/GENETgt$ ? [SEP] Interestingly , fructose-fed rats treated with ChREBP ASO had increased plasma uric acid , @CHEMICALSrc$ alanine @/CHEMICALSrc$ transaminase , and @GENETgt$ aspartate aminotransferase @/GENETgt$ concentrations .	10 10 4 10 4 8 8 5 10 13 13 13 13 13 17|14 17 17|14 13 13 13 18|23 18|23 23 18|23 13 13	None-BC7
23161873	CHEMICAL	GENE	T2	T22	True	0	What is [Drugprot] between @CHEMICALSrc$ fructose @/CHEMICALSrc$ and @GENETgt$ alanine transaminase @/GENETgt$ ? [SEP] Interestingly , @CHEMICALSrc$ fructose-fed @/CHEMICALSrc$ rats treated with ChREBP ASO had increased plasma uric acid , @GENETgt$ alanine transaminase @/GENETgt$ , and aspartate aminotransferase concentrations .	11 11 2|5 5 2|5 11 5 9 9 6 11 14 14 14 14 14 16|14 16|14 16|14 16|14 14 14 23 23 14 14	INDIRECT-UPREGULATOR
23161873	CHEMICAL	GENE	T1	T18	True	0	What is [Drugprot] between @CHEMICALSrc$ glucose @/CHEMICALSrc$ and @GENETgt$ insulin @/GENETgt$ ? [SEP] This was associated with an increase in @GENETgt$ insulin-stimulated @/GENETgt$ peripheral @CHEMICALSrc$ glucose @/CHEMICALSrc$ uptake , as assessed by the hyperinsulinemic-euglycemic clamp .	3 3 3 6 6 3 13 13|7 13 13|7 13 9|13 13 9|13 6 3 16 3 20 20 20 16 3	None-BC7
23161873	CHEMICAL	GENE	T14	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ fructose @/CHEMICALSrc$ and @GENETgt$ MTTP @/GENETgt$ ? [SEP] The reduction was more pronounced in the @CHEMICALSrc$ fructose-fed @/CHEMICALSrc$ group and attributed to decreased hepatic expression of ACC2 , FAS , SCD1 , and @GENETgt$ MTTP @/GENETgt$ and a decrease in the rate of hepatic triglyceride secretion .	2 5 5 5 5 10 10 10|7 10 10|7 5 5 5 16 16 16 12 18 16 18 18 18 18 18 18 18|23 18 18|23 16 29 16 32 32 29 36 36 36 32 5	INDIRECT-DOWNREGULATOR
23161873	CHEMICAL	GENE	T15	T35	True	0	What is [Drugprot] between @CHEMICALSrc$ triglyceride @/CHEMICALSrc$ and @GENETgt$ SCD1 @/GENETgt$ ? [SEP] The reduction was more pronounced in the fructose-fed group and attributed to decreased hepatic expression of ACC2 , FAS , @GENETgt$ SCD1 @/GENETgt$ , and MTTP and a decrease in the rate of hepatic @CHEMICALSrc$ triglyceride @/CHEMICALSrc$ secretion .	2 5 5 5 5 9 9 9 5 5 5 15 15 15 11 17 15 17 17 17 17|20 17 17|20 17 17 17 15 28 15 31 31 28 36 36 32|36 36 32|36 31 5	None-BC7
23161873	CHEMICAL	GENE	T11	T29	True	0	What is [Drugprot] between @CHEMICALSrc$ carbohydrate @/CHEMICALSrc$ and @GENETgt$ ChREBP @/GENETgt$ ? [SEP] In addition to serving as substrates , monosaccharides also increase the expression of key enzymes involved in de novo lipogenesis via the @CHEMICALSrc$ carbohydrate @/CHEMICALSrc$ response element-binding protein ( @GENETgt$ ChREBP @/GENETgt$ ) .	2 10 4 2 6 4 10 10 10 10 12 10 15 15 12 15 20 20 18 16 27 27 27|22 27 27|22 27 27 16 29 27 27 27 29 10	None-BC7
23161873	CHEMICAL	GENE	T13	T32	True	0	What is [Drugprot] between @CHEMICALSrc$ triglyceride @/CHEMICALSrc$ and @GENETgt$ ChREBP @/GENETgt$ ? [SEP] @GENETgt$ ChREBP @/GENETgt$ ASO treatment decreased plasma @CHEMICALSrc$ triglyceride @/CHEMICALSrc$ concentrations compared with control ASO treatment in both diet groups .	0|4 4 0|4 4 5 5 9 9|5 9 9|5 5 14 14 14 14 5 18 18 18 14 5	None-BC7
23161873	CHEMICAL	GENE	T14	T35	True	0	What is [Drugprot] between @CHEMICALSrc$ fructose @/CHEMICALSrc$ and @GENETgt$ SCD1 @/GENETgt$ ? [SEP] The reduction was more pronounced in the @CHEMICALSrc$ fructose-fed @/CHEMICALSrc$ group and attributed to decreased hepatic expression of ACC2 , FAS , @GENETgt$ SCD1 @/GENETgt$ , and MTTP and a decrease in the rate of hepatic triglyceride secretion .	2 5 5 5 5 10 10 10|7 10 10|7 5 5 5 16 16 16 12 18 16 18 18 18 18|20 18 18|20 18 18 18 16 29 16 32 32 29 36 36 36 32 5	INDIRECT-DOWNREGULATOR
23161873	CHEMICAL	GENE	T17	T37	True	0	What is [Drugprot] between @CHEMICALSrc$ fructose @/CHEMICALSrc$ and @GENETgt$ carbohydrate response element-binding protein @/GENETgt$ ? [SEP] The role of the @GENETgt$ carbohydrate response element-binding protein @/GENETgt$ in male @CHEMICALSrc$ fructose-fed @/CHEMICALSrc$ rats .	2 2 5 5 2|4|5 2|4|5 2|4|5 2|4|5 2|5 2|4|5 14 14 14|7 14 14|7 2 2	None-BC7
23161873	CHEMICAL	GENE	T6	T25	True	0	What is [Drugprot] between @CHEMICALSrc$ fructose @/CHEMICALSrc$ and @GENETgt$ fructokinase @/GENETgt$ ? [SEP] This was associated with decreased expression of @CHEMICALSrc$ fructose @/CHEMICALSrc$ aldolase and @GENETgt$ fructokinase @/GENETgt$ , reminiscent of inherited disorders of fructose metabolism .	3 3 3 6 6 3 10 10|7 10 10|7 6 10 10 10 10 3 3 18 18 15 21 21 18 3	None-BC7
23161873	CHEMICAL	GENE	T14	T33	True	0	What is [Drugprot] between @CHEMICALSrc$ fructose @/CHEMICALSrc$ and @GENETgt$ ACC2 @/GENETgt$ ? [SEP] The reduction was more pronounced in the @CHEMICALSrc$ fructose-fed @/CHEMICALSrc$ group and attributed to decreased hepatic expression of @GENETgt$ ACC2 @/GENETgt$ , FAS , SCD1 , and MTTP and a decrease in the rate of hepatic triglyceride secretion .	2 5 5 5 5 10 10 10|7 10 10|7 5 5 5 16 16 16 12 18 16 16 16 18 18 18 18 18 18 18 16 29 16 32 32 29 36 36 36 32 5	INDIRECT-DOWNREGULATOR
23161873	CHEMICAL	GENE	T14	T34	True	0	What is [Drugprot] between @CHEMICALSrc$ fructose @/CHEMICALSrc$ and @GENETgt$ FAS @/GENETgt$ ? [SEP] The reduction was more pronounced in the @CHEMICALSrc$ fructose-fed @/CHEMICALSrc$ group and attributed to decreased hepatic expression of ACC2 , @GENETgt$ FAS @/GENETgt$ , SCD1 , and MTTP and a decrease in the rate of hepatic triglyceride secretion .	2 5 5 5 5 10 10 10|7 10 10|7 5 5 5 16 16 16 12 18 16 18 18 18 18 18 18 18 18 18 16 29 16 32 32 29 36 36 36 32 5	INDIRECT-DOWNREGULATOR
23161873	CHEMICAL	GENE	T2	T23	True	0	What is [Drugprot] between @CHEMICALSrc$ fructose @/CHEMICALSrc$ and @GENETgt$ aspartate aminotransferase @/GENETgt$ ? [SEP] Interestingly , @CHEMICALSrc$ fructose-fed @/CHEMICALSrc$ rats treated with ChREBP ASO had increased plasma uric acid , alanine transaminase , and @GENETgt$ aspartate aminotransferase @/GENETgt$ concentrations .	11 11 2|5 5 2|5 11 5 9 9 6 11 14 14 14 14 14 17 14 14 14 18|23 18|23 23 18|23 14 14	INDIRECT-UPREGULATOR
23161873	CHEMICAL	GENE	T8	T26	True	0	What is [Drugprot] between @CHEMICALSrc$ fructose @/CHEMICALSrc$ and @GENETgt$ ChREBP @/GENETgt$ ? [SEP] In summary , these studies suggest that targeting @GENETgt$ ChREBP @/GENETgt$ may prevent @CHEMICALSrc$ fructose-induced @/CHEMICALSrc$ hypertriglyceridemia but without the improvements in hepatic steatosis and hepatic insulin responsiveness .	2 6 6 5 6 6 12 12 8 8 8 12 6 11|15 15 11|15 12 12 19 19 12 22 22 19 22 26 26 22 6	None-BC7
23161873	CHEMICAL	GENE	T2	T21	True	0	What is [Drugprot] between @CHEMICALSrc$ fructose @/CHEMICALSrc$ and @GENETgt$ ChREBP @/GENETgt$ ? [SEP] Interestingly , @CHEMICALSrc$ fructose-fed @/CHEMICALSrc$ rats treated with @GENETgt$ ChREBP @/GENETgt$ ASO had increased plasma uric acid , alanine transaminase , and aspartate aminotransferase concentrations .	12 12 2|5 5 2|5 12 5 10 10|6 10 10|6 6 12 15 15 15 15 15 18 15 15 15 23 23 15 15	None-BC7
23161873	CHEMICAL	GENE	T4	T21	True	0	What is [Drugprot] between @CHEMICALSrc$ alanine @/CHEMICALSrc$ and @GENETgt$ ChREBP @/GENETgt$ ? [SEP] Interestingly , fructose-fed rats treated with @GENETgt$ ChREBP @/GENETgt$ ASO had increased plasma uric acid , @CHEMICALSrc$ alanine @/CHEMICALSrc$ transaminase , and aspartate aminotransferase concentrations .	11 11 4 11 4 9 9|6 9 9|6 5 11 14 14 14 14 14 18|14 18 18|14 14 14 14 23 23 14 14	None-BC7
23161873	CHEMICAL	GENE	T3	T21	True	0	What is [Drugprot] between @CHEMICALSrc$ uric acid @/CHEMICALSrc$ and @GENETgt$ ChREBP @/GENETgt$ ? [SEP] Interestingly , fructose-fed rats treated with @GENETgt$ ChREBP @/GENETgt$ ASO had increased plasma @CHEMICALSrc$ uric acid @/CHEMICALSrc$ , alanine transaminase , and aspartate aminotransferase concentrations .	11 11 4 11 4 9 9|6 9 9|6 5 11 13 13 11|13 11|13 13 11|13 13 18 13 13 13 23 23 13 13	None-BC7
23161873	CHEMICAL	GENE	T8	T27	True	0	What is [Drugprot] between @CHEMICALSrc$ fructose @/CHEMICALSrc$ and @GENETgt$ insulin @/GENETgt$ ? [SEP] In summary , these studies suggest that targeting ChREBP may prevent @CHEMICALSrc$ fructose-induced @/CHEMICALSrc$ hypertriglyceridemia but without the improvements in hepatic steatosis and hepatic @GENETgt$ insulin @/GENETgt$ responsiveness .	2 6 6 5 6 6 11 11 8 11 6 11|14 14 11|14 11 11 18 18 11 21 21 18 21 26 26|22 26 26|22 21 6	None-BC7
23161873	CHEMICAL	GENE	T15	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ triglyceride @/CHEMICALSrc$ and @GENETgt$ MTTP @/GENETgt$ ? [SEP] The reduction was more pronounced in the fructose-fed group and attributed to decreased hepatic expression of ACC2 , FAS , SCD1 , and @GENETgt$ MTTP @/GENETgt$ and a decrease in the rate of hepatic @CHEMICALSrc$ triglyceride @/CHEMICALSrc$ secretion .	2 5 5 5 5 9 9 9 5 5 5 15 15 15 11 17 15 17 17 17 17 17 17 17|23 17 17|23 15 28 15 31 31 28 36 36 32|36 36 32|36 31 5	None-BC7
23161873	CHEMICAL	GENE	T7	T25	True	0	What is [Drugprot] between @CHEMICALSrc$ fructose @/CHEMICALSrc$ and @GENETgt$ fructokinase @/GENETgt$ ? [SEP] This was associated with decreased expression of fructose aldolase and @GENETgt$ fructokinase @/GENETgt$ , reminiscent of inherited disorders of @CHEMICALSrc$ fructose @/CHEMICALSrc$ metabolism .	3 3 3 6 6 3 9 9 6 9 9|10 9 9|10 3 3 17 17 14 21 17|21 21 17|21 17 3	SUBSTRATE
23161873	CHEMICAL	GENE	T10	T29	True	0	What is [Drugprot] between @CHEMICALSrc$ monosaccharides @/CHEMICALSrc$ and @GENETgt$ ChREBP @/GENETgt$ ? [SEP] In addition to serving as substrates , @CHEMICALSrc$ monosaccharides @/CHEMICALSrc$ also increase the expression of key enzymes involved in de novo lipogenesis via the carbohydrate response element-binding protein ( @GENETgt$ ChREBP @/GENETgt$ ) .	2 11 4 2 6 4 11 11|7 11 11|7 11 11 13 11 16 16 13 16 21 21 19 17 27 27 27 27 27 17 29 27 27 27 29 11	None-BC7
23161873	CHEMICAL	GENE	T12	T31	True	0	What is [Drugprot] between @CHEMICALSrc$ fructose @/CHEMICALSrc$ and @GENETgt$ ChREBP @/GENETgt$ ? [SEP] To determine whether ChREBP is a potential therapeutic target , we decreased hepatic expression of @GENETgt$ ChREBP @/GENETgt$ with a specific antisense oligonucleotide ( ASO ) in male Sprague-Dawley rats fed either a @CHEMICALSrc$ high-fructose @/CHEMICALSrc$ or high-fat diet .	2 12 9 9 9 9 9 9 2 12 12 12 14 12 16 14|15 14 14|15 22 22 22 22 12 24 22 24 29 29 29 22 12 33 33 30|31 30 30|31 33 33 30 12	None-BC7
23161873	CHEMICAL	GENE	T7	T24	True	0	What is [Drugprot] between @CHEMICALSrc$ fructose @/CHEMICALSrc$ and @GENETgt$ fructose aldolase @/GENETgt$ ? [SEP] This was associated with decreased expression of @GENETgt$ fructose aldolase @/GENETgt$ and fructokinase , reminiscent of inherited disorders of @CHEMICALSrc$ fructose @/CHEMICALSrc$ metabolism .	3 3 3 6 6 3 8 8|6|7 8|6|7 8|6 8|6|7 8 8 3 3 17 17 14 21 16|21 21 16|21 17 3	SUBSTRATE
23161873	CHEMICAL	GENE	T15	T34	True	0	What is [Drugprot] between @CHEMICALSrc$ triglyceride @/CHEMICALSrc$ and @GENETgt$ FAS @/GENETgt$ ? [SEP] The reduction was more pronounced in the fructose-fed group and attributed to decreased hepatic expression of ACC2 , @GENETgt$ FAS @/GENETgt$ , SCD1 , and MTTP and a decrease in the rate of hepatic @CHEMICALSrc$ triglyceride @/CHEMICALSrc$ secretion .	2 5 5 5 5 9 9 9 5 5 5 15 15 15 11 17 15 17 17|18 17 17|18 17 17 17 17 17 15 28 15 31 31 28 36 36 32|36 36 32|36 31 5	None-BC7
17292977	CHEMICAL	GENE	T3	T11	True	0	What is [Drugprot] between @CHEMICALSrc$ glucose @/CHEMICALSrc$ and @GENETgt$ insulin @/GENETgt$ ? [SEP] Administration of AC3174 resulted in a 4-fold increase in @GENETgt$ insulin @/GENETgt$ concentrations in normal mice following an IP @CHEMICALSrc$ glucose @/CHEMICALSrc$ challenge .	4 3 1 4 8 8 8 4 12 9|12 12 9|12 8 15 15 8 21 21 21 17|21 21 17|21 4 4	INDIRECT-UPREGULATOR
17292977	CHEMICAL	GENE	T6	T19	True	0	What is [Drugprot] between @CHEMICALSrc$ (125)I @/CHEMICALSrc$ and @GENETgt$ GLP-1 @/GENETgt$ ? [SEP] In RINm5f cell membranes , the potency of AC3174 for the displacement of @CHEMICALSrc$ [(125)I]GLP-1 @/CHEMICALSrc$ and activation of adenylate cyclase was similar to that of exenatide and @GENETgt$ GLP-1 @/GENETgt$ .	4 4 4 22 22 7 22 9 7 12 12 7 14 12|13 12 12|13 14 14 20 20 14 22 22 24 22 26 24 26 26 26 26 22	None-BC7
17292977	CHEMICAL	GENE	T7	T17	True	0	What is [Drugprot] between @CHEMICALSrc$ adenylate @/CHEMICALSrc$ and @GENETgt$ GLP-1 @/GENETgt$ ? [SEP] In RINm5f cell membranes , the potency of AC3174 for the displacement of @GENETgt$ [(125)I]GLP-1 @/GENETgt$ and activation of @CHEMICALSrc$ adenylate @/CHEMICALSrc$ cyclase was similar to that of exenatide and GLP-1 .	4 4 4 23 23 7 23 9 7 12 12 7 14 12|13 12 12|13 14 14 21 17|21 21 17|21 14 23 23 25 23 27 25 27 27 23	None-BC7
17292977	CHEMICAL	GENE	T7	T19	True	0	What is [Drugprot] between @CHEMICALSrc$ adenylate @/CHEMICALSrc$ and @GENETgt$ GLP-1 @/GENETgt$ ? [SEP] In RINm5f cell membranes , the potency of AC3174 for the displacement of [(125)I]GLP-1 and activation of @CHEMICALSrc$ adenylate @/CHEMICALSrc$ cyclase was similar to that of exenatide and @GENETgt$ GLP-1 @/GENETgt$ .	4 4 4 22 22 7 22 9 7 12 12 7 14 12 14 14 20 17|20 20 17|20 14 22 22 24 22 26 24 26 26 26 26 22	None-BC7
17292977	CHEMICAL	GENE	T6	T18	True	0	What is [Drugprot] between @CHEMICALSrc$ (125)I @/CHEMICALSrc$ and @GENETgt$ adenylate cyclase @/GENETgt$ ? [SEP] In RINm5f cell membranes , the potency of AC3174 for the displacement of @CHEMICALSrc$ [(125)I]GLP-1 @/CHEMICALSrc$ and activation of @GENETgt$ adenylate cyclase @/GENETgt$ was similar to that of exenatide and GLP-1 .	4 4 4 23 23 7 23 9 7 12 12 7 14 12|13 12 12|13 14 14 19 17|19|14 17|19|14 19|14 17|19|14 23 23 25 23 27 25 27 27 23	None-BC7
23348500	CHEMICAL	GENE	T10	T28	True	0	What is [Drugprot] between @CHEMICALSrc$ CPPHA @/CHEMICALSrc$ and @GENETgt$ mGlu5 @/GENETgt$ ? [SEP] However , one @GENETgt$ mGlu5 @/GENETgt$ PAM , @CHEMICALSrc$ CPPHA @/CHEMICALSrc$ ( N-(4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl)-2-hydroxybenzamide ) , interacts with a separate allosteric site on mGlu5 .	14 14 6 3|6 6 3|6 14 6 6 6 6 11 8 11 6 14 19 19 19 19 14 21 19 14	None-BC7
23348500	CHEMICAL	GENE	T1	T17	True	0	What is [Drugprot] between @CHEMICALSrc$ NCFP @/CHEMICALSrc$ and @GENETgt$ mGlu5 @/GENETgt$ ? [SEP] @CHEMICALSrc$ NCFP @/CHEMICALSrc$ binds to the CPPHA site on @GENETgt$ mGlu5 @/GENETgt$ and potentiates mGlu5-mediated responses in both recombinant and native systems .	0|3 3 0|3 3 7 7 7 3 9 3|7 3 3|7 3 3 14 12 17 17 14 17 17 17 3	DIRECT-REGULATOR
23348500	CHEMICAL	GENE	T3	T20	True	0	What is [Drugprot] between @CHEMICALSrc$ NCFP @/CHEMICALSrc$ and @GENETgt$ mGlu5 @/GENETgt$ ? [SEP] However , @CHEMICALSrc$ NCFP @/CHEMICALSrc$ provides greater mGlu5 subtype selectivity than does CPPHA , making it more suitable for studies of effects on @GENETgt$ mGlu5 @/GENETgt$ in CNS preparations .	5 5 2|5 5 2|5 5 9 9 9 5 11 5 11 5 5 17 17 14 19 17 21 19 23 21 21 21 27 27 19 5	None-BC7
23348500	CHEMICAL	GENE	T12	T30	True	0	What is [Drugprot] between @CHEMICALSrc$ CPPHA @/CHEMICALSrc$ and @GENETgt$ mGlu5 @/GENETgt$ ? [SEP] Using cell-based assays and brain slice preparations , we characterized the interaction of a potent and efficacious @GENETgt$ mGlu5 @/GENETgt$ PAM from the @CHEMICALSrc$ CPPHA @/CHEMICALSrc$ series termed NCFP ( N-(4-chloro-2-((4-fluoro-1,3-dioxoisoindolin-2-yl)methyl)phenyl)picolinamide ) .	10 3 1 3 6 7 3 10 10 10 12 10 20 20 20 15 15 17|20 20 17|20 12 25 25 25|21 25 25|21 12 25 26 29 27 29 10	None-BC7
23348500	CHEMICAL	GENE	T15	T32	True	0	What is [Drugprot] between @CHEMICALSrc$ glutamate @/CHEMICALSrc$ and @GENETgt$ metabotropic glutamate receptor 5 @/GENETgt$ ? [SEP] A novel @GENETgt$ metabotropic @/GENETgt$ @CHEMICALSrc$ glutamate receptor 5 @/CHEMICALSrc$ positive allosteric modulator acts at a unique site and confers stimulus bias to mGlu5 signaling .	11 11 2|11 11 2|11 11|3 11|3 11|3 11 11|3 11 11 12 12 16 16 16 12 12 12 20 18 23 23 20 12	None-BC7
23348500	CHEMICAL	GENE	T1	T18	True	0	What is [Drugprot] between @CHEMICALSrc$ NCFP @/CHEMICALSrc$ and @GENETgt$ mGlu5 @/GENETgt$ ? [SEP] @CHEMICALSrc$ NCFP @/CHEMICALSrc$ binds to the CPPHA site on mGlu5 and potentiates @GENETgt$ mGlu5-mediated @/GENETgt$ responses in both recombinant and native systems .	0|3 3 0|3 3 7 7 7 3 9 3 3 3 10|14 14 10|14 11 17 17 14 17 17 17 3	ACTIVATOR
23348500	CHEMICAL	GENE	T11	T29	True	0	What is [Drugprot] between @CHEMICALSrc$ N-(4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl)-2-hydroxybenzamide @/CHEMICALSrc$ and @GENETgt$ mGlu5 @/GENETgt$ ? [SEP] However , one mGlu5 PAM , CPPHA ( @CHEMICALSrc$ N-(4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl)-2-hydroxybenzamide @/CHEMICALSrc$ ) , interacts with a separate allosteric site on @GENETgt$ mGlu5 @/GENETgt$ .	13 13 5 5 13 5 5 9 8|7 7 8|7 9 5 13 18 18 18 18 13 20 18 18 18 13	DIRECT-REGULATOR
23348500	CHEMICAL	GENE	T2	T17	True	0	What is [Drugprot] between @CHEMICALSrc$ CPPHA @/CHEMICALSrc$ and @GENETgt$ mGlu5 @/GENETgt$ ? [SEP] NCFP binds to the @CHEMICALSrc$ CPPHA @/CHEMICALSrc$ site on @GENETgt$ mGlu5 @/GENETgt$ and potentiates mGlu5-mediated responses in both recombinant and native systems .	2 2 7 7 4|7 7 4|7 2 9 2|7 2 2|7 2 2 14 12 17 17 14 17 17 17 2	None-BC7
23348500	CHEMICAL	GENE	T13	T30	True	0	What is [Drugprot] between @CHEMICALSrc$ NCFP @/CHEMICALSrc$ and @GENETgt$ mGlu5 @/GENETgt$ ? [SEP] Using cell-based assays and brain slice preparations , we characterized the interaction of a potent and efficacious @GENETgt$ mGlu5 @/GENETgt$ PAM from the CPPHA series termed @CHEMICALSrc$ NCFP @/CHEMICALSrc$ ( N-(4-chloro-2-((4-fluoro-1,3-dioxoisoindolin-2-yl)methyl)phenyl)picolinamide ) .	10 3 1 3 6 7 3 10 10 10 12 10 20 20 20 15 15 17|20 20 17|20 12 24 24 24 12 24 24|25 25 24|25 29 26 29 10	None-BC7
23348500	CHEMICAL	GENE	T9	T27	True	0	What is [Drugprot] between @CHEMICALSrc$ 2-Methyl-6-(phenylethynyl)pyridine @/CHEMICALSrc$ and @GENETgt$ mGlu5 @/GENETgt$ ? [SEP] Previous work has extensively characterized a common allosteric site on @GENETgt$ mGlu5 @/GENETgt$ , termed the MPEP ( @CHEMICALSrc$ 2-Methyl-6-(phenylethynyl)pyridine @/CHEMICALSrc$ ) binding site .	2 5 5 5 5 9 9 9 5 11 9|10 9 9|10 5 5 22 22 22 16|22 22 16|22 22 22 14 5	PART-OF
23348500	CHEMICAL	GENE	T8	T27	True	0	What is [Drugprot] between @CHEMICALSrc$ MPEP @/CHEMICALSrc$ and @GENETgt$ mGlu5 @/GENETgt$ ? [SEP] Previous work has extensively characterized a common allosteric site on @GENETgt$ mGlu5 @/GENETgt$ , termed the @CHEMICALSrc$ MPEP @/CHEMICALSrc$ ( 2-Methyl-6-(phenylethynyl)pyridine ) binding site .	2 5 5 5 5 9 9 9 5 11 9|10 9 9|10 5 5 22 14|22 22 14|22 22 22 22 22 14 5	PART-OF
23348500	CHEMICAL	GENE	T4	T20	True	0	What is [Drugprot] between @CHEMICALSrc$ CPPHA @/CHEMICALSrc$ and @GENETgt$ mGlu5 @/GENETgt$ ? [SEP] However , NCFP provides greater mGlu5 subtype selectivity than does @CHEMICALSrc$ CPPHA @/CHEMICALSrc$ , making it more suitable for studies of effects on @GENETgt$ mGlu5 @/GENETgt$ in CNS preparations .	4 4 4 4 8 8 8 4 10 4 10 10 10 4 4 17 17 14 19 17 21 19 23 21 21 21 27 27 19 4	None-BC7
23348500	CHEMICAL	GENE	T5	T25	True	0	What is [Drugprot] between @CHEMICALSrc$ glutamate @/CHEMICALSrc$ and @GENETgt$ mGlu5 @/GENETgt$ ? [SEP] Metabotropic @CHEMICALSrc$ glutamate @/CHEMICALSrc$ receptor 5 ( @GENETgt$ mGlu5 @/GENETgt$ ) is a target for the treatment of central nervous system ( CNS ) disorders , such as schizophrenia and Alzheimer 's disease .	4 1|4 4 1|4 12 4 7 4|5 4 4|5 7 12 12 12 15 15 12 23 19 19 23 21 19 21 15 23 27 25 23 27 31 29 27 12	None-BC7
23348500	CHEMICAL	GENE	T5	T16	True	0	What is [Drugprot] between @CHEMICALSrc$ glutamate @/CHEMICALSrc$ and @GENETgt$ Metabotropic glutamate receptor 5 @/GENETgt$ ? [SEP] @GENETgt$ Metabotropic @/GENETgt$ @CHEMICALSrc$ glutamate receptor 5 @/CHEMICALSrc$ ( mGlu5 ) is a target for the treatment of central nervous system ( CNS ) disorders , such as schizophrenia and Alzheimer 's disease .	0|3 3 0|3 1|3|12 1|3|12 1|3|12 3|12 1|3|12 8 3 8 12 12 12 15 15 12 23 19 19 23 21 19 21 15 23 27 25 23 27 31 29 27 12	None-BC7
23348500	CHEMICAL	GENE	T2	T18	True	0	What is [Drugprot] between @CHEMICALSrc$ CPPHA @/CHEMICALSrc$ and @GENETgt$ mGlu5 @/GENETgt$ ? [SEP] NCFP binds to the @CHEMICALSrc$ CPPHA @/CHEMICALSrc$ site on mGlu5 and potentiates @GENETgt$ mGlu5-mediated @/GENETgt$ responses in both recombinant and native systems .	2 2 7 7 4|7 7 4|7 2 9 2 2 2 10|14 14 10|14 11 17 17 14 17 17 17 2	None-BC7
23348500	CHEMICAL	GENE	T15	T31	True	0	What is [Drugprot] between @CHEMICALSrc$ glutamate @/CHEMICALSrc$ and @GENETgt$ mGlu5 @/GENETgt$ ? [SEP] A novel metabotropic @CHEMICALSrc$ glutamate @/CHEMICALSrc$ receptor 5 positive allosteric modulator acts at a unique site and confers stimulus bias to @GENETgt$ mGlu5 @/GENETgt$ signaling .	10 10 10 10|3 10 10|3 10 10 10 10 11 11 15 15 15 11 11 11 19 17 23 19|23 23 19|23 19 11	None-BC7
23348500	CHEMICAL	GENE	T10	T29	True	0	What is [Drugprot] between @CHEMICALSrc$ CPPHA @/CHEMICALSrc$ and @GENETgt$ mGlu5 @/GENETgt$ ? [SEP] However , one mGlu5 PAM , @CHEMICALSrc$ CPPHA @/CHEMICALSrc$ ( N-(4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl)-2-hydroxybenzamide ) , interacts with a separate allosteric site on @GENETgt$ mGlu5 @/GENETgt$ .	13 13 5 5 13 5 5|6 5 5|6 10 7 10 5 13 18 18 18 18 13 20 18 18 18 13	DIRECT-REGULATOR
23348500	CHEMICAL	GENE	T3	T19	True	0	What is [Drugprot] between @CHEMICALSrc$ NCFP @/CHEMICALSrc$ and @GENETgt$ mGlu5 @/GENETgt$ ? [SEP] However , @CHEMICALSrc$ NCFP @/CHEMICALSrc$ provides greater @GENETgt$ mGlu5 @/GENETgt$ subtype selectivity than does CPPHA , making it more suitable for studies of effects on mGlu5 in CNS preparations .	5 5 2|5 5 2|5 5 10 10|5 10 10|5 10 5 12 5 12 5 5 18 18 15 20 18 22 20 24 22 27 27 20 5	None-BC7
23348500	CHEMICAL	GENE	T4	T19	True	0	What is [Drugprot] between @CHEMICALSrc$ CPPHA @/CHEMICALSrc$ and @GENETgt$ mGlu5 @/GENETgt$ ? [SEP] However , NCFP provides greater @GENETgt$ mGlu5 @/GENETgt$ subtype selectivity than does @CHEMICALSrc$ CPPHA @/CHEMICALSrc$ , making it more suitable for studies of effects on mGlu5 in CNS preparations .	4 4 4 4 9 9|5 9 9|5 9 4 11 4 10|11 11 10|11 4 4 18 18 15 20 18 22 20 24 22 27 27 20 4	None-BC7
23348500	CHEMICAL	GENE	T14	T30	True	0	What is [Drugprot] between @CHEMICALSrc$ N-(4-chloro-2-((4-fluoro-1,3-dioxoisoindolin-2-yl)methyl)phenyl)picolinamide @/CHEMICALSrc$ and @GENETgt$ mGlu5 @/GENETgt$ ? [SEP] Using cell-based assays and brain slice preparations , we characterized the interaction of a potent and efficacious @GENETgt$ mGlu5 @/GENETgt$ PAM from the CPPHA series termed NCFP ( @CHEMICALSrc$ N-(4-chloro-2-((4-fluoro-1,3-dioxoisoindolin-2-yl)methyl)phenyl)picolinamide @/CHEMICALSrc$ ) .	10 3 1 3 6 7 3 10 10 10 12 10 20 20 20 15 15 17|20 20 17|20 12 24 24 24 12 24 25 28 26 26 26 28 10	None-BC7
23348500	CHEMICAL	GENE	T11	T28	True	0	What is [Drugprot] between @CHEMICALSrc$ N-(4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl)-2-hydroxybenzamide @/CHEMICALSrc$ and @GENETgt$ mGlu5 @/GENETgt$ ? [SEP] However , one @GENETgt$ mGlu5 @/GENETgt$ PAM , CPPHA ( @CHEMICALSrc$ N-(4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl)-2-hydroxybenzamide @/CHEMICALSrc$ ) , interacts with a separate allosteric site on mGlu5 .	14 14 6 3|6 6 3|6 14 6 6 10 8 8 8 10 6 14 19 19 19 19 14 21 19 14	None-BC7
7828655	CHEMICAL	GENE	T16	T46	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ glutamic acid decarboxylase @/GENETgt$ ? [SEP] Dopamine D1 and @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D2 receptors were determined by receptor autoradiography , and dopamine D1 and dopamine D2 receptor mRNA and @GENETgt$ glutamic acid decarboxylase @/GENETgt$ mRNA were determined by in situ hybridization histochemistry .	2 9 2 3|7 7 3|7 7 2 9 9 12 12 9 9 9 16 29 16 21 21 21 16 16 27|21 27|21 27|21 27 27|21 16 29 9 34 34 31 34 29 9	None-BC7
7828655	CHEMICAL	GENE	T29	T55	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ glutamic acid decarboxylase @/GENETgt$ ? [SEP] Dopamine receptor blockade increases @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D2 receptor and @GENETgt$ glutamic acid decarboxylase @/GENETgt$ mRNAs in mouse substantia nigra .	3 3 4 4 8|4 8 8|4 8 4 8 8|14 8|14 8|14 14 8|14 8 18 18 18 4 4	None-BC7
7828655	CHEMICAL	GENE	T30	T54	True	0	What is [Drugprot] between @CHEMICALSrc$ glutamic acid @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptor @/GENETgt$ ? [SEP] Dopamine receptor blockade increases @GENETgt$ dopamine D2 receptor @/GENETgt$ and @CHEMICALSrc$ glutamic acid @/CHEMICALSrc$ decarboxylase mRNAs in mouse substantia nigra .	3 3 4 4 4|5 4|5 4|5 4|5 4|5 5 6|14 6|14 14 6|14 14 5 18 18 18 4 4	None-BC7
7828655	CHEMICAL	GENE	T15	T44	True	0	What is [Drugprot] between @CHEMICALSrc$ Dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D1 @/GENETgt$ ? [SEP] @CHEMICALSrc$ Dopamine @/CHEMICALSrc$ D1 and dopamine D2 receptors were determined by receptor autoradiography , and @GENETgt$ dopamine D1 @/GENETgt$ and dopamine D2 receptor mRNA and glutamic acid decarboxylase mRNA were determined by in situ hybridization histochemistry .	0|3 3 0|3 9 3 7 7 3 9 9 12 12 9 9 9 29|13|15 29|13|15 29|15 29|13|15 15 22 22 22 15 15 27 27 27 15 29 9 34 34 31 34 29 9	None-BC7
7828655	CHEMICAL	GENE	T13	T47	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptors @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of @GENETgt$ dopamine D2 receptors @/GENETgt$ and glutamic acid decarboxylase in substantia nigra , mice were treated daily for several days with an irreversibly acting dopamine D1 and dopamine D2 receptor antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline ( EEDQ ) or with a selective irreversible D2 @CHEMICALSrc$ dopamine @/CHEMICALSrc$ receptor antagonist fluphenazine-N-mustard .	2 26 4 2 7 7 4 10 10 4 12 10|11|12 10|11|12 10|11|12 10|12 10|11|12 12 19 19 12 22 22 10 26 26 26 26 26 30 30 26 36 36 34 36 36 26 36 42 42 42 42 36 44 42 44 36 56 56 56 56 56 48|56 56 48|56 56 56 36 26	None-BC7
7828655	CHEMICAL	GENE	T1	T52	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptors @/GENETgt$ ? [SEP] Treatment with fluphenazine-N-mustard , which blocked about 85 % of the @GENETgt$ dopamine D2 receptors @/GENETgt$ in substantia nigra but had no significant effect on @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D1 receptors , increased the levels of dopamine D2 receptor mRNA by about 34 % .	30 3 1 3 6 1 8 9 6 12 12 9|11|12 9|11|12 9|11|12 9|12 9|11|12 18 18 6 6 6 23 23 20 28 28|21 28 28|21 28 20 1 30 32 30 37 37 37 37 32 41 40 41 30 30	None-BC7
7828655	CHEMICAL	GENE	T18	T42	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ Dopamine D1 @/GENETgt$ ? [SEP] @GENETgt$ Dopamine D1 @/GENETgt$ and dopamine D2 receptors were determined by receptor autoradiography , and dopamine D1 and @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D2 receptor mRNA and glutamic acid decarboxylase mRNA were determined by in situ hybridization histochemistry .	0|1|9 0|1|9 1|9 0|1|9 1 7 7 1 9 9 12 12 9 9 9 16 29 16 22|15 22 22|15 22 22 16 16 27 27 27 16 29 9 34 34 31 34 29 9	None-BC7
7828655	CHEMICAL	GENE	T28	T54	True	0	What is [Drugprot] between @CHEMICALSrc$ Dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptor @/GENETgt$ ? [SEP] @CHEMICALSrc$ Dopamine @/CHEMICALSrc$ receptor blockade increases @GENETgt$ dopamine D2 receptor @/GENETgt$ and glutamic acid decarboxylase mRNAs in mouse substantia nigra .	0|4 4 0|4 4 5 5 4|5|6 4|5|6 4|5|6 5|6 4|5|6 6 14 14 14 6 18 18 18 5 5	None-BC7
7828655	CHEMICAL	GENE	T15	T46	True	0	What is [Drugprot] between @CHEMICALSrc$ Dopamine @/CHEMICALSrc$ and @GENETgt$ glutamic acid decarboxylase @/GENETgt$ ? [SEP] @CHEMICALSrc$ Dopamine @/CHEMICALSrc$ D1 and dopamine D2 receptors were determined by receptor autoradiography , and dopamine D1 and dopamine D2 receptor mRNA and @GENETgt$ glutamic acid decarboxylase @/GENETgt$ mRNA were determined by in situ hybridization histochemistry .	0|3 3 0|3 9 3 7 7 3 9 9 12 12 9 9 9 16 29 16 21 21 21 16 16 27|21 27|21 27|21 27 27|21 16 29 9 34 34 31 34 29 9	None-BC7
7828655	CHEMICAL	GENE	T3	T34	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptor @/GENETgt$ ? [SEP] There were no detectable levels of @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D1 receptors , increased the levels of @GENETgt$ dopamine D2 receptor @/GENETgt$ mRNA by about 34 % .	2 2 5 5 2 10 10|6 10 10|6 10 5 12 2 14 12 20 20|14 20|14 20|14 20 20|14 14 24 23 24 12 12	None-BC7
7828655	CHEMICAL	GENE	T12	T39	True	0	What is [Drugprot] between @CHEMICALSrc$ EEDQ @/CHEMICALSrc$ and @GENETgt$ dopamine D1 @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of dopamine D2 receptors and glutamic acid decarboxylase in substantia nigra , mice were treated daily for several days with an irreversibly acting @GENETgt$ dopamine D1 @/GENETgt$ and dopamine D2 receptor antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline ( @CHEMICALSrc$ EEDQ @/CHEMICALSrc$ ) or with a selective irreversible D2 dopamine receptor antagonist fluphenazine-N-mustard .	2 25 4 2 7 7 4 10 10 4 14 14 14 10 14 18 18 14 21 21 10 25 25 25 25 25 29 29 25 34 34 33 34 33|34|25 33|34|25 25|34 33|34|25 34 42 42 42 42 34 44 41|42 42 41|42 44 34 56 56 56 56 56 56 56 56 34 25	ANTAGONIST
7828655	CHEMICAL	GENE	T13	T39	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D1 @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of dopamine D2 receptors and glutamic acid decarboxylase in substantia nigra , mice were treated daily for several days with an irreversibly acting @GENETgt$ dopamine D1 @/GENETgt$ and dopamine D2 receptor antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline ( EEDQ ) or with a selective irreversible D2 @CHEMICALSrc$ dopamine @/CHEMICALSrc$ receptor antagonist fluphenazine-N-mustard .	2 25 4 2 7 7 4 10 10 4 14 14 14 10 14 18 18 14 21 21 10 25 25 25 25 25 29 29 25 34 34 33 34 33|34|25 33|34|25 25|34 33|34|25 34 42 42 42 42 34 44 42 44 34 56 56 56 56 56 56|49 56 56|49 56 56 34 25	None-BC7
7828655	CHEMICAL	GENE	T9	T40	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptor @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of dopamine D2 receptors and glutamic acid decarboxylase in substantia nigra , mice were treated daily for several days with an irreversibly acting @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D1 and @GENETgt$ dopamine D2 receptor @/GENETgt$ antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline ( EEDQ ) or with a selective irreversible D2 dopamine receptor antagonist fluphenazine-N-mustard .	2 25 4 2 7 7 4 10 10 4 14 14 14 10 14 18 18 14 21 21 10 25 25 25 25 25 29 29 25 36 36 33 36 33|36 36 33|36 25 36 43|36 43|36 43|36 43 43|36 43 36 45 43 45 36 56 56 56 56 56 56 56 56 36 25	None-BC7
7828655	CHEMICAL	GENE	T16	T44	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D1 @/GENETgt$ ? [SEP] Dopamine D1 and @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D2 receptors were determined by receptor autoradiography , and @GENETgt$ dopamine D1 @/GENETgt$ and dopamine D2 receptor mRNA and glutamic acid decarboxylase mRNA were determined by in situ hybridization histochemistry .	2 9 2 3|7 7 3|7 7 2 9 9 12 12 9 9 9 29|13|15 29|13|15 29|15 29|13|15 15 22 22 22 15 15 27 27 27 15 29 9 34 34 31 34 29 9	None-BC7
7828655	CHEMICAL	GENE	T13	T51	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ glutamic acid decarboxylase @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of dopamine D2 receptors and @GENETgt$ glutamic acid decarboxylase @/GENETgt$ in substantia nigra , mice were treated daily for several days with an irreversibly acting dopamine D1 and dopamine D2 receptor antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline ( EEDQ ) or with a selective irreversible D2 @CHEMICALSrc$ dopamine @/CHEMICALSrc$ receptor antagonist fluphenazine-N-mustard .	2 26 4 2 7 7 4 10 10 4 14 14 14 10 14 16|14|15 16|14|15 16|14|15 16|14 16|14|15 22 22 10 26 26 26 26 26 30 30 26 36 36 34 36 36 26 36 42 42 42 42 36 44 42 44 36 56 56 56 56 56 48|56 56 48|56 56 56 36 26	None-BC7
7828655	CHEMICAL	GENE	T18	T44	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D1 @/GENETgt$ ? [SEP] Dopamine D1 and dopamine D2 receptors were determined by receptor autoradiography , and @GENETgt$ dopamine D1 @/GENETgt$ and @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D2 receptor mRNA and glutamic acid decarboxylase mRNA were determined by in situ hybridization histochemistry .	2 8 2 6 6 2 8 8 11 11 8 8 8 29|13|14 29|13|14 29|14 29|13|14 14 22|15 22 22|15 22 22 14 14 27 27 27 14 29 8 34 34 31 34 29 8	None-BC7
7828655	CHEMICAL	GENE	T18	T46	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ glutamic acid decarboxylase @/GENETgt$ ? [SEP] Dopamine D1 and dopamine D2 receptors were determined by receptor autoradiography , and dopamine D1 and @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D2 receptor mRNA and @GENETgt$ glutamic acid decarboxylase @/GENETgt$ mRNA were determined by in situ hybridization histochemistry .	2 8 2 6 6 2 8 8 11 11 8 8 8 15 29 15 16|21 21 16|21 21 21 15 15 27|21 27|21 27|21 27 27|21 15 29 8 34 34 31 34 29 8	None-BC7
7828655	CHEMICAL	GENE	T12	T47	True	0	What is [Drugprot] between @CHEMICALSrc$ EEDQ @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptors @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of @GENETgt$ dopamine D2 receptors @/GENETgt$ and glutamic acid decarboxylase in substantia nigra , mice were treated daily for several days with an irreversibly acting dopamine D1 and dopamine D2 receptor antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline ( @CHEMICALSrc$ EEDQ @/CHEMICALSrc$ ) or with a selective irreversible D2 dopamine receptor antagonist fluphenazine-N-mustard .	2 26 4 2 7 7 4 10 10 4 12 10|11|12 10|11|12 10|11|12 10|12 10|11|12 12 19 19 12 22 22 10 26 26 26 26 26 30 30 26 36 36 34 36 36 26 36 42 42 42 42 36 44 40|42 42 40|42 44 36 56 56 56 56 56 56 56 56 36 26	None-BC7
7828655	CHEMICAL	GENE	T14	T47	True	0	What is [Drugprot] between @CHEMICALSrc$ fluphenazine-N-mustard @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptors @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of @GENETgt$ dopamine D2 receptors @/GENETgt$ and glutamic acid decarboxylase in substantia nigra , mice were treated daily for several days with an irreversibly acting dopamine D1 and dopamine D2 receptor antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline ( EEDQ ) or with a selective irreversible D2 dopamine receptor antagonist @CHEMICALSrc$ fluphenazine-N-mustard @/CHEMICALSrc$ .	2 26 4 2 7 7 4 10 10 4 12 10|11|12 10|11|12 10|11|12 10|12 10|11|12 12 19 19 12 22 22 10 26 26 26 26 26 30 30 26 36 36 34 36 36 26 36 42 42 42 42 36 44 42 44 36 55 55 55 55 55 55 55 55 51|36 36 51|36 26	None-BC7
7828655	CHEMICAL	GENE	T14	T40	True	0	What is [Drugprot] between @CHEMICALSrc$ fluphenazine-N-mustard @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptor @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of dopamine D2 receptors and glutamic acid decarboxylase in substantia nigra , mice were treated daily for several days with an irreversibly acting dopamine D1 and @GENETgt$ dopamine D2 receptor @/GENETgt$ antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline ( EEDQ ) or with a selective irreversible D2 dopamine receptor antagonist @CHEMICALSrc$ fluphenazine-N-mustard @/CHEMICALSrc$ .	2 25 4 2 7 7 4 10 10 4 14 14 14 10 14 18 18 14 21 21 10 25 25 25 25 25 29 29 25 35 35 33 35 35 25 35 42|36 42|36 42|36 42 42|36 42 35 44 42 44 35 55 55 55 55 55 55 55 55 35|51 35 35|51 25	None-BC7
7828655	CHEMICAL	GENE	T20	T39	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D1 @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D2 receptors and glutamic acid decarboxylase in substantia nigra , mice were treated daily for several days with an irreversibly acting @GENETgt$ dopamine D1 @/GENETgt$ and dopamine D2 receptor antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline ( EEDQ ) or with a selective irreversible D2 dopamine receptor antagonist fluphenazine-N-mustard .	2 26 4 2 7 7 4 10 10 4 15 11|15 15 11|15 15 10 15 19 19 15 22 22 10 26 26 26 26 26 30 30 26 35 35 34 35 33|26|35 33|26|35 26|35 33|26|35 35 43 43 43 43 35 45 43 45 35 56 56 56 56 56 56 56 56 35 26	None-BC7
7828655	CHEMICAL	GENE	T10	T39	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D1 @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of dopamine D2 receptors and glutamic acid decarboxylase in substantia nigra , mice were treated daily for several days with an irreversibly acting @GENETgt$ dopamine D1 @/GENETgt$ and @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D2 receptor antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline ( EEDQ ) or with a selective irreversible D2 dopamine receptor antagonist fluphenazine-N-mustard .	2 25 4 2 7 7 4 10 10 4 14 14 14 10 14 18 18 14 21 21 10 25 25 25 25 25 29 29 25 34 34 33 34 33|34|25 33|34|25 25|34 33|34|25 34 43|35 43 43|35 43 43 43 34 45 43 45 34 56 56 56 56 56 56 56 56 34 25	None-BC7
7828655	CHEMICAL	GENE	T17	T42	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ Dopamine D1 @/GENETgt$ ? [SEP] @GENETgt$ Dopamine D1 @/GENETgt$ and dopamine D2 receptors were determined by receptor autoradiography , and @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D1 and dopamine D2 receptor mRNA and glutamic acid decarboxylase mRNA were determined by in situ hybridization histochemistry .	0|1|9 0|1|9 1|9 0|1|9 1 7 7 1 9 9 12 12 9 9 9 17|12 17 17|12 29 17 22 22 22 17 17 27 27 27 17 29 9 34 34 31 34 29 9	None-BC7
7828655	CHEMICAL	GENE	T29	T53	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ Dopamine receptor @/GENETgt$ ? [SEP] @GENETgt$ Dopamine receptor @/GENETgt$ blockade increases @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D2 receptor and glutamic acid decarboxylase mRNAs in mouse substantia nigra .	0|4 0|4 4 0|4 5 5 9|3 9 9|3 9 5 9 14 14 14 9 18 18 18 5 5	None-BC7
7828655	CHEMICAL	GENE	T2	T52	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptors @/GENETgt$ ? [SEP] Treatment with fluphenazine-N-mustard , which blocked about 85 % of the @GENETgt$ dopamine D2 receptors @/GENETgt$ in substantia nigra but had no significant effect on dopamine D1 receptors , increased the levels of @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D2 receptor mRNA by about 34 % .	29 3 1 3 6 1 8 9 6 12 12 9|11|12 9|11|12 9|11|12 9|12 9|11|12 18 18 6 6 6 23 23 20 27 27 27 20 1 29 31 29 37 37|29 37 37|29 37 37 31 41 40 41 29 29	None-BC7
7828655	CHEMICAL	GENE	T12	T41	True	0	What is [Drugprot] between @CHEMICALSrc$ EEDQ @/CHEMICALSrc$ and @GENETgt$ D2 dopamine receptor @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of dopamine D2 receptors and glutamic acid decarboxylase in substantia nigra , mice were treated daily for several days with an irreversibly acting dopamine D1 and dopamine D2 receptor antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline ( @CHEMICALSrc$ EEDQ @/CHEMICALSrc$ ) or with a selective irreversible @GENETgt$ D2 dopamine receptor @/GENETgt$ antagonist fluphenazine-N-mustard .	2 25 4 2 7 7 4 10 10 4 14 14 14 10 14 18 18 14 21 21 10 25 25 25 25 25 29 29 25 35 35 33 35 35 25 35 41 41 41 41 35 43 41|42 41 41|42 43 35 56 56 56 56 56|49 56|49 56|49 56 56|49 56 35 25	None-BC7
7828655	CHEMICAL	GENE	T18	T43	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptors @/GENETgt$ ? [SEP] Dopamine D1 and @GENETgt$ dopamine D2 receptors @/GENETgt$ were determined by receptor autoradiography , and dopamine D1 and @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D2 receptor mRNA and glutamic acid decarboxylase mRNA were determined by in situ hybridization histochemistry .	2 9 2 2|3|4 2|3|4 2|3|4 2|4 2|3|4 9 9 12 12 9 9 9 16 29 16 14|22 22 14|22 22 22 16 16 27 27 27 16 29 9 34 34 31 34 29 9	None-BC7
7828655	CHEMICAL	GENE	T6	T35	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D1 receptor @/GENETgt$ ? [SEP] There were no detectable levels of @GENETgt$ dopamine D1 receptor @/GENETgt$ mRNA in substantia nigra either in control animals or in animals treated with the @CHEMICALSrc$ dopamine @/CHEMICALSrc$ receptor antagonists .	2 2 5 5 2 11 11|6 11|6 11|6 11 11|6 5 14 14 5 18 18 18 2 18 21 18 21 28 28 28|21 28 28|21 28 22 2	None-BC7
7828655	CHEMICAL	GENE	T14	T51	True	0	What is [Drugprot] between @CHEMICALSrc$ fluphenazine-N-mustard @/CHEMICALSrc$ and @GENETgt$ glutamic acid decarboxylase @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of dopamine D2 receptors and @GENETgt$ glutamic acid decarboxylase @/GENETgt$ in substantia nigra , mice were treated daily for several days with an irreversibly acting dopamine D1 and dopamine D2 receptor antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline ( EEDQ ) or with a selective irreversible D2 dopamine receptor antagonist @CHEMICALSrc$ fluphenazine-N-mustard @/CHEMICALSrc$ .	2 26 4 2 7 7 4 10 10 4 14 14 14 10 14 16|14|15 16|14|15 16|14|15 16|14 16|14|15 22 22 10 26 26 26 26 26 30 30 26 36 36 34 36 36 26 36 42 42 42 42 36 44 42 44 36 55 55 55 55 55 55 55 55 51|36 36 51|36 26	None-BC7
7828655	CHEMICAL	GENE	T13	T40	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptor @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of dopamine D2 receptors and glutamic acid decarboxylase in substantia nigra , mice were treated daily for several days with an irreversibly acting dopamine D1 and @GENETgt$ dopamine D2 receptor @/GENETgt$ antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline ( EEDQ ) or with a selective irreversible D2 @CHEMICALSrc$ dopamine @/CHEMICALSrc$ receptor antagonist fluphenazine-N-mustard .	2 25 4 2 7 7 4 10 10 4 14 14 14 10 14 18 18 14 21 21 10 25 25 25 25 25 29 29 25 35 35 33 35 35 25 35 42|36 42|36 42|36 42 42|36 42 35 44 42 44 35 56 56 56 56 56 48|56 56 48|56 56 56 35 25	None-BC7
7828655	CHEMICAL	GENE	T11	T40	True	0	What is [Drugprot] between @CHEMICALSrc$ N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptor @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of dopamine D2 receptors and glutamic acid decarboxylase in substantia nigra , mice were treated daily for several days with an irreversibly acting dopamine D1 and @GENETgt$ dopamine D2 receptor @/GENETgt$ antagonist @CHEMICALSrc$ N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline @/CHEMICALSrc$ ( EEDQ ) or with a selective irreversible D2 dopamine receptor antagonist fluphenazine-N-mustard .	2 25 4 2 7 7 4 10 10 4 14 14 14 10 14 18 18 14 21 21 10 25 25 25 25 25 29 29 25 35 35 33 35 35 25 35 42|36 42|36 42|36 42 42|36 42 35|38 35 35|38 45 42 45 35 56 56 56 56 56 56 56 56 35 25	ANTAGONIST
7828655	CHEMICAL	GENE	T16	T42	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ Dopamine D1 @/GENETgt$ ? [SEP] @GENETgt$ Dopamine D1 @/GENETgt$ and @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D2 receptors were determined by receptor autoradiography , and dopamine D1 and dopamine D2 receptor mRNA and glutamic acid decarboxylase mRNA were determined by in situ hybridization histochemistry .	0|1|10 0|1|10 1|10 0|1|10 1 8|2 8 8|2 8 1 10 10 13 13 10 10 10 17 29 17 22 22 22 17 17 27 27 27 17 29 10 34 34 31 34 29 10	None-BC7
7828655	CHEMICAL	GENE	T24	T48	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D2 @/GENETgt$ ? [SEP] The results showed that treatment with EEDQ , which blocked 80 % to 85 % of the @GENETgt$ dopamine D2 @/GENETgt$ and dopamine D1 receptors in substantia nigra , increased the levels of @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D2 receptor mRNA in substantia nigra by about 27 % .	2 3 3 29 29 7 5 7 10 5 12 10 15 15 10 18 18 17|18|15 17|18|15 18|15 17|18|15 18 24 24 10 27 27 10 29 3 31 29 37 37|30 37 37|30 37 37 31 40 40 31 44 43 44 29 3	None-BC7
7828655	CHEMICAL	GENE	T15	T45	True	0	What is [Drugprot] between @CHEMICALSrc$ Dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptor @/GENETgt$ ? [SEP] @CHEMICALSrc$ Dopamine @/CHEMICALSrc$ D1 and dopamine D2 receptors were determined by receptor autoradiography , and dopamine D1 and @GENETgt$ dopamine D2 receptor @/GENETgt$ mRNA and glutamic acid decarboxylase mRNA were determined by in situ hybridization histochemistry .	0|3 3 0|3 9 3 7 7 3 9 9 12 12 9 9 9 16 29 16 16|22 16|22 16|22 22 16|22 16 16 27 27 27 16 29 9 34 34 31 34 29 9	None-BC7
7828655	CHEMICAL	GENE	T22	T49	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D1 receptors @/GENETgt$ ? [SEP] The results showed that treatment with EEDQ , which blocked 80 % to 85 % of the @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D2 and @GENETgt$ dopamine D1 receptors @/GENETgt$ in substantia nigra , increased the levels of dopamine D2 receptor mRNA in substantia nigra by about 27 % .	2 3 3 30 30 7 5 7 10 5 12 10 15 15 10 20 20 17|20 20 17|20 15 20 10|20|22 10|20|22 10|20|22 10|22 10|20|22 28 28 10 30 3 32 30 37 37 37 37 32 40 40 32 44 43 44 30 3	None-BC7
7828655	CHEMICAL	GENE	T19	T42	True	0	What is [Drugprot] between @CHEMICALSrc$ glutamic acid @/CHEMICALSrc$ and @GENETgt$ Dopamine D1 @/GENETgt$ ? [SEP] @GENETgt$ Dopamine D1 @/GENETgt$ and dopamine D2 receptors were determined by receptor autoradiography , and dopamine D1 and dopamine D2 receptor mRNA and @CHEMICALSrc$ glutamic acid @/CHEMICALSrc$ decarboxylase mRNA were determined by in situ hybridization histochemistry .	0|1|9 0|1|9 1|9 0|1|9 1 7 7 1 9 9 12 12 9 9 9 16 29 16 21 21 21 16 16 27|20 27|20 27 27|20 27 16 29 9 34 34 31 34 29 9	None-BC7
7828655	CHEMICAL	GENE	T20	T41	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ D2 dopamine receptor @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D2 receptors and glutamic acid decarboxylase in substantia nigra , mice were treated daily for several days with an irreversibly acting dopamine D1 and dopamine D2 receptor antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline ( EEDQ ) or with a selective irreversible @GENETgt$ D2 dopamine receptor @/GENETgt$ antagonist fluphenazine-N-mustard .	2 26 4 2 7 7 4 10 10 4 15 11|15 15 11|15 15 10 15 19 19 15 22 22 10 26 26 26 26 26 30 30 26 36 36 34 36 36 26 36 42 42 42 42 36 44 42 44 36 56 56 56 56 56|49 56|49 56|49 56 56|49 56 36 26	None-BC7
7828655	CHEMICAL	GENE	T25	T31	True	0	What is [Drugprot] between @CHEMICALSrc$ fluphenazine-N-mustard @/CHEMICALSrc$ and @GENETgt$ dopamine D1 receptors @/GENETgt$ ? [SEP] Treatment with @CHEMICALSrc$ fluphenazine-N-mustard @/CHEMICALSrc$ , which blocked about 85 % of the dopamine D2 receptors in substantia nigra but had no significant effect on @GENETgt$ dopamine D1 receptors @/GENETgt$ , increased the levels of dopamine D2 receptor mRNA by about 34 % .	30 3 1|2 1 1|2 3 7 1 9 10 7 15 15 15 15 10 18 18 7 7 7 23 23 20 25 25|20|23 25|20|23 25|20|23 25|20 25|20|23 1 30 32 30 37 37 37 37 32 41 40 41 30 30	None-BC7
7828655	CHEMICAL	GENE	T17	T43	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptors @/GENETgt$ ? [SEP] Dopamine D1 and @GENETgt$ dopamine D2 receptors @/GENETgt$ were determined by receptor autoradiography , and @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D1 and dopamine D2 receptor mRNA and glutamic acid decarboxylase mRNA were determined by in situ hybridization histochemistry .	2 9 2 2|3|4 2|3|4 2|3|4 2|4 2|3|4 9 9 12 12 9 9 9 17|11 17 17|11 29 17 22 22 22 17 17 27 27 27 17 29 9 34 34 31 34 29 9	None-BC7
7828655	CHEMICAL	GENE	T16	T45	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptor @/GENETgt$ ? [SEP] Dopamine D1 and @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D2 receptors were determined by receptor autoradiography , and dopamine D1 and @GENETgt$ dopamine D2 receptor @/GENETgt$ mRNA and glutamic acid decarboxylase mRNA were determined by in situ hybridization histochemistry .	2 9 2 3|7 7 3|7 7 2 9 9 12 12 9 9 9 16 29 16 16|22 16|22 16|22 22 16|22 16 16 27 27 27 16 29 9 34 34 31 34 29 9	None-BC7
7828655	CHEMICAL	GENE	T11	T39	True	0	What is [Drugprot] between @CHEMICALSrc$ N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline @/CHEMICALSrc$ and @GENETgt$ dopamine D1 @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of dopamine D2 receptors and glutamic acid decarboxylase in substantia nigra , mice were treated daily for several days with an irreversibly acting @GENETgt$ dopamine D1 @/GENETgt$ and dopamine D2 receptor antagonist @CHEMICALSrc$ N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline @/CHEMICALSrc$ ( EEDQ ) or with a selective irreversible D2 dopamine receptor antagonist fluphenazine-N-mustard .	2 25 4 2 7 7 4 10 10 4 14 14 14 10 14 18 18 14 21 21 10 25 25 25 25 25 29 29 25 34 34 33 34 33|34|25 33|34|25 25|34 33|34|25 34 42 42 42 42 34|39 34 34|39 45 42 45 34 56 56 56 56 56 56 56 56 34 25	ANTAGONIST
7828655	CHEMICAL	GENE	T13	T41	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ D2 dopamine receptor @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of dopamine D2 receptors and glutamic acid decarboxylase in substantia nigra , mice were treated daily for several days with an irreversibly acting dopamine D1 and dopamine D2 receptor antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline ( EEDQ ) or with a selective irreversible @GENETgt$ D2 @/GENETgt$ @CHEMICALSrc$ dopamine receptor @/CHEMICALSrc$ antagonist fluphenazine-N-mustard .	2 25 4 2 7 7 4 10 10 4 14 14 14 10 14 18 18 14 21 21 10 25 25 25 25 25 29 29 25 35 35 33 35 35 25 35 41 41 41 41 35 43 41 43 35 56 56 56 56 56|49 56 56|49 56|50 56|50 56 56|50 56 35 25	None-BC7
7828655	CHEMICAL	GENE	T14	T39	True	0	What is [Drugprot] between @CHEMICALSrc$ fluphenazine-N-mustard @/CHEMICALSrc$ and @GENETgt$ dopamine D1 @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of dopamine D2 receptors and glutamic acid decarboxylase in substantia nigra , mice were treated daily for several days with an irreversibly acting @GENETgt$ dopamine D1 @/GENETgt$ and dopamine D2 receptor antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline ( EEDQ ) or with a selective irreversible D2 dopamine receptor antagonist @CHEMICALSrc$ fluphenazine-N-mustard @/CHEMICALSrc$ .	2 25 4 2 7 7 4 10 10 4 14 14 14 10 14 18 18 14 21 21 10 25 25 25 25 25 29 29 25 34 34 33 34 33|34|25 33|34|25 25|34 33|34|25 34 42 42 42 42 34 44 42 44 34 55 55 55 55 55 55 55 55 34|52 34 34|52 25	None-BC7
7828655	CHEMICAL	GENE	T4	T33	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D1 receptors @/GENETgt$ ? [SEP] There were no detectable levels of @GENETgt$ dopamine D1 receptors @/GENETgt$ , increased the levels of @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D2 receptor mRNA by about 34 % .	2 2 5 5 2 7 5|6|7 5|6|7 5|6|7 5|7 5|6|7 12 2 14 12 20 12|20 20 12|20 20 20 14 24 23 24 12 12	None-BC7
7828655	CHEMICAL	GENE	T9	T51	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ glutamic acid decarboxylase @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of dopamine D2 receptors and @GENETgt$ glutamic acid decarboxylase @/GENETgt$ in substantia nigra , mice were treated daily for several days with an irreversibly acting @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D1 and dopamine D2 receptor antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline ( EEDQ ) or with a selective irreversible D2 dopamine receptor antagonist fluphenazine-N-mustard .	2 26 4 2 7 7 4 10 10 4 14 14 14 10 14 16|14|15 16|14|15 16|14|15 16|14 16|14|15 22 22 10 26 26 26 26 26 30 30 26 37 37 34 37 37|31 37 37|31 26 37 43 43 43 43 37 45 43 45 37 56 56 56 56 56 56 56 56 37 26	None-BC7
7828655	CHEMICAL	GENE	T17	T45	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptor @/GENETgt$ ? [SEP] Dopamine D1 and dopamine D2 receptors were determined by receptor autoradiography , and @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D1 and @GENETgt$ dopamine D2 receptor @/GENETgt$ mRNA and glutamic acid decarboxylase mRNA were determined by in situ hybridization histochemistry .	2 8 2 6 6 2 8 8 11 11 8 8 8 16|13 16 16|13 29 16 16|22 16|22 16|22 22 16|22 16 16 27 27 27 16 29 8 34 34 31 34 29 8	None-BC7
7828655	CHEMICAL	GENE	T21	T48	True	0	What is [Drugprot] between @CHEMICALSrc$ EEDQ @/CHEMICALSrc$ and @GENETgt$ dopamine D2 @/GENETgt$ ? [SEP] The results showed that treatment with @CHEMICALSrc$ EEDQ @/CHEMICALSrc$ , which blocked 80 % to 85 % of the @GENETgt$ dopamine D2 @/GENETgt$ and dopamine D1 receptors in substantia nigra , increased the levels of dopamine D2 receptor mRNA in substantia nigra by about 27 % .	2 3 3 30 30 7 5|6 5 5|6 7 11 5 13 11 16 16 11 19 19 16|17|19 16|17|19 16|19 16|17|19 19 25 25 11 28 28 11 30 3 32 30 37 37 37 37 32 40 40 32 44 43 44 30 3	INHIBITOR
7828655	CHEMICAL	GENE	T9	T41	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ D2 dopamine receptor @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of dopamine D2 receptors and glutamic acid decarboxylase in substantia nigra , mice were treated daily for several days with an irreversibly acting @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D1 and dopamine D2 receptor antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline ( EEDQ ) or with a selective irreversible @GENETgt$ D2 dopamine receptor @/GENETgt$ antagonist fluphenazine-N-mustard .	2 25 4 2 7 7 4 10 10 4 14 14 14 10 14 18 18 14 21 21 10 25 25 25 25 25 29 29 25 36 36 33 36 33|36 36 33|36 25 36 42 42 42 42 36 44 42 44 36 56 56 56 56 56|49 56|49 56|49 56 56|49 56 36 25	None-BC7
7828655	CHEMICAL	GENE	T20	T51	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ glutamic acid decarboxylase @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D2 receptors and @GENETgt$ glutamic acid decarboxylase @/GENETgt$ in substantia nigra , mice were treated daily for several days with an irreversibly acting dopamine D1 and dopamine D2 receptor antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline ( EEDQ ) or with a selective irreversible D2 dopamine receptor antagonist fluphenazine-N-mustard .	2 27 4 2 7 7 4 10 10 4 15 11|15 15 11|15 15 10 15 17|15 17|15 17|15 17|15 17|15 23 23 10 27 27 27 27 27 31 31 27 37 37 35 37 37 27 37 43 43 43 43 37 45 43 45 37 56 56 56 56 56 56 56 56 37 27	None-BC7
7828655	CHEMICAL	GENE	T1	T32	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptor @/GENETgt$ ? [SEP] Treatment with fluphenazine-N-mustard , which blocked about 85 % of the dopamine D2 receptors in substantia nigra but had no significant effect on @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D1 receptors , increased the levels of @GENETgt$ dopamine D2 receptor @/GENETgt$ mRNA by about 34 % .	29 3 1 3 6 1 8 9 6 14 14 14 14 9 17 17 6 6 6 22 22 19 27 27|23 27 27|23 27 19 1 29 31 29 37 37|31 37|31 37|31 37 37|31 31 41 40 41 29 29	None-BC7
7828655	CHEMICAL	GENE	T26	T41	True	0	What is [Drugprot] between @CHEMICALSrc$ glutamic acid @/CHEMICALSrc$ and @GENETgt$ D2 dopamine receptor @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of dopamine D2 receptors and @CHEMICALSrc$ glutamic acid @/CHEMICALSrc$ decarboxylase in substantia nigra , mice were treated daily for several days with an irreversibly acting dopamine D1 and dopamine D2 receptor antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline ( EEDQ ) or with a selective irreversible @GENETgt$ D2 dopamine receptor @/GENETgt$ antagonist fluphenazine-N-mustard .	2 26 4 2 7 7 4 10 10 4 14 14 14 10 14 19|15 19|15 19 19|15 14 22 22 10 26 26 26 26 26 30 30 26 36 36 34 36 36 26 36 42 42 42 42 36 44 42 44 36 56 56 56 56 48|56 48|56 48|56 56 48|56 56 36 26	None-BC7
7828655	CHEMICAL	GENE	T2	T31	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D1 receptors @/GENETgt$ ? [SEP] Treatment with fluphenazine-N-mustard , which blocked about 85 % of the dopamine D2 receptors in substantia nigra but had no significant effect on @GENETgt$ dopamine D1 receptors @/GENETgt$ , increased the levels of @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D2 receptor mRNA by about 34 % .	29 3 1 3 6 1 8 9 6 14 14 14 14 9 17 17 6 6 6 22 22 19 24 24|19|23 24|19|23 24|19|23 24|19 24|19|23 1 29 31 29 37 37|29 37 37|29 37 37 31 41 40 41 29 29	None-BC7
7828655	CHEMICAL	GENE	T28	T55	True	0	What is [Drugprot] between @CHEMICALSrc$ Dopamine @/CHEMICALSrc$ and @GENETgt$ glutamic acid decarboxylase @/GENETgt$ ? [SEP] @CHEMICALSrc$ Dopamine @/CHEMICALSrc$ receptor blockade increases dopamine D2 receptor and @GENETgt$ glutamic acid decarboxylase @/GENETgt$ mRNAs in mouse substantia nigra .	0|4 4 0|4 4 5 5 8 8 5 8 8|14 8|14 8|14 14 8|14 8 18 18 18 5 5	None-BC7
7828655	CHEMICAL	GENE	T21	T49	True	0	What is [Drugprot] between @CHEMICALSrc$ EEDQ @/CHEMICALSrc$ and @GENETgt$ dopamine D1 receptors @/GENETgt$ ? [SEP] The results showed that treatment with @CHEMICALSrc$ EEDQ @/CHEMICALSrc$ , which blocked 80 % to 85 % of the dopamine D2 and @GENETgt$ dopamine D1 receptors @/GENETgt$ in substantia nigra , increased the levels of dopamine D2 receptor mRNA in substantia nigra by about 27 % .	2 3 3 30 30 7 5|6 5 5|6 7 11 5 13 11 16 16 11 20 20 20 16 20 11|20|22 11|20|22 11|20|22 11|22 11|20|22 28 28 11 30 3 32 30 37 37 37 37 32 40 40 32 44 43 44 30 3	INHIBITOR
7828655	CHEMICAL	GENE	T9	T47	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptors @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of @GENETgt$ dopamine D2 receptors @/GENETgt$ and glutamic acid decarboxylase in substantia nigra , mice were treated daily for several days with an irreversibly acting @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D1 and dopamine D2 receptor antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline ( EEDQ ) or with a selective irreversible D2 dopamine receptor antagonist fluphenazine-N-mustard .	2 26 4 2 7 7 4 10 10 4 12 10|11|12 10|11|12 10|11|12 10|12 10|11|12 12 19 19 12 22 22 10 26 26 26 26 26 30 30 26 37 37 34 37 37|31 37 37|31 26 37 43 43 43 43 37 45 43 45 37 56 56 56 56 56 56 56 56 37 26	None-BC7
7828655	CHEMICAL	GENE	T11	T41	True	0	What is [Drugprot] between @CHEMICALSrc$ N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline @/CHEMICALSrc$ and @GENETgt$ D2 dopamine receptor @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of dopamine D2 receptors and glutamic acid decarboxylase in substantia nigra , mice were treated daily for several days with an irreversibly acting dopamine D1 and dopamine D2 receptor antagonist @CHEMICALSrc$ N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline @/CHEMICALSrc$ ( EEDQ ) or with a selective irreversible @GENETgt$ D2 dopamine receptor @/GENETgt$ antagonist fluphenazine-N-mustard .	2 25 4 2 7 7 4 10 10 4 14 14 14 10 14 18 18 14 21 21 10 25 25 25 25 25 29 29 25 35 35 33 35 35 25 35 41 41 41 41 40|35 35 40|35 44 41 44 35 56 56 56 56 56|49 56|49 56|49 56 56|49 56 35 25	None-BC7
7828655	CHEMICAL	GENE	T12	T51	True	0	What is [Drugprot] between @CHEMICALSrc$ EEDQ @/CHEMICALSrc$ and @GENETgt$ glutamic acid decarboxylase @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of dopamine D2 receptors and @GENETgt$ glutamic acid decarboxylase @/GENETgt$ in substantia nigra , mice were treated daily for several days with an irreversibly acting dopamine D1 and dopamine D2 receptor antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline ( @CHEMICALSrc$ EEDQ @/CHEMICALSrc$ ) or with a selective irreversible D2 dopamine receptor antagonist fluphenazine-N-mustard .	2 26 4 2 7 7 4 10 10 4 14 14 14 10 14 16|14|15 16|14|15 16|14|15 16|14 16|14|15 22 22 10 26 26 26 26 26 30 30 26 36 36 34 36 36 26 36 42 42 42 42 36 44 40|42 42 40|42 44 36 56 56 56 56 56 56 56 56 36 26	None-BC7
7828655	CHEMICAL	GENE	T21	T50	True	0	What is [Drugprot] between @CHEMICALSrc$ EEDQ @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptor @/GENETgt$ ? [SEP] The results showed that treatment with @CHEMICALSrc$ EEDQ @/CHEMICALSrc$ , which blocked 80 % to 85 % of the dopamine D2 and dopamine D1 receptors in substantia nigra , increased the levels of @GENETgt$ dopamine D2 receptor @/GENETgt$ mRNA in substantia nigra by about 27 % .	2 3 3 29 29 7 5|6 5 5|6 7 11 5 13 11 16 16 11 20 20 20 16 20 24 24 11 27 27 11 29 3 31 29 37 37|31 37|31 37|31 37 37|31 31 40 40 31 44 43 44 29 3	INDIRECT-UPREGULATOR
7828655	CHEMICAL	GENE	T27	T31	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D1 receptors @/GENETgt$ ? [SEP] Treatment with fluphenazine-N-mustard , which blocked about 85 % of the @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D2 receptors in substantia nigra but had no significant effect on @GENETgt$ dopamine D1 receptors @/GENETgt$ , increased the levels of dopamine D2 receptor mRNA by about 34 % .	30 3 1 3 6 1 8 9 6 15 15 11|15 15 11|15 15 9 18 18 6 6 6 23 23 20 25 25|20|23 25|20|23 25|20|23 25|20 25|20|23 1 30 32 30 37 37 37 37 32 41 40 41 30 30	None-BC7
7828655	CHEMICAL	GENE	T26	T47	True	0	What is [Drugprot] between @CHEMICALSrc$ glutamic acid @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptors @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of @GENETgt$ dopamine D2 receptors @/GENETgt$ and @CHEMICALSrc$ glutamic acid @/CHEMICALSrc$ decarboxylase in substantia nigra , mice were treated daily for several days with an irreversibly acting dopamine D1 and dopamine D2 receptor antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline ( EEDQ ) or with a selective irreversible D2 dopamine receptor antagonist fluphenazine-N-mustard .	2 27 4 2 7 7 4 10 10 4 12 10|11|12 10|11|12 10|11|12 10|12 10|11|12 12 20|13 20|13 20 20|13 12 23 23 10 27 27 27 27 27 31 31 27 37 37 35 37 37 27 37 43 43 43 43 37 45 43 45 37 56 56 56 56 56 56 56 56 37 27	None-BC7
7828655	CHEMICAL	GENE	T10	T41	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ D2 dopamine receptor @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of dopamine D2 receptors and glutamic acid decarboxylase in substantia nigra , mice were treated daily for several days with an irreversibly acting dopamine D1 and @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D2 receptor antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline ( EEDQ ) or with a selective irreversible @GENETgt$ D2 dopamine receptor @/GENETgt$ antagonist fluphenazine-N-mustard .	2 25 4 2 7 7 4 10 10 4 14 14 14 10 14 18 18 14 21 21 10 25 25 25 25 25 29 29 25 35 35 33 35 35 25 35 42|36 42 42|36 42 42 42 35 44 42 44 35 56 56 56 56 56|49 56|49 56|49 56 56|49 56 35 25	None-BC7
7828655	CHEMICAL	GENE	T7	T38	True	0	What is [Drugprot] between @CHEMICALSrc$ Glutamic acid @/CHEMICALSrc$ and @GENETgt$ dopamine receptor @/GENETgt$ ? [SEP] @CHEMICALSrc$ Glutamic acid @/CHEMICALSrc$ decarboxylase mRNA was expressed in several regions of the mid-brain but only that expressed in substantia nigra was altered by treatment with @GENETgt$ dopamine receptor @/GENETgt$ antagonists.(ABSTRACT TRUNCATED AT 250 WORDS )	0|5 0|5 5 0|5 5 7 7 7 10 10 7 13 13 10 13 16 22 16 20 20 17 22 7 24 22 26 24|26|23 24|26|23 24|26 24|26|23 26 24 33 33 30 7	None-BC7
7828655	CHEMICAL	GENE	T30	T53	True	0	What is [Drugprot] between @CHEMICALSrc$ glutamic acid @/CHEMICALSrc$ and @GENETgt$ Dopamine receptor @/GENETgt$ ? [SEP] @GENETgt$ Dopamine receptor @/GENETgt$ blockade increases dopamine D2 receptor and @CHEMICALSrc$ glutamic acid @/CHEMICALSrc$ decarboxylase mRNAs in mouse substantia nigra .	0|4 0|4 4 0|4 5 5 8 8 5 8 14|7 14|7 14 14|7 14 8 18 18 18 5 5	None-BC7
7828655	CHEMICAL	GENE	T10	T51	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ glutamic acid decarboxylase @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of dopamine D2 receptors and @GENETgt$ glutamic acid decarboxylase @/GENETgt$ in substantia nigra , mice were treated daily for several days with an irreversibly acting dopamine D1 and @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D2 receptor antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline ( EEDQ ) or with a selective irreversible D2 dopamine receptor antagonist fluphenazine-N-mustard .	2 26 4 2 7 7 4 10 10 4 14 14 14 10 14 16|14|15 16|14|15 16|14|15 16|14 16|14|15 22 22 10 26 26 26 26 26 30 30 26 36 36 34 36 36 26 36 34|43 43 34|43 43 43 43 36 45 43 45 36 56 56 56 56 56 56 56 56 36 26	None-BC7
7828655	CHEMICAL	GENE	T23	T48	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D2 @/GENETgt$ ? [SEP] The results showed that treatment with EEDQ , which blocked 80 % to 85 % of the @GENETgt$ dopamine D2 @/GENETgt$ and @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D1 receptors in substantia nigra , increased the levels of dopamine D2 receptor mRNA in substantia nigra by about 27 % .	2 3 3 30 30 7 5 7 10 5 12 10 15 15 10 18 18 17|18|15 17|18|15 18|15 17|18|15 18 25|19 25 25|19 25 10 28 28 10 30 3 32 30 37 37 37 37 32 40 40 32 44 43 44 30 3	None-BC7
7828655	CHEMICAL	GENE	T11	T47	True	0	What is [Drugprot] between @CHEMICALSrc$ N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptors @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of @GENETgt$ dopamine D2 receptors @/GENETgt$ and glutamic acid decarboxylase in substantia nigra , mice were treated daily for several days with an irreversibly acting dopamine D1 and dopamine D2 receptor antagonist @CHEMICALSrc$ N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline @/CHEMICALSrc$ ( EEDQ ) or with a selective irreversible D2 dopamine receptor antagonist fluphenazine-N-mustard .	2 26 4 2 7 7 4 10 10 4 12 10|11|12 10|11|12 10|11|12 10|12 10|11|12 12 19 19 12 22 22 10 26 26 26 26 26 30 30 26 36 36 34 36 36 26 36 42 42 42 42 36|38 36 36|38 45 42 45 36 56 56 56 56 56 56 56 56 36 26	None-BC7
7828655	CHEMICAL	GENE	T19	T43	True	0	What is [Drugprot] between @CHEMICALSrc$ glutamic acid @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptors @/GENETgt$ ? [SEP] Dopamine D1 and @GENETgt$ dopamine D2 receptors @/GENETgt$ were determined by receptor autoradiography , and dopamine D1 and dopamine D2 receptor mRNA and @CHEMICALSrc$ glutamic acid @/CHEMICALSrc$ decarboxylase mRNA were determined by in situ hybridization histochemistry .	2 9 2 2|3|4 2|3|4 2|3|4 2|4 2|3|4 9 9 12 12 9 9 9 16 29 16 21 21 21 16 16 27|19 27|19 27 27|19 27 16 29 9 34 34 31 34 29 9	None-BC7
7828655	CHEMICAL	GENE	T22	T50	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptor @/GENETgt$ ? [SEP] The results showed that treatment with EEDQ , which blocked 80 % to 85 % of the @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D2 and dopamine D1 receptors in substantia nigra , increased the levels of @GENETgt$ dopamine D2 receptor @/GENETgt$ mRNA in substantia nigra by about 27 % .	2 3 3 29 29 7 5 7 10 5 12 10 15 15 10 20 20 17|20 20 17|20 15 20 24 24 10 27 27 10 29 3 31 29 37 37|31 37|31 37|31 37 37|31 31 40 40 31 44 43 44 29 3	None-BC7
7828655	CHEMICAL	GENE	T8	T37	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ Glutamic acid decarboxylase @/GENETgt$ ? [SEP] @GENETgt$ Glutamic acid decarboxylase @/GENETgt$ mRNA was expressed in several regions of the mid-brain but only that expressed in substantia nigra was altered by treatment with @CHEMICALSrc$ dopamine @/CHEMICALSrc$ receptor antagonists.(ABSTRACT TRUNCATED AT 250 WORDS )	0|5 0|5 0|5 5 0|5 7 7 7 10 10 7 13 13 10 13 16 22 16 20 20 17 22 7 24 22 28 28|22 28 28|22 24 28 24 33 33 30 7	None-BC7
7828655	CHEMICAL	GENE	T19	T45	True	0	What is [Drugprot] between @CHEMICALSrc$ glutamic acid @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptor @/GENETgt$ ? [SEP] Dopamine D1 and dopamine D2 receptors were determined by receptor autoradiography , and dopamine D1 and @GENETgt$ dopamine D2 receptor @/GENETgt$ mRNA and @CHEMICALSrc$ glutamic acid @/CHEMICALSrc$ decarboxylase mRNA were determined by in situ hybridization histochemistry .	2 8 2 6 6 2 8 8 11 11 8 8 8 15 29 15 16|21 16|21 16|21 21 16|21 15 15 27|19 27|19 27 27|19 27 15 29 8 34 34 31 34 29 8	None-BC7
7828655	CHEMICAL	GENE	T23	T50	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptor @/GENETgt$ ? [SEP] The results showed that treatment with EEDQ , which blocked 80 % to 85 % of the dopamine D2 and @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D1 receptors in substantia nigra , increased the levels of @GENETgt$ dopamine D2 receptor @/GENETgt$ mRNA in substantia nigra by about 27 % .	2 3 3 29 29 7 5 7 10 5 12 10 15 15 10 19 19 19 15 19 24|20 24 24|20 24 10 27 27 10 29 3 31 29 37 37|31 37|31 37|31 37 37|31 31 40 40 31 44 43 44 29 3	None-BC7
7828655	CHEMICAL	GENE	T24	T49	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D1 receptors @/GENETgt$ ? [SEP] The results showed that treatment with EEDQ , which blocked 80 % to 85 % of the dopamine D2 and @GENETgt$ dopamine D1 receptors @/GENETgt$ in substantia nigra , increased the levels of @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D2 receptor mRNA in substantia nigra by about 27 % .	2 3 3 29 29 7 5 7 10 5 12 10 15 15 10 19 19 19 15 19 10|20|21 10|20|21 10|20|21 10|21 10|20|21 27 27 10 29 3 31 29 37 37|29 37 37|29 37 37 31 40 40 31 44 43 44 29 3	None-BC7
7828655	CHEMICAL	GENE	T20	T40	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptor @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D2 receptors and glutamic acid decarboxylase in substantia nigra , mice were treated daily for several days with an irreversibly acting dopamine D1 and @GENETgt$ dopamine D2 receptor @/GENETgt$ antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline ( EEDQ ) or with a selective irreversible D2 dopamine receptor antagonist fluphenazine-N-mustard .	2 26 4 2 7 7 4 10 10 4 15 11|15 15 11|15 15 10 15 19 19 15 22 22 10 26 26 26 26 26 30 30 26 36 36 34 36 36 26 36 43|36 43|36 43|36 43 43|36 43 36 45 43 45 36 56 56 56 56 56 56 56 56 36 26	None-BC7
7828655	CHEMICAL	GENE	T25	T32	True	0	What is [Drugprot] between @CHEMICALSrc$ fluphenazine-N-mustard @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptor @/GENETgt$ ? [SEP] Treatment with @CHEMICALSrc$ fluphenazine-N-mustard @/CHEMICALSrc$ , which blocked about 85 % of the dopamine D2 receptors in substantia nigra but had no significant effect on dopamine D1 receptors , increased the levels of @GENETgt$ dopamine D2 receptor @/GENETgt$ mRNA by about 34 % .	29 3 1|2 1 1|2 3 7 1 9 10 7 15 15 15 15 10 18 18 7 7 7 23 23 20 27 27 27 20 1 29 31 29 37 37|31 37|31 37|31 37 37|31 31 41 40 41 29 29	INDIRECT-UPREGULATOR
7828655	CHEMICAL	GENE	T25	T52	True	0	What is [Drugprot] between @CHEMICALSrc$ fluphenazine-N-mustard @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptors @/GENETgt$ ? [SEP] Treatment with @CHEMICALSrc$ fluphenazine-N-mustard @/CHEMICALSrc$ , which blocked about 85 % of the @GENETgt$ dopamine D2 receptors @/GENETgt$ in substantia nigra but had no significant effect on dopamine D1 receptors , increased the levels of dopamine D2 receptor mRNA by about 34 % .	30 3 1|2 1 1|2 3 7 1 9 10 7 13 13 10|11|13 10|11|13 10|11|13 10|13 10|11|13 19 19 7 7 7 24 24 21 28 28 28 21 1 30 32 30 37 37 37 37 32 41 40 41 30 30	INHIBITOR
7828655	CHEMICAL	GENE	T12	T40	True	0	What is [Drugprot] between @CHEMICALSrc$ EEDQ @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptor @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of dopamine D2 receptors and glutamic acid decarboxylase in substantia nigra , mice were treated daily for several days with an irreversibly acting dopamine D1 and @GENETgt$ dopamine D2 receptor @/GENETgt$ antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline ( @CHEMICALSrc$ EEDQ @/CHEMICALSrc$ ) or with a selective irreversible D2 dopamine receptor antagonist fluphenazine-N-mustard .	2 25 4 2 7 7 4 10 10 4 14 14 14 10 14 18 18 14 21 21 10 25 25 25 25 25 29 29 25 35 35 33 35 35 25 35 42|36 42|36 42|36 42 42|36 42 35 44 40|42 42 40|42 44 35 56 56 56 56 56 56 56 56 35 25	ANTAGONIST
7828655	CHEMICAL	GENE	T5	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine receptor @/GENETgt$ ? [SEP] There were no detectable levels of @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D1 receptor mRNA in substantia nigra either in control animals or in animals treated with the @GENETgt$ dopamine receptor @/GENETgt$ antagonists .	2 2 5 5 2 11 11|6 11 11|6 11 11 5 14 14 5 18 18 18 2 18 21 18 21 28 28 28|23 28|23 28 28|23 22 2	None-BC7
7828655	CHEMICAL	GENE	T14	T41	True	0	What is [Drugprot] between @CHEMICALSrc$ fluphenazine-N-mustard @/CHEMICALSrc$ and @GENETgt$ D2 dopamine receptor @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of dopamine D2 receptors and glutamic acid decarboxylase in substantia nigra , mice were treated daily for several days with an irreversibly acting dopamine D1 and dopamine D2 receptor antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline ( EEDQ ) or with a selective irreversible @GENETgt$ D2 dopamine receptor @/GENETgt$ antagonist @CHEMICALSrc$ fluphenazine-N-mustard @/CHEMICALSrc$ .	2 25 4 2 7 7 4 10 10 4 14 14 14 10 14 18 18 14 21 21 10 25 25 25 25 25 29 29 25 35 35 33 35 35 25 35 41 41 41 41 35 43 41 43 35 55 55 55 55 49|55 49|55 49|55 55 49|55 55 35|51 35 35|51 25	ANTAGONIST
7828655	CHEMICAL	GENE	T15	T43	True	0	What is [Drugprot] between @CHEMICALSrc$ Dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptors @/GENETgt$ ? [SEP] @CHEMICALSrc$ Dopamine @/CHEMICALSrc$ D1 and @GENETgt$ dopamine D2 receptors @/GENETgt$ were determined by receptor autoradiography , and dopamine D1 and dopamine D2 receptor mRNA and glutamic acid decarboxylase mRNA were determined by in situ hybridization histochemistry .	0|3 3 0|3 10 3 3|5 3|5 3|5 3|5 3|5 10 10 13 13 10 10 10 17 29 17 22 22 22 17 17 27 27 27 17 29 10 34 34 31 34 29 10	None-BC7
7828655	CHEMICAL	GENE	T26	T40	True	0	What is [Drugprot] between @CHEMICALSrc$ glutamic acid @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptor @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of dopamine D2 receptors and @CHEMICALSrc$ glutamic acid @/CHEMICALSrc$ decarboxylase in substantia nigra , mice were treated daily for several days with an irreversibly acting dopamine D1 and @GENETgt$ dopamine D2 receptor @/GENETgt$ antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline ( EEDQ ) or with a selective irreversible D2 dopamine receptor antagonist fluphenazine-N-mustard .	2 26 4 2 7 7 4 10 10 4 14 14 14 10 14 19|15 19|15 19 19|15 14 22 22 10 26 26 26 26 26 30 30 26 36 36 34 36 36 26 36 43|35 43|35 43|35 43 43|35 43 36 45 43 45 36 56 56 56 56 56 56 56 56 36 26	None-BC7
7828655	CHEMICAL	GENE	T19	T44	True	0	What is [Drugprot] between @CHEMICALSrc$ glutamic acid @/CHEMICALSrc$ and @GENETgt$ dopamine D1 @/GENETgt$ ? [SEP] Dopamine D1 and dopamine D2 receptors were determined by receptor autoradiography , and @GENETgt$ dopamine D1 @/GENETgt$ and dopamine D2 receptor mRNA and @CHEMICALSrc$ glutamic acid @/CHEMICALSrc$ decarboxylase mRNA were determined by in situ hybridization histochemistry .	2 8 2 6 6 2 8 8 11 11 8 8 8 29|13|14 29|13|14 29|14 29|13|14 14 21 21 21 14 14 27|20 27|20 27 27|20 27 14 29 8 34 34 31 34 29 8	None-BC7
7828655	CHEMICAL	GENE	T17	T46	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ glutamic acid decarboxylase @/GENETgt$ ? [SEP] Dopamine D1 and dopamine D2 receptors were determined by receptor autoradiography , and @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D1 and dopamine D2 receptor mRNA and @GENETgt$ glutamic acid decarboxylase @/GENETgt$ mRNA were determined by in situ hybridization histochemistry .	2 8 2 6 6 2 8 8 11 11 8 8 8 16|13 16 16|13 29 16 21 21 21 16 16 27|21 27|21 27|21 27 27|21 16 29 8 34 34 31 34 29 8	None-BC7
7828655	CHEMICAL	GENE	T11	T51	True	0	What is [Drugprot] between @CHEMICALSrc$ N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline @/CHEMICALSrc$ and @GENETgt$ glutamic acid decarboxylase @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of dopamine D2 receptors and @GENETgt$ glutamic acid decarboxylase @/GENETgt$ in substantia nigra , mice were treated daily for several days with an irreversibly acting dopamine D1 and dopamine D2 receptor antagonist @CHEMICALSrc$ N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline @/CHEMICALSrc$ ( EEDQ ) or with a selective irreversible D2 dopamine receptor antagonist fluphenazine-N-mustard .	2 26 4 2 7 7 4 10 10 4 14 14 14 10 14 16|14|15 16|14|15 16|14|15 16|14 16|14|15 22 22 10 26 26 26 26 26 30 30 26 36 36 34 36 36 26 36 42 42 42 42 36|38 36 36|38 45 42 45 36 56 56 56 56 56 56 56 56 36 26	None-BC7
7828655	CHEMICAL	GENE	T10	T47	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptors @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of @GENETgt$ dopamine D2 receptors @/GENETgt$ and glutamic acid decarboxylase in substantia nigra , mice were treated daily for several days with an irreversibly acting dopamine D1 and @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D2 receptor antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline ( EEDQ ) or with a selective irreversible D2 dopamine receptor antagonist fluphenazine-N-mustard .	2 26 4 2 7 7 4 10 10 4 12 10|11|12 10|11|12 10|11|12 10|12 10|11|12 12 19 19 12 22 22 10 26 26 26 26 26 30 30 26 36 36 34 36 36 26 36 34|43 43 34|43 43 43 43 36 45 43 45 36 56 56 56 56 56 56 56 56 36 26	None-BC7
7828655	CHEMICAL	GENE	T26	T39	True	0	What is [Drugprot] between @CHEMICALSrc$ glutamic acid @/CHEMICALSrc$ and @GENETgt$ dopamine D1 @/GENETgt$ ? [SEP] To study the influence of dopaminergic activity on the expression of dopamine D2 receptors and @CHEMICALSrc$ glutamic acid @/CHEMICALSrc$ decarboxylase in substantia nigra , mice were treated daily for several days with an irreversibly acting @GENETgt$ dopamine D1 @/GENETgt$ and dopamine D2 receptor antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline ( EEDQ ) or with a selective irreversible D2 dopamine receptor antagonist fluphenazine-N-mustard .	2 26 4 2 7 7 4 10 10 4 14 14 14 10 14 19|15 19|15 19 19|15 14 22 22 10 26 26 26 26 26 30 30 26 35 35 34 35 32|26|35 32|26|35 26|35 32|26|35 35 43 43 43 43 35 45 43 45 35 56 56 56 56 56 56 56 56 35 26	None-BC7
7828655	CHEMICAL	GENE	T27	T32	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ dopamine D2 receptor @/GENETgt$ ? [SEP] Treatment with fluphenazine-N-mustard , which blocked about 85 % of the @CHEMICALSrc$ dopamine @/CHEMICALSrc$ D2 receptors in substantia nigra but had no significant effect on dopamine D1 receptors , increased the levels of @GENETgt$ dopamine D2 receptor @/GENETgt$ mRNA by about 34 % .	29 3 1 3 6 1 8 9 6 15 15 11|15 15 11|15 15 9 18 18 6 6 6 23 23 20 27 27 27 20 1 29 31 29 37 37|31 37|31 37|31 37 37|31 31 41 40 41 29 29	None-BC7
15456329	CHEMICAL	GENE	T15	T33	True	0	What is [Drugprot] between @CHEMICALSrc$ nabumetone @/CHEMICALSrc$ and @GENETgt$ COX-1 @/GENETgt$ ? [SEP] This has been attributed mainly to the non-acidic chemical properties of @CHEMICALSrc$ nabumetone @/CHEMICALSrc$ but also to its @GENETgt$ COX-1/COX-2 @/GENETgt$ inhibitor profile .	4 4 4 4 4 10 10 10 10 4 12 10|11 10 10|11 12 21 21 21 16|21 21 16|21 21 12 4	INHIBITOR
15456329	CHEMICAL	GENE	T19	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ 6-MNA @/CHEMICALSrc$ and @GENETgt$ cyclo-oxygenase (COX)-2 @/GENETgt$ ? [SEP] Nabumetone itself is non-acidic and , following absorption , it undergoes extensive first-pass metabolism to form the main circulating active metabolite ( @CHEMICALSrc$ 6-MNA @/CHEMICALSrc$ ) which is a much more potent inhibitor of preferentially @GENETgt$ cyclo-oxygenase (COX)-2 @/GENETgt$ .	4 1 4 4 4 4 8 11 11 11 4 14 14 11 16 11 21 21 21 21 16 23 21|22 21 21|22 23 32 32 32 30 31 32 21 35 35 32|33|35 32|33|35 32|35 32|33|35 4	INHIBITOR
15456329	CHEMICAL	GENE	T13	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ Nabumetone @/CHEMICALSrc$ and @GENETgt$ cyclo-oxygenase (COX)-2 @/GENETgt$ ? [SEP] @CHEMICALSrc$ Nabumetone @/CHEMICALSrc$ itself is non-acidic and , following absorption , it undergoes extensive first-pass metabolism to form the main circulating active metabolite ( 6-MNA ) which is a much more potent inhibitor of preferentially @GENETgt$ cyclo-oxygenase (COX)-2 @/GENETgt$ .	0|5 5 0|5 1 5 5 5 5 9 12 12 12 5 15 15 12 17 12 22 22 22 22 17 24 22 24 32 32 32 30 31 32 22 35 35 32|33|35 32|33|35 32|35 32|33|35 5	INHIBITOR
15456329	CHEMICAL	GENE	T18	T35	True	0	What is [Drugprot] between @CHEMICALSrc$ nabumetone @/CHEMICALSrc$ and @GENETgt$ COX-2 @/GENETgt$ ? [SEP] Compared with @GENETgt$ COX-2 @/GENETgt$ selective inhibitors , @CHEMICALSrc$ nabumetone @/CHEMICALSrc$ exhibits similar anti-inflammatory and analgesic properties in patients with arthritis and there is no evidence of excess GI or other forms of complications to date .	6 6 2|6 6 2|6 6 10 10 10|6 10 10|6 10 12 10 12 12 12 17 10 19 17 10 22 10 24 22 27 27 24 27 30 27 32 30 34 24 10	INHIBITOR
15456329	CHEMICAL	GENE	T15	T34	True	0	What is [Drugprot] between @CHEMICALSrc$ nabumetone @/CHEMICALSrc$ and @GENETgt$ COX-2 @/GENETgt$ ? [SEP] This has been attributed mainly to the non-acidic chemical properties of @CHEMICALSrc$ nabumetone @/CHEMICALSrc$ but also to its @GENETgt$ COX-1/COX-2 @/GENETgt$ inhibitor profile .	4 4 4 4 4 10 10 10 10 4 12 10|11 10 10|11 12 21 21 21 16|21 21 16|21 21 12 4	INHIBITOR
17258485	CHEMICAL	GENE	T8	T32	True	0	What is [Drugprot] between @CHEMICALSrc$ phorbol ester @/CHEMICALSrc$ and @GENETgt$ protein kinase C @/GENETgt$ ? [SEP] Phorbol 12-myristate 13 acetate ( PMA ) , the @CHEMICALSrc$ phorbol ester @/CHEMICALSrc$ activator of @GENETgt$ protein kinase C @/GENETgt$ , caused a 37 % decrease in the I(SC ) response to ASC .	4 4 4 20 6 4 6 4 13 9|13 9|13 13 9|13 4 15 12|13|15 12|13|15 12|13|15 13|15 12|13|15 4 20 24 23 24 20 29 29 29 29 24 31 29 20	ACTIVATOR
17258485	CHEMICAL	GENE	T9	T32	True	0	What is [Drugprot] between @CHEMICALSrc$ ASC @/CHEMICALSrc$ and @GENETgt$ protein kinase C @/GENETgt$ ? [SEP] Phorbol 12-myristate 13 acetate ( PMA ) , the phorbol ester activator of @GENETgt$ protein kinase C @/GENETgt$ , caused a 37 % decrease in the I(SC ) response to @CHEMICALSrc$ ASC @/CHEMICALSrc$ .	4 4 4 19 6 4 6 4 12 12 12 4 14 12|13|14 12|13|14 12|13|14 12|14 12|13|14 4 19 23 22 23 19 28 28 28 28 23 30 26|28 28 26|28 19	None-BC7
17258485	CHEMICAL	GENE	T10	T34	True	0	What is [Drugprot] between @CHEMICALSrc$ vitamin C @/CHEMICALSrc$ and @GENETgt$ SVCT1 @/GENETgt$ ? [SEP] Chicken-specific primers to an EST homolog of the human @CHEMICALSrc$ vitamin C @/CHEMICALSrc$ transporter @GENETgt$ SVCT1 @/GENETgt$ ( SLC23A1 ) were designed and used to probe transporter expression in these cells .	2 20 6 6 6 2 14 14 14 9|14 9|14 14 9|14 14 11|6 6 11|6 17 14 17 20 20 20 20 26 26 26 22 29 29 22 20	None-BC7
17258485	CHEMICAL	GENE	T11	T38	True	0	What is [Drugprot] between @CHEMICALSrc$ sodium @/CHEMICALSrc$ and @GENETgt$ SVCT1 @/GENETgt$ ? [SEP] These data indicate the presence of an electrogenic , @CHEMICALSrc$ sodium-dependent @/CHEMICALSrc$ vitamin C transporter ( @GENETgt$ SVCT1 @/GENETgt$ ) in the chick renal proximal tubule .	2 3 3 5 3 14 14 14 14 9|14 14 9|14 14 14 5 16 14 14 14 16 24 24 24 24 24 5 3	None-BC7
17258485	CHEMICAL	GENE	T24	T30	True	0	What is [Drugprot] between @CHEMICALSrc$ Na(+) @/CHEMICALSrc$ and @GENETgt$ sodium-proton exchangers @/GENETgt$ ? [SEP] The I(SC ) response to ASC was completely eliminated with @CHEMICALSrc$ Na(+ ) @/CHEMICALSrc$ ion replacement , and was also eliminated by bilateral reduction of bath Cl(- ) , from 137 to 2.6 mM. There was significant inhibition of the I(SC ) responses to 30 microM ASC by the flavanoid quercetin ( 50 microM ) and by 100 microM 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid ( DIDS ) and 5-ethylisopropylamiloride ( EIPA ) , blockers of anion exchangers and @GENETgt$ sodium-proton exchangers @/GENETgt$ , respectively .	4 4 4 9 6 4 9 9 9 15 10|15 10|15 15 10|15 15 9 9 9 20 20 9 23 23 20 26 26 23 26 9 33 32 32 33 9 35 9 37 35 42 42 42 42 37 46 45 46 42 50 50 50 37 53 53 50 53 50 60 60 60 60 50 62 60 62 60 60 67 65 67 50 50 73 73 70 73 72|73|75 72|73|75 73|75 72|73|75 35 35 9	None-BC7
17258485	CHEMICAL	GENE	T1	T29	True	0	What is [Drugprot] between @CHEMICALSrc$ EIPA @/CHEMICALSrc$ and @GENETgt$ anion exchangers @/GENETgt$ ? [SEP] The I(SC ) response to ASC was completely eliminated with Na(+ ) ion replacement , and was also eliminated by bilateral reduction of bath Cl(- ) , from 137 to 2.6 mM. There was significant inhibition of the I(SC ) responses to 30 microM ASC by the flavanoid quercetin ( 50 microM ) and by 100 microM 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid ( DIDS ) and 5-ethylisopropylamiloride ( @CHEMICALSrc$ EIPA @/CHEMICALSrc$ ) , blockers of @GENETgt$ anion exchangers @/GENETgt$ and sodium-proton exchangers , respectively .	4 4 4 9 6 4 9 9 9 14 14 14 14 9 9 9 19 19 9 22 22 19 25 25 22 25 9 32 31 31 32 9 34 9 36 34 41 41 41 41 36 45 44 45 41 49 49 49 36 52 52 49 52 49 59 59 59 59 49 61 59 61 59 59 66 64|65 64 64|65 66 49 49 72 72|70 72|70 72|70 72|70 72 77 72 34 34 9	None-BC7
17258485	CHEMICAL	GENE	T25	T30	True	0	What is [Drugprot] between @CHEMICALSrc$ 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid @/CHEMICALSrc$ and @GENETgt$ sodium-proton exchangers @/GENETgt$ ? [SEP] The I(SC ) response to ASC was completely eliminated with Na(+ ) ion replacement , and was also eliminated by bilateral reduction of bath Cl(- ) , from 137 to 2.6 mM. There was significant inhibition of the I(SC ) responses to 30 microM ASC by the flavanoid quercetin ( 50 microM ) and by 100 microM @CHEMICALSrc$ 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid @/CHEMICALSrc$ ( DIDS ) and 5-ethylisopropylamiloride ( EIPA ) , blockers of anion exchangers and @GENETgt$ sodium-proton exchangers @/GENETgt$ , respectively .	4 4 4 9 6 4 9 9 9 14 14 14 14 9 9 9 19 19 9 22 22 19 25 25 22 25 9 32 31 31 32 9 34 9 36 34 41 41 41 41 36 45 44 45 41 49 49 49 36 52 52 49 52 49 58 58 58 57|58|49 57|58|49 49|58 57|58|49 62 58 62 58 58 67 65 67 49 49 73 73 70 73 72|73|75 72|73|75 73|75 72|73|75 34 34 9	None-BC7
17258485	CHEMICAL	GENE	T25	T29	True	0	What is [Drugprot] between @CHEMICALSrc$ 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid @/CHEMICALSrc$ and @GENETgt$ anion exchangers @/GENETgt$ ? [SEP] The I(SC ) response to ASC was completely eliminated with Na(+ ) ion replacement , and was also eliminated by bilateral reduction of bath Cl(- ) , from 137 to 2.6 mM. There was significant inhibition of the I(SC ) responses to 30 microM ASC by the flavanoid quercetin ( 50 microM ) and by 100 microM @CHEMICALSrc$ 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid @/CHEMICALSrc$ ( DIDS ) and 5-ethylisopropylamiloride ( EIPA ) , blockers of @GENETgt$ anion exchangers @/GENETgt$ and sodium-proton exchangers , respectively .	4 4 4 9 6 4 9 9 9 14 14 14 14 9 9 9 19 19 9 22 22 19 25 25 22 25 9 32 31 31 32 9 34 9 36 34 41 41 41 41 36 45 44 45 41 49 49 49 36 52 52 49 52 49 58 58 58 57|58|49 57|58|49 49|58 57|58|49 62 58 62 58 58 67 65 67 49 49 72 72|69|70 72|69|70 72|70 72|69|70 72 77 72 34 34 9	INHIBITOR
17258485	CHEMICAL	GENE	T24	T29	True	0	What is [Drugprot] between @CHEMICALSrc$ Na(+) @/CHEMICALSrc$ and @GENETgt$ anion exchangers @/GENETgt$ ? [SEP] The I(SC ) response to ASC was completely eliminated with @CHEMICALSrc$ Na(+ ) @/CHEMICALSrc$ ion replacement , and was also eliminated by bilateral reduction of bath Cl(- ) , from 137 to 2.6 mM. There was significant inhibition of the I(SC ) responses to 30 microM ASC by the flavanoid quercetin ( 50 microM ) and by 100 microM 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid ( DIDS ) and 5-ethylisopropylamiloride ( EIPA ) , blockers of @GENETgt$ anion exchangers @/GENETgt$ and sodium-proton exchangers , respectively .	4 4 4 9 6 4 9 9 9 15 10|15 10|15 15 10|15 15 9 9 9 20 20 9 23 23 20 26 26 23 26 9 33 32 32 33 9 35 9 37 35 42 42 42 42 37 46 45 46 42 50 50 50 37 53 53 50 53 50 60 60 60 60 50 62 60 62 60 60 67 65 67 50 50 72 72|69|70 72|69|70 72|70 72|69|70 72 77 72 35 35 9	None-BC7
17258485	CHEMICAL	GENE	T2	T29	True	0	What is [Drugprot] between @CHEMICALSrc$ sodium @/CHEMICALSrc$ and @GENETgt$ anion exchangers @/GENETgt$ ? [SEP] The I(SC ) response to ASC was completely eliminated with Na(+ ) ion replacement , and was also eliminated by bilateral reduction of bath Cl(- ) , from 137 to 2.6 mM. There was significant inhibition of the I(SC ) responses to 30 microM ASC by the flavanoid quercetin ( 50 microM ) and by 100 microM 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid ( DIDS ) and 5-ethylisopropylamiloride ( EIPA ) , blockers of @GENETgt$ anion exchangers @/GENETgt$ and @CHEMICALSrc$ sodium-proton @/CHEMICALSrc$ exchangers , respectively .	4 4 4 9 6 4 9 9 9 14 14 14 14 9 9 9 19 19 9 22 22 19 25 25 22 25 9 32 31 31 32 9 34 9 36 34 41 41 41 41 36 45 44 45 41 49 49 49 36 52 52 49 52 49 59 59 59 59 49 61 59 61 59 59 66 64 66 49 49 71 69|70|71 69|70|71 69|71 69|70|71 71 72|77 77 72|77 71 34 34 9	None-BC7
17258485	CHEMICAL	GENE	T5	T31	True	0	What is [Drugprot] between @CHEMICALSrc$ NPPB @/CHEMICALSrc$ and @GENETgt$ chloride channel @/GENETgt$ ? [SEP] There was no inhibition , however , by the @GENETgt$ chloride channel @/GENETgt$ blocker 5-nitro-2(3-phenylpropylamino)benzoic acid ( @CHEMICALSrc$ NPPB @/CHEMICALSrc$ ) .	2 2 4 2 2 2 2 15 15 9|15 9|15 15 9|15 15 15 2 17 14|15 15 14|15 17 2	INHIBITOR
17258485	CHEMICAL	GENE	T28	T39	True	0	What is [Drugprot] between @CHEMICALSrc$ Vitamin C @/CHEMICALSrc$ and @GENETgt$ SVCT1 @/GENETgt$ ? [SEP] @CHEMICALSrc$ Vitamin C @/CHEMICALSrc$ transport and @GENETgt$ SVCT1 @/GENETgt$ transporter expression in chick renal proximal tubule cells in culture .	0|4 0|4 4 0|4 9 4 8|3 8 8|3 9 9 15 15 15 15 15 9 17 9 9	None-BC7
17258485	CHEMICAL	GENE	T27	T30	True	0	What is [Drugprot] between @CHEMICALSrc$ 5-ethylisopropylamiloride @/CHEMICALSrc$ and @GENETgt$ sodium-proton exchangers @/GENETgt$ ? [SEP] The I(SC ) response to ASC was completely eliminated with Na(+ ) ion replacement , and was also eliminated by bilateral reduction of bath Cl(- ) , from 137 to 2.6 mM. There was significant inhibition of the I(SC ) responses to 30 microM ASC by the flavanoid quercetin ( 50 microM ) and by 100 microM 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid ( DIDS ) and @CHEMICALSrc$ 5-ethylisopropylamiloride @/CHEMICALSrc$ ( EIPA ) , blockers of anion exchangers and @GENETgt$ sodium-proton exchangers @/GENETgt$ , respectively .	4 4 4 9 6 4 9 9 9 14 14 14 14 9 9 9 19 19 9 22 22 19 25 25 22 25 9 32 31 31 32 9 34 9 36 34 41 41 41 41 36 45 44 45 41 49 49 49 36 52 52 49 52 49 59 59 59 59 49 61 59 61 59 59|63 59 59|63 67 64 67 49 49 73 73 70 73 73|75 73|75 73|75 73|75 34 34 9	INHIBITOR
17258485	CHEMICAL	GENE	T1	T30	True	0	What is [Drugprot] between @CHEMICALSrc$ EIPA @/CHEMICALSrc$ and @GENETgt$ sodium-proton exchangers @/GENETgt$ ? [SEP] The I(SC ) response to ASC was completely eliminated with Na(+ ) ion replacement , and was also eliminated by bilateral reduction of bath Cl(- ) , from 137 to 2.6 mM. There was significant inhibition of the I(SC ) responses to 30 microM ASC by the flavanoid quercetin ( 50 microM ) and by 100 microM 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid ( DIDS ) and 5-ethylisopropylamiloride ( @CHEMICALSrc$ EIPA @/CHEMICALSrc$ ) , blockers of anion exchangers and @GENETgt$ sodium-proton exchangers @/GENETgt$ , respectively .	4 4 4 9 6 4 9 9 9 14 14 14 14 9 9 9 19 19 9 22 22 19 25 25 22 25 9 32 31 31 32 9 34 9 36 34 41 41 41 41 36 45 44 45 41 49 49 49 36 52 52 49 52 49 59 59 59 59 49 61 59 61 59 59 66 64|65 64 64|65 66 49 49 73 73 70 73 73|75 73|75 73|75 73|75 34 34 9	INHIBITOR
17258485	CHEMICAL	GENE	T23	T29	True	0	What is [Drugprot] between @CHEMICALSrc$ ASC @/CHEMICALSrc$ and @GENETgt$ anion exchangers @/GENETgt$ ? [SEP] The I(SC ) response to @CHEMICALSrc$ ASC @/CHEMICALSrc$ was completely eliminated with Na(+ ) ion replacement , and was also eliminated by bilateral reduction of bath Cl(- ) , from 137 to 2.6 mM. There was significant inhibition of the I(SC ) responses to 30 microM ASC by the flavanoid quercetin ( 50 microM ) and by 100 microM 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid ( DIDS ) and 5-ethylisopropylamiloride ( EIPA ) , blockers of @GENETgt$ anion exchangers @/GENETgt$ and sodium-proton exchangers , respectively .	4 4 4 10 6 4|5 4 4|5 10 10 10 15 15 15 15 10 10 10 20 20 10 23 23 20 26 26 23 26 10 33 32 32 33 10 35 10 37 35 42 42 42 42 37 46 45 46 42 50 50 50 37 53 53 50 53 50 60 60 60 60 50 62 60 62 60 60 67 65 67 50 50 72 72|70 72|70 72|70 72|70 72 77 72 35 35 10	None-BC7
17258485	CHEMICAL	GENE	T7	T32	True	0	What is [Drugprot] between @CHEMICALSrc$ PMA @/CHEMICALSrc$ and @GENETgt$ protein kinase C @/GENETgt$ ? [SEP] Phorbol 12-myristate 13 acetate ( @CHEMICALSrc$ PMA @/CHEMICALSrc$ ) , the phorbol ester activator of @GENETgt$ protein kinase C @/GENETgt$ , caused a 37 % decrease in the I(SC ) response to ASC .	4 4 4 20 6 4|5 4 4|5 6 4 13 13 13 4 15 13|15 13|15 13|15 13|15 13|15 4 20 24 23 24 20 29 29 29 29 24 31 29 20	ACTIVATOR
17258485	CHEMICAL	GENE	T11	T37	True	0	What is [Drugprot] between @CHEMICALSrc$ sodium @/CHEMICALSrc$ and @GENETgt$ vitamin C transporter @/GENETgt$ ? [SEP] These data indicate the presence of an electrogenic , @CHEMICALSrc$ sodium-dependent @/CHEMICALSrc$ @GENETgt$ vitamin C transporter @/GENETgt$ ( SVCT1 ) in the chick renal proximal tubule .	2 3 3 5 3 12 12 12 12 9|12 12 9|12 10|12|5 10|12|5 10|12|5 12|5 10|12|5 17 12 17 24 24 24 24 24 5 3	None-BC7
17258485	CHEMICAL	GENE	T10	T35	True	0	What is [Drugprot] between @CHEMICALSrc$ vitamin C @/CHEMICALSrc$ and @GENETgt$ SLC23A1 @/GENETgt$ ? [SEP] Chicken-specific primers to an EST homolog of the human @CHEMICALSrc$ vitamin C @/CHEMICALSrc$ transporter SVCT1 ( @GENETgt$ SLC23A1 @/GENETgt$ ) were designed and used to probe transporter expression in these cells .	2 20 6 6 6 2 14 14 14 9|14 9|14 14 9|14 14 6 16 13|14 14 13|14 16 20 20 20 20 26 26 26 22 29 29 22 20	None-BC7
17258485	CHEMICAL	GENE	T10	T33	True	0	What is [Drugprot] between @CHEMICALSrc$ vitamin C @/CHEMICALSrc$ and @GENETgt$ human vitamin C transporter @/GENETgt$ ? [SEP] Chicken-specific primers to an EST homolog of the @GENETgt$ human @/GENETgt$ @CHEMICALSrc$ vitamin C transporter @/CHEMICALSrc$ SVCT1 ( SLC23A1 ) were designed and used to probe transporter expression in these cells .	2 20 6 6 6 2 15 15 8|15 15 8|15 9|15 9|15 9|15 15 9|15 6 17 15 17 20 20 20 20 26 26 26 22 29 29 22 20	None-BC7
17258485	CHEMICAL	GENE	T26	T29	True	0	What is [Drugprot] between @CHEMICALSrc$ DIDS @/CHEMICALSrc$ and @GENETgt$ anion exchangers @/GENETgt$ ? [SEP] The I(SC ) response to ASC was completely eliminated with Na(+ ) ion replacement , and was also eliminated by bilateral reduction of bath Cl(- ) , from 137 to 2.6 mM. There was significant inhibition of the I(SC ) responses to 30 microM ASC by the flavanoid quercetin ( 50 microM ) and by 100 microM 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid ( @CHEMICALSrc$ DIDS @/CHEMICALSrc$ ) and 5-ethylisopropylamiloride ( EIPA ) , blockers of @GENETgt$ anion exchangers @/GENETgt$ and sodium-proton exchangers , respectively .	4 4 4 9 6 4 9 9 9 14 14 14 14 9 9 9 19 19 9 22 22 19 25 25 22 25 9 32 31 31 32 9 34 9 36 34 41 41 41 41 36 45 44 45 41 49 49 49 36 52 52 49 52 49 59 59 59 59 49 61 59|60 59 59|60 61 59 59 67 65 67 49 49 72 72|70 72|70 72|70 72|70 72 77 72 34 34 9	INHIBITOR
17258485	CHEMICAL	GENE	T6	T32	True	0	What is [Drugprot] between @CHEMICALSrc$ Phorbol 12-myristate 13 acetate @/CHEMICALSrc$ and @GENETgt$ protein kinase C @/GENETgt$ ? [SEP] @CHEMICALSrc$ Phorbol 12-myristate 13 acetate @/CHEMICALSrc$ ( PMA ) , the phorbol ester activator of @GENETgt$ protein kinase C @/GENETgt$ , caused a 37 % decrease in the I(SC ) response to ASC .	0|1|20 0|1|20 0|1|20 0|1|20 1|20 0|1|20 7 1 7 1 13 13 13 1 15 10|13|15 10|13|15 10|13|15 13|15 10|13|15 1 20 24 23 24 20 29 29 29 29 24 31 29 20	ACTIVATOR
17258485	CHEMICAL	GENE	T4	T31	True	0	What is [Drugprot] between @CHEMICALSrc$ 5-nitro-2(3-phenylpropylamino)benzoic acid @/CHEMICALSrc$ and @GENETgt$ chloride channel @/GENETgt$ ? [SEP] There was no inhibition , however , by the @GENETgt$ chloride channel @/GENETgt$ blocker @CHEMICALSrc$ 5-nitro-2(3-phenylpropylamino)benzoic acid @/CHEMICALSrc$ ( NPPB ) .	2 2 4 2 2 2 2 14 14 9|14 9|14 14 9|14 14 2|11|14 2|11|14 2|14 2|11|14 18 14 18 2	INHIBITOR
17258485	CHEMICAL	GENE	T27	T29	True	0	What is [Drugprot] between @CHEMICALSrc$ 5-ethylisopropylamiloride @/CHEMICALSrc$ and @GENETgt$ anion exchangers @/GENETgt$ ? [SEP] The I(SC ) response to ASC was completely eliminated with Na(+ ) ion replacement , and was also eliminated by bilateral reduction of bath Cl(- ) , from 137 to 2.6 mM. There was significant inhibition of the I(SC ) responses to 30 microM ASC by the flavanoid quercetin ( 50 microM ) and by 100 microM 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid ( DIDS ) and @CHEMICALSrc$ 5-ethylisopropylamiloride @/CHEMICALSrc$ ( EIPA ) , blockers of @GENETgt$ anion exchangers @/GENETgt$ and sodium-proton exchangers , respectively .	4 4 4 9 6 4 9 9 9 14 14 14 14 9 9 9 19 19 9 22 22 19 25 25 22 25 9 32 31 31 32 9 34 9 36 34 41 41 41 41 36 45 44 45 41 49 49 49 36 52 52 49 52 49 59 59 59 59 49 61 59 61 59 59|63 59 59|63 67 64 67 49 49 72 72|70 72|70 72|70 72|70 72 77 72 34 34 9	None-BC7
17258485	CHEMICAL	GENE	T12	T38	True	0	What is [Drugprot] between @CHEMICALSrc$ vitamin C @/CHEMICALSrc$ and @GENETgt$ SVCT1 @/GENETgt$ ? [SEP] These data indicate the presence of an electrogenic , sodium-dependent @CHEMICALSrc$ vitamin C @/CHEMICALSrc$ transporter ( @GENETgt$ SVCT1 @/GENETgt$ ) in the chick renal proximal tubule .	2 3 3 5 3 14 14 14 14 14 10|14 10|14 14 10|14 5 16 13|14 14 13|14 16 24 24 24 24 24 5 3	None-BC7
17258485	CHEMICAL	GENE	T23	T30	True	0	What is [Drugprot] between @CHEMICALSrc$ ASC @/CHEMICALSrc$ and @GENETgt$ sodium-proton exchangers @/GENETgt$ ? [SEP] The I(SC ) response to @CHEMICALSrc$ ASC @/CHEMICALSrc$ was completely eliminated with Na(+ ) ion replacement , and was also eliminated by bilateral reduction of bath Cl(- ) , from 137 to 2.6 mM. There was significant inhibition of the I(SC ) responses to 30 microM ASC by the flavanoid quercetin ( 50 microM ) and by 100 microM 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid ( DIDS ) and 5-ethylisopropylamiloride ( EIPA ) , blockers of anion exchangers and @GENETgt$ sodium-proton exchangers @/GENETgt$ , respectively .	4 4 4 10 6 4|5 4 4|5 10 10 10 15 15 15 15 10 10 10 20 20 10 23 23 20 26 26 23 26 10 33 32 32 33 10 35 10 37 35 42 42 42 42 37 46 45 46 42 50 50 50 37 53 53 50 53 50 60 60 60 60 50 62 60 62 60 60 67 65 67 50 50 73 73 70 73 73|75 73|75 73|75 73|75 35 35 10	None-BC7
17258485	CHEMICAL	GENE	T26	T30	True	0	What is [Drugprot] between @CHEMICALSrc$ DIDS @/CHEMICALSrc$ and @GENETgt$ sodium-proton exchangers @/GENETgt$ ? [SEP] The I(SC ) response to ASC was completely eliminated with Na(+ ) ion replacement , and was also eliminated by bilateral reduction of bath Cl(- ) , from 137 to 2.6 mM. There was significant inhibition of the I(SC ) responses to 30 microM ASC by the flavanoid quercetin ( 50 microM ) and by 100 microM 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid ( @CHEMICALSrc$ DIDS @/CHEMICALSrc$ ) and 5-ethylisopropylamiloride ( EIPA ) , blockers of anion exchangers and @GENETgt$ sodium-proton exchangers @/GENETgt$ , respectively .	4 4 4 9 6 4 9 9 9 14 14 14 14 9 9 9 19 19 9 22 22 19 25 25 22 25 9 32 31 31 32 9 34 9 36 34 41 41 41 41 36 45 44 45 41 49 49 49 36 52 52 49 52 49 59 59 59 59 49 61 59|60 59 59|60 61 59 59 67 65 67 49 49 73 73 70 73 73|75 73|75 73|75 73|75 34 34 9	None-BC7
23152189	CHEMICAL	GENE	T8	T30	True	0	What is [Drugprot] between @CHEMICALSrc$ TCDD @/CHEMICALSrc$ and @GENETgt$ Aryl hydrocarbon receptor @/GENETgt$ ? [SEP] @GENETgt$ Aryl hydrocarbon receptor @/GENETgt$ ( AHR ) antagonists blocked the response of many transcripts to @CHEMICALSrc$ TCDD @/CHEMICALSrc$ , and the endpoints of decreased ATP production and differentiation , suggesting regulation by the AHR .	0|1|8 0|1|8 0|1|8 8|1 0|1|8 6 1 6 9 9 11 9 14 14 11 16 11|12 11 11|12 9 9 21 9 25 25 25 21 25 25 9 9 29 33 33 30 9	None-BC7
23152189	CHEMICAL	GENE	T4	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ ATP @/CHEMICALSrc$ and @GENETgt$ glutathione (GSH) reductase @/GENETgt$ ? [SEP] Mitochondrial @GENETgt$ glutathione ( GSH ) reductase @/GENETgt$ activity and the GSH/glutathione disulfide ratio were decreased by TCDD , ultimately leading to mitochondrial dysfunction , characterized by decreased inner mitochondrial membrane potential and @CHEMICALSrc$ ATP @/CHEMICALSrc$ production , and increased production of the reactive oxygen species ( ROS ) , hydrogen peroxide .	8 8|1 8|1 8|1 8|1 8|1 8 8|1 15 8 13 13 13 8 15 15 17 15 15 20 15 23 23 20 23 23 31 31 31 31 31 25 31 35|27 35 35|27 31 15 15 15 38 44 44 44 44 39 46 44 46 44 50 44 15	None-BC7
23152189	CHEMICAL	GENE	T1	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ GSH @/CHEMICALSrc$ and @GENETgt$ glutathione (GSH) reductase @/GENETgt$ ? [SEP] Mitochondrial @GENETgt$ glutathione ( GSH ) reductase @/GENETgt$ activity and the @CHEMICALSrc$ GSH/glutathione @/CHEMICALSrc$ disulfide ratio were decreased by TCDD , ultimately leading to mitochondrial dysfunction , characterized by decreased inner mitochondrial membrane potential and ATP production , and increased production of the reactive oxygen species ( ROS ) , hydrogen peroxide .	8 8|1 8|1 8|1 8|1 8|1 8 8|1 16 8 14 5|14 14 5|14 14 8 16 16 18 16 16 21 16 24 24 21 24 24 32 32 32 32 32 26 32 35 32 16 16 16 38 44 44 44 44 39 46 44 46 44 50 44 16	None-BC7
23152189	CHEMICAL	GENE	T8	T32	True	0	What is [Drugprot] between @CHEMICALSrc$ TCDD @/CHEMICALSrc$ and @GENETgt$ AHR @/GENETgt$ ? [SEP] Aryl hydrocarbon receptor ( AHR ) antagonists blocked the response of many transcripts to @CHEMICALSrc$ TCDD @/CHEMICALSrc$ , and the endpoints of decreased ATP production and differentiation , suggesting regulation by the @GENETgt$ AHR @/GENETgt$ .	3 3 7 5 3 5 8 8 10 8 13 13 10 15 10|14 10 10|14 8 8 20 8 24 24 24 20 24 24 8 8 28 32 32 29|30 29 29|30 8	None-BC7
23152189	CHEMICAL	GENE	T20	T35	True	0	What is [Drugprot] between @CHEMICALSrc$ TCDD @/CHEMICALSrc$ and @GENETgt$ SLC2A1 @/GENETgt$ ? [SEP] @CHEMICALSrc$ TCDD @/CHEMICALSrc$ decreased the expression of the glucose transporter , @GENETgt$ SLC2A1 @/GENETgt$ , and most of the glycolytic transcripts , followed by decreases in glycolytic intermediates , including pyruvate .	0|3 3 0|3 3 5 3 9 9 9 5 9 9 9 9 9 9 9 19 19 19 15 3 3 23 21 26 26 23 26 29 26 3	INDIRECT-DOWNREGULATOR
23152189	CHEMICAL	GENE	T22	T35	True	0	What is [Drugprot] between @CHEMICALSrc$ pyruvate @/CHEMICALSrc$ and @GENETgt$ SLC2A1 @/GENETgt$ ? [SEP] TCDD decreased the expression of the glucose transporter , @GENETgt$ SLC2A1 @/GENETgt$ , and most of the glycolytic transcripts , followed by decreases in glycolytic intermediates , including @CHEMICALSrc$ pyruvate @/CHEMICALSrc$ .	2 2 4 2 8 8 8 4 8 8|9 8 8|9 8 8 8 18 18 18 14 2 2 22 20 25 25 22 25 28 25|26 25 25|26 2	None-BC7
23152189	CHEMICAL	GENE	T6	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ hydrogen peroxide @/CHEMICALSrc$ and @GENETgt$ glutathione (GSH) reductase @/GENETgt$ ? [SEP] Mitochondrial @GENETgt$ glutathione ( GSH ) reductase @/GENETgt$ activity and the GSH/glutathione disulfide ratio were decreased by TCDD , ultimately leading to mitochondrial dysfunction , characterized by decreased inner mitochondrial membrane potential and ATP production , and increased production of the reactive oxygen species ( ROS ) , @CHEMICALSrc$ hydrogen peroxide @/CHEMICALSrc$ .	8 8|1 8|1 8|1 8|1 8|1 8 8|1 15 8 13 13 13 8 15 15 17 15 15 20 15 23 23 20 23 23 31 31 31 31 31 25 31 34 31 15 15 15 37 43 43 43 43 38 45 43 45 43 48|42|43 48|42|43 48|43 48|42|43 15	None-BC7
23152189	CHEMICAL	GENE	T9	T32	True	0	What is [Drugprot] between @CHEMICALSrc$ ATP @/CHEMICALSrc$ and @GENETgt$ AHR @/GENETgt$ ? [SEP] Aryl hydrocarbon receptor ( AHR ) antagonists blocked the response of many transcripts to TCDD , and the endpoints of decreased @CHEMICALSrc$ ATP @/CHEMICALSrc$ production and differentiation , suggesting regulation by the @GENETgt$ AHR @/GENETgt$ .	3 3 7 5 3 5 8 8 10 8 13 13 10 15 10 8 8 19 8 24 24 24|21 24 24|21 19 24 24 8 8 28 32 32 29|30 29 29|30 8	None-BC7
23152189	CHEMICAL	GENE	T20	T34	True	0	What is [Drugprot] between @CHEMICALSrc$ TCDD @/CHEMICALSrc$ and @GENETgt$ glucose transporter @/GENETgt$ ? [SEP] @CHEMICALSrc$ TCDD @/CHEMICALSrc$ decreased the expression of the @GENETgt$ glucose transporter @/GENETgt$ , SLC2A1 , and most of the glycolytic transcripts , followed by decreases in glycolytic intermediates , including pyruvate .	0|3 3 0|3 3 5 3 8 8 8|5|6 8|5|6 8|5 8|5|6 8 8 8 8 8 19 19 19 15 3 3 23 21 26 26 23 26 29 26 3	INDIRECT-DOWNREGULATOR
23152189	CHEMICAL	GENE	T27	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ GSH @/CHEMICALSrc$ and @GENETgt$ glutathione (GSH) reductase @/GENETgt$ ? [SEP] Mitochondrial @GENETgt$ glutathione ( @/GENETgt$ @CHEMICALSrc$ GSH ) reductase @/CHEMICALSrc$ activity and the GSH/glutathione disulfide ratio were decreased by TCDD , ultimately leading to mitochondrial dysfunction , characterized by decreased inner mitochondrial membrane potential and ATP production , and increased production of the reactive oxygen species ( ROS ) , hydrogen peroxide .	9 1|9 1|9 9 1|9 9|2 9|2 9|2 9 9|2 16 9 14 14 14 9 16 16 18 16 16 21 16 24 24 21 24 24 32 32 32 32 32 26 32 35 32 16 16 16 38 44 44 44 44 39 46 44 46 44 50 44 16	None-BC7
23152189	CHEMICAL	GENE	T5	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ oxygen @/CHEMICALSrc$ and @GENETgt$ glutathione (GSH) reductase @/GENETgt$ ? [SEP] Mitochondrial @GENETgt$ glutathione ( GSH ) reductase @/GENETgt$ activity and the GSH/glutathione disulfide ratio were decreased by TCDD , ultimately leading to mitochondrial dysfunction , characterized by decreased inner mitochondrial membrane potential and ATP production , and increased production of the reactive @CHEMICALSrc$ oxygen @/CHEMICALSrc$ species ( ROS ) , hydrogen peroxide .	8 8|1 8|1 8|1 8|1 8|1 8 8|1 15 8 13 13 13 8 15 15 17 15 15 20 15 23 23 20 23 23 31 31 31 31 31 25 31 34 31 15 15 15 37 44 44 44 36|44 44 36|44 38 46 44 46 44 50 44 15	None-BC7
23152189	CHEMICAL	GENE	T9	T30	True	0	What is [Drugprot] between @CHEMICALSrc$ ATP @/CHEMICALSrc$ and @GENETgt$ Aryl hydrocarbon receptor @/GENETgt$ ? [SEP] @GENETgt$ Aryl hydrocarbon receptor @/GENETgt$ ( AHR ) antagonists blocked the response of many transcripts to TCDD , and the endpoints of decreased @CHEMICALSrc$ ATP @/CHEMICALSrc$ production and differentiation , suggesting regulation by the AHR .	0|1|8 0|1|8 0|1|8 8|1 0|1|8 6 1 6 9 9 11 9 14 14 11 16 11 9 9 20 9 25 25 25|19 25 25|19 20 25 25 9 9 29 33 33 30 9	None-BC7
23152189	CHEMICAL	GENE	T8	T31	True	0	What is [Drugprot] between @CHEMICALSrc$ TCDD @/CHEMICALSrc$ and @GENETgt$ AHR @/GENETgt$ ? [SEP] Aryl hydrocarbon receptor ( @GENETgt$ AHR @/GENETgt$ ) antagonists blocked the response of many transcripts to @CHEMICALSrc$ TCDD @/CHEMICALSrc$ , and the endpoints of decreased ATP production and differentiation , suggesting regulation by the AHR .	3 3 8 5 3|4 3 3|4 5 9 9 11 9 14 14 11 16 11|14 11 11|14 9 9 21 9 25 25 25 21 25 25 9 9 29 33 33 30 9	None-BC7
23152189	CHEMICAL	GENE	T7	T31	True	0	What is [Drugprot] between @CHEMICALSrc$ Aryl hydrocarbon @/CHEMICALSrc$ and @GENETgt$ AHR @/GENETgt$ ? [SEP] @CHEMICALSrc$ Aryl hydrocarbon @/CHEMICALSrc$ receptor ( @GENETgt$ AHR @/GENETgt$ ) antagonists blocked the response of many transcripts to TCDD , and the endpoints of decreased ATP production and differentiation , suggesting regulation by the AHR .	0|4 0|4 4 0|4 9 6 3|4 4 3|4 6 10 10 12 10 15 15 12 17 12 10 10 21 10 25 25 25 21 25 25 10 10 29 33 33 30 10	None-BC7
23152189	CHEMICAL	GENE	T3	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ TCDD @/CHEMICALSrc$ and @GENETgt$ glutathione (GSH) reductase @/GENETgt$ ? [SEP] Mitochondrial @GENETgt$ glutathione ( GSH ) reductase @/GENETgt$ activity and the GSH/glutathione disulfide ratio were decreased by @CHEMICALSrc$ TCDD @/CHEMICALSrc$ , ultimately leading to mitochondrial dysfunction , characterized by decreased inner mitochondrial membrane potential and ATP production , and increased production of the reactive oxygen species ( ROS ) , hydrogen peroxide .	8 8|1 8|1 8|1 8|1 8|1 8 8|1 15 8 13 13 13 8 15 15 17 11|15 15 11|15 15 21 15 24 24 21 24 24 32 32 32 32 32 26 32 35 32 15 15 15 38 44 44 44 44 39 46 44 46 44 50 44 15	INHIBITOR
23152189	CHEMICAL	GENE	T2	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ glutathione disulfide @/CHEMICALSrc$ and @GENETgt$ glutathione (GSH) reductase @/GENETgt$ ? [SEP] Mitochondrial @GENETgt$ glutathione ( GSH ) reductase @/GENETgt$ activity and the @CHEMICALSrc$ GSH/glutathione disulfide @/CHEMICALSrc$ ratio were decreased by TCDD , ultimately leading to mitochondrial dysfunction , characterized by decreased inner mitochondrial membrane potential and ATP production , and increased production of the reactive oxygen species ( ROS ) , hydrogen peroxide .	8 8|1 8|1 8|1 8|1 8|1 8 8|1 16 8 14 5|14 5|14 14 5|14 8 16 16 18 16 16 21 16 24 24 21 24 24 32 32 32 32 32 26 32 35 32 16 16 16 38 44 44 44 44 39 46 44 46 44 50 44 16	None-BC7
23152189	CHEMICAL	GENE	T7	T32	True	0	What is [Drugprot] between @CHEMICALSrc$ Aryl hydrocarbon @/CHEMICALSrc$ and @GENETgt$ AHR @/GENETgt$ ? [SEP] @CHEMICALSrc$ Aryl hydrocarbon @/CHEMICALSrc$ receptor ( AHR ) antagonists blocked the response of many transcripts to TCDD , and the endpoints of decreased ATP production and differentiation , suggesting regulation by the @GENETgt$ AHR @/GENETgt$ .	0|4 0|4 4 0|4 8 6 4 6 9 9 11 9 14 14 11 16 11 9 9 20 9 24 24 24 20 24 24 9 9 28 32 32 29 29 29 9	None-BC7
23152189	CHEMICAL	GENE	T21	T35	True	0	What is [Drugprot] between @CHEMICALSrc$ glucose @/CHEMICALSrc$ and @GENETgt$ SLC2A1 @/GENETgt$ ? [SEP] TCDD decreased the expression of the @CHEMICALSrc$ glucose @/CHEMICALSrc$ transporter , @GENETgt$ SLC2A1 @/GENETgt$ , and most of the glycolytic transcripts , followed by decreases in glycolytic intermediates , including pyruvate .	2 2 4 2 9 9 9|6 9 9|6 4 9 9 9 9 9 9 9 19 19 19 15 2 2 23 21 26 26 23 26 29 26 2	None-BC7
23152189	CHEMICAL	GENE	T10	T33	True	0	What is [Drugprot] between @CHEMICALSrc$ TCDD @/CHEMICALSrc$ and @GENETgt$ catalase @/GENETgt$ ? [SEP] Cotreatment of cells with chemical antioxidants or the enzyme @GENETgt$ catalase @/GENETgt$ blocked the @CHEMICALSrc$ TCDD-mediated @/CHEMICALSrc$ acceleration of keratinocyte cornified envelope formation , an endpoint of terminal differentiation .	12 3 1 6 6 1 6 10 10 9|6 6 9|6 12 16 16|12 16 16|12 12 21 21 21 21 16 16 24 16 27 27 24 12	None-BC7
23152189	CHEMICAL	GENE	T9	T31	True	0	What is [Drugprot] between @CHEMICALSrc$ ATP @/CHEMICALSrc$ and @GENETgt$ AHR @/GENETgt$ ? [SEP] Aryl hydrocarbon receptor ( @GENETgt$ AHR @/GENETgt$ ) antagonists blocked the response of many transcripts to TCDD , and the endpoints of decreased @CHEMICALSrc$ ATP @/CHEMICALSrc$ production and differentiation , suggesting regulation by the AHR .	3 3 8 5 3|4 3 3|4 5 9 9 11 9 14 14 11 16 11 9 9 20 9 25 25 25|21 25 25|21 20 25 25 9 9 29 33 33 30 9	None-BC7
23152189	CHEMICAL	GENE	T22	T34	True	0	What is [Drugprot] between @CHEMICALSrc$ pyruvate @/CHEMICALSrc$ and @GENETgt$ glucose transporter @/GENETgt$ ? [SEP] TCDD decreased the expression of the @GENETgt$ glucose transporter @/GENETgt$ , SLC2A1 , and most of the glycolytic transcripts , followed by decreases in glycolytic intermediates , including @CHEMICALSrc$ pyruvate @/CHEMICALSrc$ .	2 2 4 2 7 7 4|6|7 4|6|7 4|7 4|6|7 7 7 7 7 7 18 18 18 14 2 2 22 20 25 25 22 25 28 25 25 25 2	None-BC7
11607047	CHEMICAL	GENE	T12	T21	True	0	What is [Drugprot] between @CHEMICALSrc$ norepinephrine @/CHEMICALSrc$ and @GENETgt$ 5-HT1A @/GENETgt$ ? [SEP] It enhances , therefore , the release of @CHEMICALSrc$ norepinephrine @/CHEMICALSrc$ and @GENETgt$ 5-HT1A-mediated @/GENETgt$ serotonergic transmission .	2 2 2 2 2 7 2 9 8|7 7 8|7 9 10|15 15 10|15 15 9 2	None-BC7
12512695	CHEMICAL	GENE	T5	T21	True	0	What is [Drugprot] between @CHEMICALSrc$ MF-tricyclic @/CHEMICALSrc$ and @GENETgt$ COX @/GENETgt$ ? [SEP] Neither non-selective @GENETgt$ COX @/GENETgt$ inhibitor sulindac nor COX-2 selective @CHEMICALSrc$ MF-tricyclic @/CHEMICALSrc$ were capable of preventing Ang II-induced hypertension or endothelial dysfunction in mREN2 rats , whereas ATi receptor antagonist losartan completely normalized blood pressure , vascular relaxation responses as well as urinary NOx excretion .	6 6 2|6 6 2|6 6 13 6 10 10 8|6 6 8|6 13 13 15 13 17 18 15 18 21 18 24 24 18 13 13 30 30 30 32 32 13 34 32 34 38 38 34 38 39 39 44 44 38 13	None-BC7
12512695	CHEMICAL	GENE	T14	T39	True	0	What is [Drugprot] between @CHEMICALSrc$ 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl) phenyl)-2(5H)-furanone @/CHEMICALSrc$ and @GENETgt$ COX-2 @/GENETgt$ ? [SEP] Five-to-six-week-old , heterozygous mREN2 rats received the following drug regimens for 8 weeks : 1 ) vehicle , 2 ) cyclo-oxygenase-2 ( COX-2 ) inhibitor ( MF-tricyclic [ @CHEMICALSrc$ 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl ) phenyl)-2(5H)-furanone @/CHEMICALSrc$ ] , 14 mg/kg p.o . ) , 3 ) @GENETgt$ COX-1/COX-2 @/GENETgt$ inhibitor ( sulindac , 14 mg/kg p.o . ) , 4 ) angiotensin II receptor antagonist ( losartan 40 mg/kg p.o . ) .	6 1 5 5 1 6 10 10 10 6 13 13 6 6 17 17 6 17 25 19 25 23 21 23 17 29 29 29 25|28|29 25|28|29 25|28|29 25|29 25|28|29 29 25 37 37 25 17 17 17 45 41 45|39 45 45|39 17 47 45 47 51 51 47 17 17 17 60 55 60 60 60 17 65 65 65 65 60 65 65 6	None-BC7
12512695	CHEMICAL	GENE	T10	T27	True	0	What is [Drugprot] between @CHEMICALSrc$ Ang II @/CHEMICALSrc$ and @GENETgt$ COX @/GENETgt$ ? [SEP] The present study also demonstrated that @GENETgt$ COX @/GENETgt$ does not play a central role in the pathogenesis of @CHEMICALSrc$ Ang II-induced @/CHEMICALSrc$ endothelial dysfunction in mREN2 rats .	3 3 5 5 5 11 11|6 11 11|6 11 11 5 14 14 11 17 17 11 23 17|23 17|23 23 17|23 23 17 26 26 23 5	None-BC7
12512695	CHEMICAL	GENE	T13	T40	True	0	What is [Drugprot] between @CHEMICALSrc$ MF-tricyclic @/CHEMICALSrc$ and @GENETgt$ angiotensin II receptor @/GENETgt$ ? [SEP] Five-to-six-week-old , heterozygous mREN2 rats received the following drug regimens for 8 weeks : 1 ) vehicle , 2 ) cyclo-oxygenase-2 ( COX-2 ) inhibitor ( @CHEMICALSrc$ MF-tricyclic @/CHEMICALSrc$ [ 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl ) phenyl)-2(5H)-furanone ] , 14 mg/kg p.o . ) , 3 ) COX-1/COX-2 inhibitor ( sulindac , 14 mg/kg p.o . ) , 4 ) @GENETgt$ angiotensin II receptor @/GENETgt$ antagonist ( losartan 40 mg/kg p.o . ) .	6 1 5 5 1 6 10 10 10 6 13 13 6 6 17 17 6 17 25 19 25 23 21 23 17 30 26|30 30 26|30 30 25 30 30 30 25 37 37 25 17 17 17 44 41 44 17 46 44 46 50 50 46 17 17 17 60 54 60|54 60|54 60|54 60 60|54 17 65 65 65 65 60 65 65 6	None-BC7
12512695	CHEMICAL	GENE	T7	T21	True	0	What is [Drugprot] between @CHEMICALSrc$ losartan @/CHEMICALSrc$ and @GENETgt$ COX @/GENETgt$ ? [SEP] Neither non-selective @GENETgt$ COX @/GENETgt$ inhibitor sulindac nor COX-2 selective MF-tricyclic were capable of preventing Ang II-induced hypertension or endothelial dysfunction in mREN2 rats , whereas ATi receptor antagonist @CHEMICALSrc$ losartan @/CHEMICALSrc$ completely normalized blood pressure , vascular relaxation responses as well as urinary NOx excretion .	6 6 2|6 6 2|6 6 12 6 10 10 6 12 12 14 12 16 17 14 17 20 17 23 23 17 12 12 29 29 29 32|27 32 32|27 32 12 34 32 34 38 38 34 38 39 39 44 44 38 12	None-BC7
12512695	CHEMICAL	GENE	T15	T37	True	0	What is [Drugprot] between @CHEMICALSrc$ sulindac @/CHEMICALSrc$ and @GENETgt$ COX-2 @/GENETgt$ ? [SEP] Five-to-six-week-old , heterozygous mREN2 rats received the following drug regimens for 8 weeks : 1 ) vehicle , 2 ) cyclo-oxygenase-2 ( @GENETgt$ COX-2 @/GENETgt$ ) inhibitor ( MF-tricyclic [ 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl ) phenyl)-2(5H)-furanone ] , 14 mg/kg p.o . ) , 3 ) COX-1/COX-2 inhibitor ( @CHEMICALSrc$ sulindac @/CHEMICALSrc$ , 14 mg/kg p.o . ) , 4 ) angiotensin II receptor antagonist ( losartan 40 mg/kg p.o . ) .	6 1 5 5 1 6 10 10 10 6 13 13 6 6 17 17 6 17 26 19 26 23 21|22 21 21|22 23 17 30 30 30 26 30 30 30 26 37 37 26 17 17 17 44 41 44 17 46 44 44 44 46 51 51 46 17 17 17 60 55 60 60 60 17 65 65 65 65 60 65 65 6	None-BC7
12512695	CHEMICAL	GENE	T3	T20	True	0	What is [Drugprot] between @CHEMICALSrc$ NO @/CHEMICALSrc$ and @GENETgt$ mREN2 @/GENETgt$ ? [SEP] Urinary NO , excretion , a marker of total body @CHEMICALSrc$ NO @/CHEMICALSrc$ generation , was also decreased in @GENETgt$ mREN2 @/GENETgt$ rats .	2 17 2 2 2 7 2 13 13 13 10|13 13 10|13 7 2 17 17 17 21 17|21 21 17|21 17 17	None-BC7
12512695	CHEMICAL	GENE	T5	T22	True	0	What is [Drugprot] between @CHEMICALSrc$ MF-tricyclic @/CHEMICALSrc$ and @GENETgt$ COX-2 @/GENETgt$ ? [SEP] Neither non-selective COX inhibitor sulindac nor @GENETgt$ COX-2 @/GENETgt$ selective @CHEMICALSrc$ MF-tricyclic @/CHEMICALSrc$ were capable of preventing Ang II-induced hypertension or endothelial dysfunction in mREN2 rats , whereas ATi receptor antagonist losartan completely normalized blood pressure , vascular relaxation responses as well as urinary NOx excretion .	5 5 5 5 13 5 10|6 10 10|6 10 8|5 5 8|5 13 13 15 13 17 18 15 18 21 18 24 24 18 13 13 30 30 30 32 32 13 34 32 34 38 38 34 38 39 39 44 44 38 13	None-BC7
12512695	CHEMICAL	GENE	T6	T21	True	0	What is [Drugprot] between @CHEMICALSrc$ Ang II @/CHEMICALSrc$ and @GENETgt$ COX @/GENETgt$ ? [SEP] Neither non-selective @GENETgt$ COX @/GENETgt$ inhibitor sulindac nor COX-2 selective MF-tricyclic were capable of preventing @CHEMICALSrc$ Ang II-induced @/CHEMICALSrc$ hypertension or endothelial dysfunction in mREN2 rats , whereas ATi receptor antagonist losartan completely normalized blood pressure , vascular relaxation responses as well as urinary NOx excretion .	6 6 2|6 6 2|6 6 12 6 10 10 6 12 12 14 12 18|13|15 18|13|15 18|15 18|13|15 14 18 21 18 24 24 18 12 12 30 30 30 32 32 12 34 32 34 38 38 34 38 39 39 44 44 38 12	None-BC7
12512695	CHEMICAL	GENE	T4	T23	True	0	What is [Drugprot] between @CHEMICALSrc$ sulindac @/CHEMICALSrc$ and @GENETgt$ Ang II @/GENETgt$ ? [SEP] Neither non-selective COX inhibitor @CHEMICALSrc$ sulindac @/CHEMICALSrc$ nor COX-2 selective MF-tricyclic were capable of preventing @GENETgt$ Ang II-induced @/GENETgt$ hypertension or endothelial dysfunction in mREN2 rats , whereas ATi receptor antagonist losartan completely normalized blood pressure , vascular relaxation responses as well as urinary NOx excretion .	5 5 5 5 4|12 12 4|12 5 10 10 5 12 12 14 12 18|13|15 18|13|15 18|15 18|13|15 14 18 21 18 24 24 18 12 12 30 30 30 32 32 12 34 32 34 38 38 34 38 39 39 44 44 38 12	None-BC7
12512695	CHEMICAL	GENE	T17	T18	True	0	What is [Drugprot] between @CHEMICALSrc$ superoxide @/CHEMICALSrc$ and @GENETgt$ Ang II @/GENETgt$ ? [SEP] @GENETgt$ Ang II-induced @/GENETgt$ endothelial dysfunction is associated with perivascular inflammation and increased @CHEMICALSrc$ superoxide @/CHEMICALSrc$ production in the vascular wall .	0|5 0|5 5 0|5 5 7 7 7 10 10 7 7 7 10|15 15 10|15 12 19 19 19 12 7	None-BC7
12512695	CHEMICAL	GENE	T2	T20	True	0	What is [Drugprot] between @CHEMICALSrc$ NO @/CHEMICALSrc$ and @GENETgt$ mREN2 @/GENETgt$ ? [SEP] Urinary @CHEMICALSrc$ NO @/CHEMICALSrc$ , excretion , a marker of total body NO generation , was also decreased in @GENETgt$ mREN2 @/GENETgt$ rats .	2 1|17 17 1|17 2 2 2 8 2 13 13 13 13 8 2 17 17 17 21 17|21 21 17|21 17 17	None-BC7
12512695	CHEMICAL	GENE	T11	T33	True	0	What is [Drugprot] between @CHEMICALSrc$ eicosanoids @/CHEMICALSrc$ and @GENETgt$ mouse renin-2 @/GENETgt$ ? [SEP] The present study examined the role of cyclo-oxygenase (COX)-synthetized @CHEMICALSrc$ eicosanoids @/CHEMICALSrc$ in the pathogenesis of Ang II-induced endothelial dysfunction in transgenic rats harboring @GENETgt$ mouse renin-2 @/GENETgt$ gene ( mREN2 rats ) .	3 3 4 4 6 4 10 10 10 9|6 6 9|6 14 14 6 19 19 19 19 14 22 22 19 22 27|22 27|22 27 27|22 23 30 30 27 30 4	None-BC7
12512695	CHEMICAL	GENE	T14	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl) phenyl)-2(5H)-furanone @/CHEMICALSrc$ and @GENETgt$ cyclo-oxygenase-2 @/GENETgt$ ? [SEP] Five-to-six-week-old , heterozygous mREN2 rats received the following drug regimens for 8 weeks : 1 ) vehicle , 2 ) @GENETgt$ cyclo-oxygenase-2 @/GENETgt$ ( COX-2 ) inhibitor ( MF-tricyclic [ @CHEMICALSrc$ 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl ) phenyl)-2(5H)-furanone @/CHEMICALSrc$ ] , 14 mg/kg p.o . ) , 3 ) COX-1/COX-2 inhibitor ( sulindac , 14 mg/kg p.o . ) , 4 ) angiotensin II receptor antagonist ( losartan 40 mg/kg p.o . ) .	6 1 5 5 1 6 10 10 10 6 13 13 6 6 17 17 6 17 26 19 26|20 26 26|20 24 21 24 17 30 30 30 26|28|30 26|28|30 26|28|30 26|30 26|28|30 30 26 38 38 26 17 17 17 45 42 45 17 47 45 47 51 51 47 17 17 17 60 55 60 60 60 17 65 65 65 65 60 65 65 6	None-BC7
12512695	CHEMICAL	GENE	T16	T38	True	0	What is [Drugprot] between @CHEMICALSrc$ angiotensin II @/CHEMICALSrc$ and @GENETgt$ COX-1 @/GENETgt$ ? [SEP] Five-to-six-week-old , heterozygous mREN2 rats received the following drug regimens for 8 weeks : 1 ) vehicle , 2 ) cyclo-oxygenase-2 ( COX-2 ) inhibitor ( MF-tricyclic [ 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl ) phenyl)-2(5H)-furanone ] , 14 mg/kg p.o . ) , 3 ) @GENETgt$ COX-1/COX-2 @/GENETgt$ inhibitor ( sulindac , 14 mg/kg p.o . ) , 4 ) @CHEMICALSrc$ angiotensin II @/CHEMICALSrc$ receptor antagonist ( losartan 40 mg/kg p.o . ) .	6 1 5 5 1 6 10 10 10 6 13 13 6 6 17 17 6 17 25 19 25 23 21 23 17 29 29 29 25 29 29 29 25 36 36 25 17 17 17 44 40 41|44 44 41|44 17 46 44 46 50 50 46 17 17 17 60 54 60|54 60|54 60 60|54 60 17 65 65 65 65 60 65 65 6	None-BC7
12512695	CHEMICAL	GENE	T15	T35	True	0	What is [Drugprot] between @CHEMICALSrc$ sulindac @/CHEMICALSrc$ and @GENETgt$ mREN2 @/GENETgt$ ? [SEP] Five-to-six-week-old , heterozygous @GENETgt$ mREN2 @/GENETgt$ rats received the following drug regimens for 8 weeks : 1 ) vehicle , 2 ) cyclo-oxygenase-2 ( COX-2 ) inhibitor ( MF-tricyclic [ 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl ) phenyl)-2(5H)-furanone ] , 14 mg/kg p.o . ) , 3 ) COX-1/COX-2 inhibitor ( @CHEMICALSrc$ sulindac @/CHEMICALSrc$ , 14 mg/kg p.o . ) , 4 ) angiotensin II receptor antagonist ( losartan 40 mg/kg p.o . ) .	7 1 6 3|6 6 3|6 1 7 11 11 11 7 14 14 7 7 18 18 7 18 26 20 26 24 22 24 18 30 30 30 26 30 30 30 26 37 37 26 18 18 18 44 41 44 18 46 44 44 44 46 51 51 46 18 18 18 60 55 60 60 60 18 65 65 65 65 60 65 65 7	None-BC7
12512695	CHEMICAL	GENE	T11	T34	True	0	What is [Drugprot] between @CHEMICALSrc$ eicosanoids @/CHEMICALSrc$ and @GENETgt$ mREN2 @/GENETgt$ ? [SEP] The present study examined the role of cyclo-oxygenase (COX)-synthetized @CHEMICALSrc$ eicosanoids @/CHEMICALSrc$ in the pathogenesis of Ang II-induced endothelial dysfunction in transgenic rats harboring mouse renin-2 gene ( @GENETgt$ mREN2 @/GENETgt$ rats ) .	3 3 4 4 6 4 10 10 10 9|6 6 9|6 14 14 6 19 19 19 19 14 22 22 19 22 26 26 23 30 26|30 30 26|30 26 30 4	None-BC7
12512695	CHEMICAL	GENE	T4	T25	True	0	What is [Drugprot] between @CHEMICALSrc$ sulindac @/CHEMICALSrc$ and @GENETgt$ ATi @/GENETgt$ ? [SEP] Neither non-selective COX inhibitor @CHEMICALSrc$ sulindac @/CHEMICALSrc$ nor COX-2 selective MF-tricyclic were capable of preventing Ang II-induced hypertension or endothelial dysfunction in mREN2 rats , whereas @GENETgt$ ATi @/GENETgt$ receptor antagonist losartan completely normalized blood pressure , vascular relaxation responses as well as urinary NOx excretion .	5 5 5 5 4|12 12 4|12 5 10 10 5 12 12 14 12 16 17 14 17 20 17 23 23 17 12 12 24|30 30 24|30 30 30 32 32 12 34 32 34 38 38 34 38 39 39 44 44 38 12	None-BC7
12512695	CHEMICAL	GENE	T11	T32	True	0	What is [Drugprot] between @CHEMICALSrc$ eicosanoids @/CHEMICALSrc$ and @GENETgt$ Ang II @/GENETgt$ ? [SEP] The present study examined the role of cyclo-oxygenase (COX)-synthetized @CHEMICALSrc$ eicosanoids @/CHEMICALSrc$ in the pathogenesis of @GENETgt$ Ang II-induced @/GENETgt$ endothelial dysfunction in transgenic rats harboring mouse renin-2 gene ( mREN2 rats ) .	3 3 4 4 6 4 10 10 10 9|6 6 9|6 14 14 6 20 20|14 20|14 20 20|14 20 14 23 23 20 23 27 27 24 30 30 27 30 4	None-BC7
12512695	CHEMICAL	GENE	T12	T28	True	0	What is [Drugprot] between @CHEMICALSrc$ Ang II @/CHEMICALSrc$ and @GENETgt$ cyclo-oxygenase @/GENETgt$ ? [SEP] The present study examined the role of @GENETgt$ cyclo-oxygenase @/GENETgt$ (COX)-synthetized eicosanoids in the pathogenesis of @CHEMICALSrc$ Ang II-induced @/CHEMICALSrc$ endothelial dysfunction in transgenic rats harboring mouse renin-2 gene ( mREN2 rats ) .	3 3 4 4 6 4 11 11|7 11 11|7 11 6 14 14 6 20 20|14 20|14 20 20|14 20 14 23 23 20 23 27 27 24 30 30 27 30 4	None-BC7
12512695	CHEMICAL	GENE	T6	T24	True	0	What is [Drugprot] between @CHEMICALSrc$ Ang II @/CHEMICALSrc$ and @GENETgt$ mREN2 @/GENETgt$ ? [SEP] Neither non-selective COX inhibitor sulindac nor COX-2 selective MF-tricyclic were capable of preventing @CHEMICALSrc$ Ang II-induced @/CHEMICALSrc$ hypertension or endothelial dysfunction in @GENETgt$ mREN2 @/GENETgt$ rats , whereas ATi receptor antagonist losartan completely normalized blood pressure , vascular relaxation responses as well as urinary NOx excretion .	5 5 5 5 11 5 9 9 5 11 11 13 11 17|13|14 17|13|14 17|14 17|13|14 13 17 20 17 24 24|19 24 24|19 17 11 11 30 30 30 32 32 11 34 32 34 38 38 34 38 39 39 44 44 38 11	None-BC7
12512695	CHEMICAL	GENE	T16	T37	True	0	What is [Drugprot] between @CHEMICALSrc$ angiotensin II @/CHEMICALSrc$ and @GENETgt$ COX-2 @/GENETgt$ ? [SEP] Five-to-six-week-old , heterozygous mREN2 rats received the following drug regimens for 8 weeks : 1 ) vehicle , 2 ) cyclo-oxygenase-2 ( @GENETgt$ COX-2 @/GENETgt$ ) inhibitor ( MF-tricyclic [ 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl ) phenyl)-2(5H)-furanone ] , 14 mg/kg p.o . ) , 3 ) COX-1/COX-2 inhibitor ( sulindac , 14 mg/kg p.o . ) , 4 ) @CHEMICALSrc$ angiotensin II @/CHEMICALSrc$ receptor antagonist ( losartan 40 mg/kg p.o . ) .	6 1 5 5 1 6 10 10 10 6 13 13 6 6 17 17 6 17 26 19 26 23 21|22 21 21|22 23 17 30 30 30 26 30 30 30 26 37 37 26 17 17 17 44 41 44 17 46 44 46 50 50 46 17 17 17 60 54 60|54 60|54 60 60|54 60 17 65 65 65 65 60 65 65 6	None-BC7
12512695	CHEMICAL	GENE	T16	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ angiotensin II @/CHEMICALSrc$ and @GENETgt$ cyclo-oxygenase-2 @/GENETgt$ ? [SEP] Five-to-six-week-old , heterozygous mREN2 rats received the following drug regimens for 8 weeks : 1 ) vehicle , 2 ) @GENETgt$ cyclo-oxygenase-2 @/GENETgt$ ( COX-2 ) inhibitor ( MF-tricyclic [ 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl ) phenyl)-2(5H)-furanone ] , 14 mg/kg p.o . ) , 3 ) COX-1/COX-2 inhibitor ( sulindac , 14 mg/kg p.o . ) , 4 ) @CHEMICALSrc$ angiotensin II @/CHEMICALSrc$ receptor antagonist ( losartan 40 mg/kg p.o . ) .	6 1 5 5 1 6 10 10 10 6 13 13 6 6 17 17 6 17 26 19 26|20 26 26|20 24 21 24 17 30 30 30 26 30 30 30 26 37 37 26 17 17 17 44 41 44 17 46 44 46 50 50 46 17 17 17 60 54 60|54 60|54 60 60|54 60 17 65 65 65 65 60 65 65 6	None-BC7
12512695	CHEMICAL	GENE	T14	T35	True	0	What is [Drugprot] between @CHEMICALSrc$ 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl) phenyl)-2(5H)-furanone @/CHEMICALSrc$ and @GENETgt$ mREN2 @/GENETgt$ ? [SEP] Five-to-six-week-old , heterozygous @GENETgt$ mREN2 @/GENETgt$ rats received the following drug regimens for 8 weeks : 1 ) vehicle , 2 ) cyclo-oxygenase-2 ( COX-2 ) inhibitor ( MF-tricyclic [ @CHEMICALSrc$ 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl ) phenyl)-2(5H)-furanone @/CHEMICALSrc$ ] , 14 mg/kg p.o . ) , 3 ) COX-1/COX-2 inhibitor ( sulindac , 14 mg/kg p.o . ) , 4 ) angiotensin II receptor antagonist ( losartan 40 mg/kg p.o . ) .	7 1 6 3|6 6 3|6 1 7 11 11 11 7 14 14 7 7 18 18 7 18 26 20 26 24 22 24 18 30 30 30 26|28|30 26|28|30 26|28|30 26|30 26|28|30 30 26 38 38 26 18 18 18 45 42 45 18 47 45 47 51 51 47 18 18 18 60 55 60 60 60 18 65 65 65 65 60 65 65 7	None-BC7
12512695	CHEMICAL	GENE	T13	T39	True	0	What is [Drugprot] between @CHEMICALSrc$ MF-tricyclic @/CHEMICALSrc$ and @GENETgt$ COX-2 @/GENETgt$ ? [SEP] Five-to-six-week-old , heterozygous mREN2 rats received the following drug regimens for 8 weeks : 1 ) vehicle , 2 ) cyclo-oxygenase-2 ( COX-2 ) inhibitor ( @CHEMICALSrc$ MF-tricyclic @/CHEMICALSrc$ [ 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl ) phenyl)-2(5H)-furanone ] , 14 mg/kg p.o . ) , 3 ) @GENETgt$ COX-1/COX-2 @/GENETgt$ inhibitor ( sulindac , 14 mg/kg p.o . ) , 4 ) angiotensin II receptor antagonist ( losartan 40 mg/kg p.o . ) .	6 1 5 5 1 6 10 10 10 6 13 13 6 6 17 17 6 17 25 19 25 23 21 23 17 30 26|30 30 26|30 30 25 30 30 30 25 37 37 25 17 17 17 45 41 41|45 45 41|45 17 47 45 47 51 51 47 17 17 17 60 55 60 60 60 17 65 65 65 65 60 65 65 6	None-BC7
12512695	CHEMICAL	GENE	T6	T25	True	0	What is [Drugprot] between @CHEMICALSrc$ Ang II @/CHEMICALSrc$ and @GENETgt$ ATi @/GENETgt$ ? [SEP] Neither non-selective COX inhibitor sulindac nor COX-2 selective MF-tricyclic were capable of preventing @CHEMICALSrc$ Ang II-induced @/CHEMICALSrc$ hypertension or endothelial dysfunction in mREN2 rats , whereas @GENETgt$ ATi @/GENETgt$ receptor antagonist losartan completely normalized blood pressure , vascular relaxation responses as well as urinary NOx excretion .	5 5 5 5 11 5 9 9 5 11 11 13 11 17|13|14 17|13|14 17|14 17|13|14 13 17 20 17 23 23 17 11 11 30|23 30 30|23 30 30 32 32 11 34 32 34 38 38 34 38 39 39 44 44 38 11	None-BC7
12512695	CHEMICAL	GENE	T15	T40	True	0	What is [Drugprot] between @CHEMICALSrc$ sulindac @/CHEMICALSrc$ and @GENETgt$ angiotensin II receptor @/GENETgt$ ? [SEP] Five-to-six-week-old , heterozygous mREN2 rats received the following drug regimens for 8 weeks : 1 ) vehicle , 2 ) cyclo-oxygenase-2 ( COX-2 ) inhibitor ( MF-tricyclic [ 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl ) phenyl)-2(5H)-furanone ] , 14 mg/kg p.o . ) , 3 ) COX-1/COX-2 inhibitor ( @CHEMICALSrc$ sulindac @/CHEMICALSrc$ , 14 mg/kg p.o . ) , 4 ) @GENETgt$ angiotensin II receptor @/GENETgt$ antagonist ( losartan 40 mg/kg p.o . ) .	6 1 5 5 1 6 10 10 10 6 13 13 6 6 17 17 6 17 25 19 25 23 21 23 17 29 29 29 25 29 29 29 25 36 36 25 17 17 17 43 40 43 17 45 43|44 43 43|44 45 50 50 45 17 17 17 60 54 60|54 60|54 60|54 60 60|54 17 65 65 65 65 60 65 65 6	None-BC7
12512695	CHEMICAL	GENE	T15	T39	True	0	What is [Drugprot] between @CHEMICALSrc$ sulindac @/CHEMICALSrc$ and @GENETgt$ COX-2 @/GENETgt$ ? [SEP] Five-to-six-week-old , heterozygous mREN2 rats received the following drug regimens for 8 weeks : 1 ) vehicle , 2 ) cyclo-oxygenase-2 ( COX-2 ) inhibitor ( MF-tricyclic [ 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl ) phenyl)-2(5H)-furanone ] , 14 mg/kg p.o . ) , 3 ) @GENETgt$ COX-1/COX-2 @/GENETgt$ inhibitor ( @CHEMICALSrc$ sulindac @/CHEMICALSrc$ , 14 mg/kg p.o . ) , 4 ) angiotensin II receptor antagonist ( losartan 40 mg/kg p.o . ) .	6 1 5 5 1 6 10 10 10 6 13 13 6 6 17 17 6 17 25 19 25 23 21 23 17 29 29 29 25 29 29 29 25 36 36 25 17 17 17 44 40 41|44 44 41|44 17 46 44 44 44 46 51 51 46 17 17 17 60 55 60 60 60 17 65 65 65 65 60 65 65 6	None-BC7
12512695	CHEMICAL	GENE	T14	T37	True	0	What is [Drugprot] between @CHEMICALSrc$ 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl) phenyl)-2(5H)-furanone @/CHEMICALSrc$ and @GENETgt$ COX-2 @/GENETgt$ ? [SEP] Five-to-six-week-old , heterozygous mREN2 rats received the following drug regimens for 8 weeks : 1 ) vehicle , 2 ) cyclo-oxygenase-2 ( @GENETgt$ COX-2 @/GENETgt$ ) inhibitor ( MF-tricyclic [ @CHEMICALSrc$ 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl ) phenyl)-2(5H)-furanone @/CHEMICALSrc$ ] , 14 mg/kg p.o . ) , 3 ) COX-1/COX-2 inhibitor ( sulindac , 14 mg/kg p.o . ) , 4 ) angiotensin II receptor antagonist ( losartan 40 mg/kg p.o . ) .	6 1 5 5 1 6 10 10 10 6 13 13 6 6 17 17 6 17 26 19 26 23 21|22 21 21|22 23 17 30 30 30 26|28|30 26|28|30 26|28|30 26|30 26|28|30 30 26 38 38 26 17 17 17 45 42 45 17 47 45 47 51 51 47 17 17 17 60 55 60 60 60 17 65 65 65 65 60 65 65 6	None-BC7
12512695	CHEMICAL	GENE	T5	T24	True	0	What is [Drugprot] between @CHEMICALSrc$ MF-tricyclic @/CHEMICALSrc$ and @GENETgt$ mREN2 @/GENETgt$ ? [SEP] Neither non-selective COX inhibitor sulindac nor COX-2 selective @CHEMICALSrc$ MF-tricyclic @/CHEMICALSrc$ were capable of preventing Ang II-induced hypertension or endothelial dysfunction in @GENETgt$ mREN2 @/GENETgt$ rats , whereas ATi receptor antagonist losartan completely normalized blood pressure , vascular relaxation responses as well as urinary NOx excretion .	5 5 5 5 12 5 9 9 8|5 5 8|5 12 12 14 12 16 17 14 17 20 17 24 24|20 24 24|20 17 12 12 30 30 30 32 32 12 34 32 34 38 38 34 38 39 39 44 44 38 12	None-BC7
12512695	CHEMICAL	GENE	T6	T22	True	0	What is [Drugprot] between @CHEMICALSrc$ Ang II @/CHEMICALSrc$ and @GENETgt$ COX-2 @/GENETgt$ ? [SEP] Neither non-selective COX inhibitor sulindac nor @GENETgt$ COX-2 @/GENETgt$ selective MF-tricyclic were capable of preventing @CHEMICALSrc$ Ang II-induced @/CHEMICALSrc$ hypertension or endothelial dysfunction in mREN2 rats , whereas ATi receptor antagonist losartan completely normalized blood pressure , vascular relaxation responses as well as urinary NOx excretion .	5 5 5 5 12 5 10|6 10 10|6 10 5 12 12 14 12 18|13|15 18|13|15 18|15 18|13|15 14 18 21 18 24 24 18 12 12 30 30 30 32 32 12 34 32 34 38 38 34 38 39 39 44 44 38 12	None-BC7
12512695	CHEMICAL	GENE	T13	T38	True	0	What is [Drugprot] between @CHEMICALSrc$ MF-tricyclic @/CHEMICALSrc$ and @GENETgt$ COX-1 @/GENETgt$ ? [SEP] Five-to-six-week-old , heterozygous mREN2 rats received the following drug regimens for 8 weeks : 1 ) vehicle , 2 ) cyclo-oxygenase-2 ( COX-2 ) inhibitor ( @CHEMICALSrc$ MF-tricyclic @/CHEMICALSrc$ [ 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl ) phenyl)-2(5H)-furanone ] , 14 mg/kg p.o . ) , 3 ) @GENETgt$ COX-1/COX-2 @/GENETgt$ inhibitor ( sulindac , 14 mg/kg p.o . ) , 4 ) angiotensin II receptor antagonist ( losartan 40 mg/kg p.o . ) .	6 1 5 5 1 6 10 10 10 6 13 13 6 6 17 17 6 17 25 19 25 23 21 23 17 30 26|30 30 26|30 30 25 30 30 30 25 37 37 25 17 17 17 45 41 41|45 45 41|45 17 47 45 47 51 51 47 17 17 17 60 55 60 60 60 17 65 65 65 65 60 65 65 6	None-BC7
12512695	CHEMICAL	GENE	T15	T38	True	0	What is [Drugprot] between @CHEMICALSrc$ sulindac @/CHEMICALSrc$ and @GENETgt$ COX-1 @/GENETgt$ ? [SEP] Five-to-six-week-old , heterozygous mREN2 rats received the following drug regimens for 8 weeks : 1 ) vehicle , 2 ) cyclo-oxygenase-2 ( COX-2 ) inhibitor ( MF-tricyclic [ 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl ) phenyl)-2(5H)-furanone ] , 14 mg/kg p.o . ) , 3 ) @GENETgt$ COX-1/COX-2 @/GENETgt$ inhibitor ( @CHEMICALSrc$ sulindac @/CHEMICALSrc$ , 14 mg/kg p.o . ) , 4 ) angiotensin II receptor antagonist ( losartan 40 mg/kg p.o . ) .	6 1 5 5 1 6 10 10 10 6 13 13 6 6 17 17 6 17 25 19 25 23 21 23 17 29 29 29 25 29 29 29 25 36 36 25 17 17 17 44 40 41|44 44 41|44 17 46 44 44 44 46 51 51 46 17 17 17 60 55 60 60 60 17 65 65 65 65 60 65 65 6	None-BC7
12512695	CHEMICAL	GENE	T11	T31	True	0	What is [Drugprot] between @CHEMICALSrc$ eicosanoids @/CHEMICALSrc$ and @GENETgt$ COX @/GENETgt$ ? [SEP] The present study examined the role of cyclo-oxygenase @GENETgt$ (COX)-synthetized @/GENETgt$ @CHEMICALSrc$ eicosanoids @/CHEMICALSrc$ in the pathogenesis of Ang II-induced endothelial dysfunction in transgenic rats harboring mouse renin-2 gene ( mREN2 rats ) .	3 3 4 4 6 4 11 11 8|11 11 8|11 9|6 6 9|6 15 15 6 20 20 20 20 15 23 23 20 23 27 27 24 30 30 27 30 4	PRODUCT-OF
12512695	CHEMICAL	GENE	T8	T26	True	0	What is [Drugprot] between @CHEMICALSrc$ NO @/CHEMICALSrc$ and @GENETgt$ mREN2 @/GENETgt$ ? [SEP] Our findings indicate that @CHEMICALSrc$ NO @/CHEMICALSrc$ synthesis and/or bioavailability as well as the sensitivity of arterial smooth muscle cells to NO are decreased in @GENETgt$ mREN2 @/GENETgt$ rats .	2 3 3 23 4|7 7 4|7 23 7 7 7 10 10 14 7 19 19 19 19 14 21 14 23 3 27 27|23 27 27|23 23 3	None-BC7
12512695	CHEMICAL	GENE	T14	T40	True	0	What is [Drugprot] between @CHEMICALSrc$ 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl) phenyl)-2(5H)-furanone @/CHEMICALSrc$ and @GENETgt$ angiotensin II receptor @/GENETgt$ ? [SEP] Five-to-six-week-old , heterozygous mREN2 rats received the following drug regimens for 8 weeks : 1 ) vehicle , 2 ) cyclo-oxygenase-2 ( COX-2 ) inhibitor ( MF-tricyclic [ @CHEMICALSrc$ 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl ) phenyl)-2(5H)-furanone @/CHEMICALSrc$ ] , 14 mg/kg p.o . ) , 3 ) COX-1/COX-2 inhibitor ( sulindac , 14 mg/kg p.o . ) , 4 ) @GENETgt$ angiotensin II receptor @/GENETgt$ antagonist ( losartan 40 mg/kg p.o . ) .	6 1 5 5 1 6 10 10 10 6 13 13 6 6 17 17 6 17 25 19 25 23 21 23 17 29 29 29 25|28|29 25|28|29 25|28|29 25|29 25|28|29 29 25 37 37 25 17 17 17 44 41 44 17 46 44 46 50 50 46 17 17 17 60 54 52|60 52|60 52|60 60 52|60 17 65 65 65 65 60 65 65 6	None-BC7
12512695	CHEMICAL	GENE	T4	T21	True	0	What is [Drugprot] between @CHEMICALSrc$ sulindac @/CHEMICALSrc$ and @GENETgt$ COX @/GENETgt$ ? [SEP] Neither non-selective @GENETgt$ COX @/GENETgt$ inhibitor @CHEMICALSrc$ sulindac @/CHEMICALSrc$ nor COX-2 selective MF-tricyclic were capable of preventing Ang II-induced hypertension or endothelial dysfunction in mREN2 rats , whereas ATi receptor antagonist losartan completely normalized blood pressure , vascular relaxation responses as well as urinary NOx excretion .	6 6 2|6 6 2|6 6 4|13 13 4|13 6 11 11 6 13 13 15 13 17 18 15 18 21 18 24 24 18 13 13 30 30 30 32 32 13 34 32 34 38 38 34 38 39 39 44 44 38 13	None-BC7
12512695	CHEMICAL	GENE	T12	T33	True	0	What is [Drugprot] between @CHEMICALSrc$ Ang II @/CHEMICALSrc$ and @GENETgt$ mouse renin-2 @/GENETgt$ ? [SEP] The present study examined the role of cyclo-oxygenase (COX)-synthetized eicosanoids in the pathogenesis of @CHEMICALSrc$ Ang II-induced @/CHEMICALSrc$ endothelial dysfunction in transgenic rats harboring @GENETgt$ mouse renin-2 @/GENETgt$ gene ( mREN2 rats ) .	3 3 4 4 6 4 10 10 10 6 13 13 6 19 19|14 19|14 19 19|14 19 13 22 22 19 22 27|21 27|21 27 27|21 23 30 30 27 30 4	None-BC7
12512695	CHEMICAL	GENE	T15	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ sulindac @/CHEMICALSrc$ and @GENETgt$ cyclo-oxygenase-2 @/GENETgt$ ? [SEP] Five-to-six-week-old , heterozygous mREN2 rats received the following drug regimens for 8 weeks : 1 ) vehicle , 2 ) @GENETgt$ cyclo-oxygenase-2 @/GENETgt$ ( COX-2 ) inhibitor ( MF-tricyclic [ 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl ) phenyl)-2(5H)-furanone ] , 14 mg/kg p.o . ) , 3 ) COX-1/COX-2 inhibitor ( @CHEMICALSrc$ sulindac @/CHEMICALSrc$ , 14 mg/kg p.o . ) , 4 ) angiotensin II receptor antagonist ( losartan 40 mg/kg p.o . ) .	6 1 5 5 1 6 10 10 10 6 13 13 6 6 17 17 6 17 26 19 26|20 26 26|20 24 21 24 17 30 30 30 26 30 30 30 26 37 37 26 17 17 17 44 41 44 17 46 44 44 44 46 51 51 46 17 17 17 60 55 60 60 60 17 65 65 65 65 60 65 65 6	None-BC7
12512695	CHEMICAL	GENE	T4	T22	True	0	What is [Drugprot] between @CHEMICALSrc$ sulindac @/CHEMICALSrc$ and @GENETgt$ COX-2 @/GENETgt$ ? [SEP] Neither non-selective COX inhibitor @CHEMICALSrc$ sulindac @/CHEMICALSrc$ nor @GENETgt$ COX-2 @/GENETgt$ selective MF-tricyclic were capable of preventing Ang II-induced hypertension or endothelial dysfunction in mREN2 rats , whereas ATi receptor antagonist losartan completely normalized blood pressure , vascular relaxation responses as well as urinary NOx excretion .	5 5 5 5 4|13 13 4|13 5 11|6 11 11|6 11 5 13 13 15 13 17 18 15 18 21 18 24 24 18 13 13 30 30 30 32 32 13 34 32 34 38 38 34 38 39 39 44 44 38 13	None-BC7
12512695	CHEMICAL	GENE	T5	T25	True	0	What is [Drugprot] between @CHEMICALSrc$ MF-tricyclic @/CHEMICALSrc$ and @GENETgt$ ATi @/GENETgt$ ? [SEP] Neither non-selective COX inhibitor sulindac nor COX-2 selective @CHEMICALSrc$ MF-tricyclic @/CHEMICALSrc$ were capable of preventing Ang II-induced hypertension or endothelial dysfunction in mREN2 rats , whereas @GENETgt$ ATi @/GENETgt$ receptor antagonist losartan completely normalized blood pressure , vascular relaxation responses as well as urinary NOx excretion .	5 5 5 5 12 5 9 9 8|5 5 8|5 12 12 14 12 16 17 14 17 20 17 23 23 17 12 12 24|30 30 24|30 30 30 32 32 12 34 32 34 38 38 34 38 39 39 44 44 38 12	None-BC7
12512695	CHEMICAL	GENE	T7	T23	True	0	What is [Drugprot] between @CHEMICALSrc$ losartan @/CHEMICALSrc$ and @GENETgt$ Ang II @/GENETgt$ ? [SEP] Neither non-selective COX inhibitor sulindac nor COX-2 selective MF-tricyclic were capable of preventing @GENETgt$ Ang II-induced @/GENETgt$ hypertension or endothelial dysfunction in mREN2 rats , whereas ATi receptor antagonist @CHEMICALSrc$ losartan @/CHEMICALSrc$ completely normalized blood pressure , vascular relaxation responses as well as urinary NOx excretion .	5 5 5 5 11 5 9 9 5 11 11 13 11 17|13|14 17|13|14 17|14 17|13|14 13 17 20 17 23 23 17 11 11 29 29 29 32|26 32 32|26 32 11 34 32 34 38 38 34 38 39 39 44 44 38 11	None-BC7
12512695	CHEMICAL	GENE	T9	T26	True	0	What is [Drugprot] between @CHEMICALSrc$ NO @/CHEMICALSrc$ and @GENETgt$ mREN2 @/GENETgt$ ? [SEP] Our findings indicate that NO synthesis and/or bioavailability as well as the sensitivity of arterial smooth muscle cells to @CHEMICALSrc$ NO @/CHEMICALSrc$ are decreased in @GENETgt$ mREN2 @/GENETgt$ rats .	2 3 3 23 6 23 6 6 6 9 9 13 6 18 18 18 18 13 20 19|13 13 19|13 23 3 27 27|23 27 27|23 23 3	None-BC7
12512695	CHEMICAL	GENE	T5	T23	True	0	What is [Drugprot] between @CHEMICALSrc$ MF-tricyclic @/CHEMICALSrc$ and @GENETgt$ Ang II @/GENETgt$ ? [SEP] Neither non-selective COX inhibitor sulindac nor COX-2 selective @CHEMICALSrc$ MF-tricyclic @/CHEMICALSrc$ were capable of preventing @GENETgt$ Ang II-induced @/GENETgt$ hypertension or endothelial dysfunction in mREN2 rats , whereas ATi receptor antagonist losartan completely normalized blood pressure , vascular relaxation responses as well as urinary NOx excretion .	5 5 5 5 12 5 9 9 8|5 5 8|5 12 12 14 12 18|13|15 18|13|15 18|15 18|13|15 14 18 21 18 24 24 18 12 12 30 30 30 32 32 12 34 32 34 38 38 34 38 39 39 44 44 38 12	None-BC7
12512695	CHEMICAL	GENE	T7	T25	True	0	What is [Drugprot] between @CHEMICALSrc$ losartan @/CHEMICALSrc$ and @GENETgt$ ATi @/GENETgt$ ? [SEP] Neither non-selective COX inhibitor sulindac nor COX-2 selective MF-tricyclic were capable of preventing Ang II-induced hypertension or endothelial dysfunction in mREN2 rats , whereas @GENETgt$ ATi @/GENETgt$ receptor antagonist @CHEMICALSrc$ losartan @/CHEMICALSrc$ completely normalized blood pressure , vascular relaxation responses as well as urinary NOx excretion .	5 5 5 5 11 5 9 9 5 11 11 13 11 15 16 13 16 19 16 22 22 16 11 11 24|29 29 24|29 29 29 32|27 32 32|27 32 11 34 32 34 38 38 34 38 39 39 44 44 38 11	None-BC7
12512695	CHEMICAL	GENE	T16	T39	True	0	What is [Drugprot] between @CHEMICALSrc$ angiotensin II @/CHEMICALSrc$ and @GENETgt$ COX-2 @/GENETgt$ ? [SEP] Five-to-six-week-old , heterozygous mREN2 rats received the following drug regimens for 8 weeks : 1 ) vehicle , 2 ) cyclo-oxygenase-2 ( COX-2 ) inhibitor ( MF-tricyclic [ 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl ) phenyl)-2(5H)-furanone ] , 14 mg/kg p.o . ) , 3 ) @GENETgt$ COX-1/COX-2 @/GENETgt$ inhibitor ( sulindac , 14 mg/kg p.o . ) , 4 ) @CHEMICALSrc$ angiotensin II @/CHEMICALSrc$ receptor antagonist ( losartan 40 mg/kg p.o . ) .	6 1 5 5 1 6 10 10 10 6 13 13 6 6 17 17 6 17 25 19 25 23 21 23 17 29 29 29 25 29 29 29 25 36 36 25 17 17 17 44 40 41|44 44 41|44 17 46 44 46 50 50 46 17 17 17 60 54 60|54 60|54 60 60|54 60 17 65 65 65 65 60 65 65 6	None-BC7
12512695	CHEMICAL	GENE	T7	T22	True	0	What is [Drugprot] between @CHEMICALSrc$ losartan @/CHEMICALSrc$ and @GENETgt$ COX-2 @/GENETgt$ ? [SEP] Neither non-selective COX inhibitor sulindac nor @GENETgt$ COX-2 @/GENETgt$ selective MF-tricyclic were capable of preventing Ang II-induced hypertension or endothelial dysfunction in mREN2 rats , whereas ATi receptor antagonist @CHEMICALSrc$ losartan @/CHEMICALSrc$ completely normalized blood pressure , vascular relaxation responses as well as urinary NOx excretion .	5 5 5 5 12 5 10|6 10 10|6 10 5 12 12 14 12 16 17 14 17 20 17 23 23 17 12 12 29 29 29 32|27 32 32|27 32 12 34 32 34 38 38 34 38 39 39 44 44 38 12	None-BC7
12512695	CHEMICAL	GENE	T13	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ MF-tricyclic @/CHEMICALSrc$ and @GENETgt$ cyclo-oxygenase-2 @/GENETgt$ ? [SEP] Five-to-six-week-old , heterozygous mREN2 rats received the following drug regimens for 8 weeks : 1 ) vehicle , 2 ) @GENETgt$ cyclo-oxygenase-2 @/GENETgt$ ( COX-2 ) inhibitor ( @CHEMICALSrc$ MF-tricyclic @/CHEMICALSrc$ [ 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl ) phenyl)-2(5H)-furanone ] , 14 mg/kg p.o . ) , 3 ) COX-1/COX-2 inhibitor ( sulindac , 14 mg/kg p.o . ) , 4 ) angiotensin II receptor antagonist ( losartan 40 mg/kg p.o . ) .	6 1 5 5 1 6 10 10 10 6 13 13 6 6 17 17 6 17 26 19 26|20 26 26|20 24 21 24 17 31 26|31 31 26|31 31 26 31 31 31 26 38 38 26 17 17 17 45 42 45 17 47 45 47 51 51 47 17 17 17 60 55 60 60 60 17 65 65 65 65 60 65 65 6	None-BC7
12512695	CHEMICAL	GENE	T10	T30	True	0	What is [Drugprot] between @CHEMICALSrc$ Ang II @/CHEMICALSrc$ and @GENETgt$ mREN2 @/GENETgt$ ? [SEP] The present study also demonstrated that COX does not play a central role in the pathogenesis of @CHEMICALSrc$ Ang II-induced @/CHEMICALSrc$ endothelial dysfunction in @GENETgt$ mREN2 @/GENETgt$ rats .	3 3 5 5 5 10 10 10 10 5 13 13 10 16 16 10 22 17|22 17|22 22 17|22 22 16 26 26|21 26 26|21 22 5	None-BC7
12512695	CHEMICAL	GENE	T13	T35	True	0	What is [Drugprot] between @CHEMICALSrc$ MF-tricyclic @/CHEMICALSrc$ and @GENETgt$ mREN2 @/GENETgt$ ? [SEP] Five-to-six-week-old , heterozygous @GENETgt$ mREN2 @/GENETgt$ rats received the following drug regimens for 8 weeks : 1 ) vehicle , 2 ) cyclo-oxygenase-2 ( COX-2 ) inhibitor ( @CHEMICALSrc$ MF-tricyclic @/CHEMICALSrc$ [ 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl ) phenyl)-2(5H)-furanone ] , 14 mg/kg p.o . ) , 3 ) COX-1/COX-2 inhibitor ( sulindac , 14 mg/kg p.o . ) , 4 ) angiotensin II receptor antagonist ( losartan 40 mg/kg p.o . ) .	7 1 6 3|6 6 3|6 1 7 11 11 11 7 14 14 7 7 18 18 7 18 26 20 26 24 22 24 18 31 26|31 31 26|31 31 26 31 31 31 26 38 38 26 18 18 18 45 42 45 18 47 45 47 51 51 47 18 18 18 60 55 60 60 60 18 65 65 65 65 60 65 65 7	None-BC7
12512695	CHEMICAL	GENE	T12	T31	True	0	What is [Drugprot] between @CHEMICALSrc$ Ang II @/CHEMICALSrc$ and @GENETgt$ COX @/GENETgt$ ? [SEP] The present study examined the role of cyclo-oxygenase @GENETgt$ (COX)-synthetized @/GENETgt$ eicosanoids in the pathogenesis of @CHEMICALSrc$ Ang II-induced @/CHEMICALSrc$ endothelial dysfunction in transgenic rats harboring mouse renin-2 gene ( mREN2 rats ) .	3 3 4 4 6 4 11 11 8|11 11 8|11 6 14 14 6 20 20|14 20|14 20 20|14 20 14 23 23 20 23 27 27 24 30 30 27 30 4	None-BC7
12512695	CHEMICAL	GENE	T12	T34	True	0	What is [Drugprot] between @CHEMICALSrc$ Ang II @/CHEMICALSrc$ and @GENETgt$ mREN2 @/GENETgt$ ? [SEP] The present study examined the role of cyclo-oxygenase (COX)-synthetized eicosanoids in the pathogenesis of @CHEMICALSrc$ Ang II-induced @/CHEMICALSrc$ endothelial dysfunction in transgenic rats harboring mouse renin-2 gene ( @GENETgt$ mREN2 @/GENETgt$ rats ) .	3 3 4 4 6 4 10 10 10 6 13 13 6 19 19|14 19|14 19 19|14 19 13 22 22 19 22 26 26 23 30 25|30 30 25|30 26 30 4	None-BC7
12512695	CHEMICAL	GENE	T4	T24	True	0	What is [Drugprot] between @CHEMICALSrc$ sulindac @/CHEMICALSrc$ and @GENETgt$ mREN2 @/GENETgt$ ? [SEP] Neither non-selective COX inhibitor @CHEMICALSrc$ sulindac @/CHEMICALSrc$ nor COX-2 selective MF-tricyclic were capable of preventing Ang II-induced hypertension or endothelial dysfunction in @GENETgt$ mREN2 @/GENETgt$ rats , whereas ATi receptor antagonist losartan completely normalized blood pressure , vascular relaxation responses as well as urinary NOx excretion .	5 5 5 5 4|12 12 4|12 5 10 10 5 12 12 14 12 16 17 14 17 20 17 24 24|20 24 24|20 17 12 12 30 30 30 32 32 12 34 32 34 38 38 34 38 39 39 44 44 38 12	None-BC7
12512695	CHEMICAL	GENE	T11	T28	True	0	What is [Drugprot] between @CHEMICALSrc$ eicosanoids @/CHEMICALSrc$ and @GENETgt$ cyclo-oxygenase @/GENETgt$ ? [SEP] The present study examined the role of @GENETgt$ cyclo-oxygenase @/GENETgt$ (COX)-synthetized @CHEMICALSrc$ eicosanoids @/CHEMICALSrc$ in the pathogenesis of Ang II-induced endothelial dysfunction in transgenic rats harboring mouse renin-2 gene ( mREN2 rats ) .	3 3 4 4 6 4 11 11|7 11 11|7 11 9|6 6 9|6 15 15 6 20 20 20 20 15 23 23 20 23 27 27 24 30 30 27 30 4	PRODUCT-OF
12512695	CHEMICAL	GENE	T13	T37	True	0	What is [Drugprot] between @CHEMICALSrc$ MF-tricyclic @/CHEMICALSrc$ and @GENETgt$ COX-2 @/GENETgt$ ? [SEP] Five-to-six-week-old , heterozygous mREN2 rats received the following drug regimens for 8 weeks : 1 ) vehicle , 2 ) cyclo-oxygenase-2 ( @GENETgt$ COX-2 @/GENETgt$ ) inhibitor ( @CHEMICALSrc$ MF-tricyclic @/CHEMICALSrc$ [ 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl ) phenyl)-2(5H)-furanone ] , 14 mg/kg p.o . ) , 3 ) COX-1/COX-2 inhibitor ( sulindac , 14 mg/kg p.o . ) , 4 ) angiotensin II receptor antagonist ( losartan 40 mg/kg p.o . ) .	6 1 5 5 1 6 10 10 10 6 13 13 6 6 17 17 6 17 26 19 26 23 21|22 21 21|22 23 17 31 26|31 31 26|31 31 26 31 31 31 26 38 38 26 17 17 17 45 42 45 17 47 45 47 51 51 47 17 17 17 60 55 60 60 60 17 65 65 65 65 60 65 65 6	None-BC7
12512695	CHEMICAL	GENE	T16	T35	True	0	What is [Drugprot] between @CHEMICALSrc$ angiotensin II @/CHEMICALSrc$ and @GENETgt$ mREN2 @/GENETgt$ ? [SEP] Five-to-six-week-old , heterozygous @GENETgt$ mREN2 @/GENETgt$ rats received the following drug regimens for 8 weeks : 1 ) vehicle , 2 ) cyclo-oxygenase-2 ( COX-2 ) inhibitor ( MF-tricyclic [ 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl ) phenyl)-2(5H)-furanone ] , 14 mg/kg p.o . ) , 3 ) COX-1/COX-2 inhibitor ( sulindac , 14 mg/kg p.o . ) , 4 ) @CHEMICALSrc$ angiotensin II @/CHEMICALSrc$ receptor antagonist ( losartan 40 mg/kg p.o . ) .	7 1 6 3|6 6 3|6 1 7 11 11 11 7 14 14 7 7 18 18 7 18 26 20 26 24 22 24 18 30 30 30 26 30 30 30 26 37 37 26 18 18 18 44 41 44 18 46 44 46 50 50 46 18 18 18 60 54 60|54 60|54 60 60|54 60 18 65 65 65 65 60 65 65 7	None-BC7
12512695	CHEMICAL	GENE	T7	T24	True	0	What is [Drugprot] between @CHEMICALSrc$ losartan @/CHEMICALSrc$ and @GENETgt$ mREN2 @/GENETgt$ ? [SEP] Neither non-selective COX inhibitor sulindac nor COX-2 selective MF-tricyclic were capable of preventing Ang II-induced hypertension or endothelial dysfunction in @GENETgt$ mREN2 @/GENETgt$ rats , whereas ATi receptor antagonist @CHEMICALSrc$ losartan @/CHEMICALSrc$ completely normalized blood pressure , vascular relaxation responses as well as urinary NOx excretion .	5 5 5 5 11 5 9 9 5 11 11 13 11 15 16 13 16 19 16 23 20|23 23 20|23 16 11 11 29 29 29 32|27 32 32|27 32 11 34 32 34 38 38 34 38 39 39 44 44 38 11	None-BC7
12512695	CHEMICAL	GENE	T14	T38	True	0	What is [Drugprot] between @CHEMICALSrc$ 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl) phenyl)-2(5H)-furanone @/CHEMICALSrc$ and @GENETgt$ COX-1 @/GENETgt$ ? [SEP] Five-to-six-week-old , heterozygous mREN2 rats received the following drug regimens for 8 weeks : 1 ) vehicle , 2 ) cyclo-oxygenase-2 ( COX-2 ) inhibitor ( MF-tricyclic [ @CHEMICALSrc$ 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl ) phenyl)-2(5H)-furanone @/CHEMICALSrc$ ] , 14 mg/kg p.o . ) , 3 ) @GENETgt$ COX-1/COX-2 @/GENETgt$ inhibitor ( sulindac , 14 mg/kg p.o . ) , 4 ) angiotensin II receptor antagonist ( losartan 40 mg/kg p.o . ) .	6 1 5 5 1 6 10 10 10 6 13 13 6 6 17 17 6 17 25 19 25 23 21 23 17 29 29 29 25|28|29 25|28|29 25|28|29 25|29 25|28|29 29 25 37 37 25 17 17 17 45 41 45|39 45 45|39 17 47 45 47 51 51 47 17 17 17 60 55 60 60 60 17 65 65 65 65 60 65 65 6	None-BC7
23237733	CHEMICAL	GENE	T7	T21	True	0	What is [Drugprot] between @CHEMICALSrc$ chalcone @/CHEMICALSrc$ and @GENETgt$ UGT @/GENETgt$ ? [SEP] Isoliquiritigenin , a herbal ingredient with @CHEMICALSrc$ chalcone @/CHEMICALSrc$ structure , has been speculated to be able to inhibit one of the most drug-metabolizing enzymes ( DMEs ) UDP-glucuronosyltransferase ( @GENETgt$ UGT @/GENETgt$ ) .	13 1 5 5 1 9 9|6 9 9|6 5 1 13 13 13 16 16 13 18 16 18 28 28 23 24 28 26 28 26 19 30 28 28 28 30 13	INHIBITOR
23237733	CHEMICAL	GENE	T5	T22	True	0	What is [Drugprot] between @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ and @GENETgt$ UGT @/GENETgt$ ? [SEP] Therefore , the aim of the present study was to investigate the inhibition of @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ towards important @GENETgt$ UGT @/GENETgt$ isoforms in the liver and intestine , including UGT1A1 , 1A3 , 1A6 , 1A7 , 1A8 , 1A9 and 1A10 .	9 9 4 9 8 8 8 4 9 11 9 13 11 15 13|14 13 13|14 21 21 17|21 21 17|21 13 24 24 13 24 24 24 29 24 29 29 29 29 29 29 29 29 29 29 39 39 9	None-BC7
23237733	CHEMICAL	GENE	T11	T17	True	0	What is [Drugprot] between @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ and @GENETgt$ UGT1A9 @/GENETgt$ ? [SEP] The data fitting using Dixon plot and Lineweaver-Burk plot showed that the inhibition of UGT1A1 , UGT1A9 and UGT1A10 by isoliquiritigenin was all best fit to the competitive inhibition , and the second plot using the slopes from the Lineweaver-Burk plot versus @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ concentrations was used to calculate the inhibition kinetic parameter ( K(i ) ) to be 0.7μM , 0.3μM , and 18.3μM for UGT1A1 , @GENETgt$ UGT1A9 @/GENETgt$ , and UGT1A10 , respectively .	2 10 2 2 6 4 6 9 6 10 25 13 25 15 13 15 15 15 15 21 13 25 25 25 10 29 29 29 25 25 25 34 34 47 34 37 35 41 41 41 37 41 42|45 45 42|45 37 47 25 49 47 53 53 53 49 55 53 55 53 60 60 25 60 60 60 60 60 67 60 67 67 67 67 67 67 67 60 60 10	INHIBITOR
23237733	CHEMICAL	GENE	T11	T18	True	0	What is [Drugprot] between @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ and @GENETgt$ UGT1A10 @/GENETgt$ ? [SEP] The data fitting using Dixon plot and Lineweaver-Burk plot showed that the inhibition of UGT1A1 , UGT1A9 and UGT1A10 by isoliquiritigenin was all best fit to the competitive inhibition , and the second plot using the slopes from the Lineweaver-Burk plot versus @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ concentrations was used to calculate the inhibition kinetic parameter ( K(i ) ) to be 0.7μM , 0.3μM , and 18.3μM for UGT1A1 , UGT1A9 , and @GENETgt$ UGT1A10 @/GENETgt$ , respectively .	2 10 2 2 6 4 6 9 6 10 25 13 25 15 13 15 15 15 15 21 13 25 25 25 10 29 29 29 25 25 25 34 34 47 34 37 35 41 41 41 37 41 42|45 45 42|45 37 47 25 49 47 53 53 53 49 55 53 55 53 60 60 25 60 60 60 60 60 67 60 67 67 67 67 67|70 67 67|70 60 60 10	INHIBITOR
23237733	CHEMICAL	GENE	T10	T34	True	0	What is [Drugprot] between @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ and @GENETgt$ UGT1A10 @/GENETgt$ ? [SEP] The data fitting using Dixon plot and Lineweaver-Burk plot showed that the inhibition of UGT1A1 , UGT1A9 and @GENETgt$ UGT1A10 @/GENETgt$ by @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ was all best fit to the competitive inhibition , and the second plot using the slopes from the Lineweaver-Burk plot versus isoliquiritigenin concentrations was used to calculate the inhibition kinetic parameter ( K(i ) ) to be 0.7μM , 0.3μM , and 18.3μM for UGT1A1 , UGT1A9 , and UGT1A10 , respectively .	2 10 2 2 6 4 6 9 6 10 27 13 27 15 13 15 15 15 18|15 15 18|15 22 20|13 13 20|13 27 27 27 10 31 31 31 27 27 27 36 36 48 36 39 37 43 43 43 39 43 46 39 48 27 50 48 54 54 54 50 56 54 56 54 61 61 27 61 61 61 61 61 68 61 68 68 68 68 68 61 61 10	INHIBITOR
23237733	CHEMICAL	GENE	T12	T35	True	0	What is [Drugprot] between @CHEMICALSrc$ Isoliquiritigenin @/CHEMICALSrc$ and @GENETgt$ UDP-glucuronosyltransferase @/GENETgt$ ? [SEP] @CHEMICALSrc$ Isoliquiritigenin @/CHEMICALSrc$ showed strong inhibitory effects towards multiple @GENETgt$ UDP-glucuronosyltransferase @/GENETgt$ ( UGT ) isoform-catalyzed 4-methylumbelliferone ( 4-MU ) glucuronidation .	0|3 3 0|3 3 6 6 3 19 9 19|7 19 19|7 19 19 15 15 19 17 15 17 6 3	INHIBITOR
23237733	CHEMICAL	GENE	T11	T33	True	0	What is [Drugprot] between @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ and @GENETgt$ UGT1A9 @/GENETgt$ ? [SEP] The data fitting using Dixon plot and Lineweaver-Burk plot showed that the inhibition of UGT1A1 , @GENETgt$ UGT1A9 @/GENETgt$ and UGT1A10 by isoliquiritigenin was all best fit to the competitive inhibition , and the second plot using the slopes from the Lineweaver-Burk plot versus @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ concentrations was used to calculate the inhibition kinetic parameter ( K(i ) ) to be 0.7μM , 0.3μM , and 18.3μM for UGT1A1 , UGT1A9 , and UGT1A10 , respectively .	2 10 2 2 6 4 6 9 6 10 26 13 26 15 13 15 16|15 15 16|15 15 15 22 13 26 26 26 10 30 30 30 26 26 26 35 35 48 35 38 36 42 42 42 38 42 42|46 46 42|46 38 48 26 50 48 54 54 54 50 56 54 56 54 61 61 26 61 61 61 61 61 68 61 68 68 68 68 68 61 61 10	None-BC7
23237733	CHEMICAL	GENE	T14	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ 4-MU @/CHEMICALSrc$ and @GENETgt$ UGT @/GENETgt$ ? [SEP] Isoliquiritigenin showed strong inhibitory effects towards multiple UDP-glucuronosyltransferase ( @GENETgt$ UGT @/GENETgt$ ) isoform-catalyzed 4-methylumbelliferone ( @CHEMICALSrc$ 4-MU @/CHEMICALSrc$ ) glucuronidation .	2 2 5 5 2 19 8 19 19 9|19 19 9|19 14 14 19 16 14 14 14 16 5 2	SUBSTRATE
23237733	CHEMICAL	GENE	T11	T34	True	0	What is [Drugprot] between @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ and @GENETgt$ UGT1A10 @/GENETgt$ ? [SEP] The data fitting using Dixon plot and Lineweaver-Burk plot showed that the inhibition of UGT1A1 , UGT1A9 and @GENETgt$ UGT1A10 @/GENETgt$ by isoliquiritigenin was all best fit to the competitive inhibition , and the second plot using the slopes from the Lineweaver-Burk plot versus @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ concentrations was used to calculate the inhibition kinetic parameter ( K(i ) ) to be 0.7μM , 0.3μM , and 18.3μM for UGT1A1 , UGT1A9 , and UGT1A10 , respectively .	2 10 2 2 6 4 6 9 6 10 26 13 26 15 13 15 15 15 18|15 15 18|15 22 13 26 26 26 10 30 30 30 26 26 26 35 35 48 35 38 36 42 42 42 38 42 42|46 46 42|46 38 48 26 50 48 54 54 54 50 56 54 56 54 61 61 26 61 61 61 61 61 68 61 68 68 68 68 68 61 61 10	None-BC7
23237733	CHEMICAL	GENE	T11	T32	True	0	What is [Drugprot] between @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ and @GENETgt$ UGT1A1 @/GENETgt$ ? [SEP] The data fitting using Dixon plot and Lineweaver-Burk plot showed that the inhibition of @GENETgt$ UGT1A1 @/GENETgt$ , UGT1A9 and UGT1A10 by isoliquiritigenin was all best fit to the competitive inhibition , and the second plot using the slopes from the Lineweaver-Burk plot versus @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ concentrations was used to calculate the inhibition kinetic parameter ( K(i ) ) to be 0.7μM , 0.3μM , and 18.3μM for UGT1A1 , UGT1A9 , and UGT1A10 , respectively .	2 10 2 2 6 4 6 9 6 10 26 13 26 15 13|14 13 13|14 15 15 15 15 22 13 26 26 26 10 30 30 30 26 26 26 35 35 48 35 38 36 42 42 42 38 42 42|46 46 42|46 38 48 26 50 48 54 54 54 50 56 54 56 54 61 61 26 61 61 61 61 61 68 61 68 68 68 68 68 61 61 10	None-BC7
23237733	CHEMICAL	GENE	T6	T24	True	0	What is [Drugprot] between @CHEMICALSrc$ 4-methylumbelliferone @/CHEMICALSrc$ and @GENETgt$ UGT @/GENETgt$ ? [SEP] The recombinant @GENETgt$ UGT-catalyzed @/GENETgt$ @CHEMICALSrc$ 4-methylumbelliferone @/CHEMICALSrc$ ( 4-MU ) glucuronidation was used as probe reactions .	10 5 2|5 5 2|5 10|3 10 10|3 8 5 8 12 12 12 15 15 12 12	SUBSTRATE
23237733	CHEMICAL	GENE	T9	T25	True	0	What is [Drugprot] between @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ and @GENETgt$ UGT1A1 @/GENETgt$ ? [SEP] The results showed that 100μM of @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ inhibited the activity of @GENETgt$ UGT1A1 @/GENETgt$ , UGT1A3 , UGT1A6 , UGT1A7 , UGT1A8 , UGT1A9 , and UGT1A10 by 95.2 % , 76.1 % , 78.9 % , 87.2 % , 67.2 % , 94.8 % , and 91.7 % , respectively .	2 3 3 9 9 7 5|6 5 5|6 3 11 9 13 11 11 11 13 13 13 13 13 13 13 13 13 13 13 13 13 30 30 9 30 33 30 33 36 33 36 39 36 39 42 39 42 45 42 45 45 49 45 49 49 3	INHIBITOR
23237733	CHEMICAL	GENE	T14	T35	True	0	What is [Drugprot] between @CHEMICALSrc$ 4-MU @/CHEMICALSrc$ and @GENETgt$ UDP-glucuronosyltransferase @/GENETgt$ ? [SEP] Isoliquiritigenin showed strong inhibitory effects towards multiple @GENETgt$ UDP-glucuronosyltransferase @/GENETgt$ ( UGT ) isoform-catalyzed 4-methylumbelliferone ( @CHEMICALSrc$ 4-MU @/CHEMICALSrc$ ) glucuronidation .	2 2 5 5 2 19 8 19|7 19 19|7 19 19 14 14 19 16 14 14 14 16 5 2	SUBSTRATE
23237733	CHEMICAL	GENE	T9	T30	True	0	What is [Drugprot] between @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ and @GENETgt$ UGT1A9 @/GENETgt$ ? [SEP] The results showed that 100μM of @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ inhibited the activity of UGT1A1 , UGT1A3 , UGT1A6 , UGT1A7 , UGT1A8 , @GENETgt$ UGT1A9 @/GENETgt$ , and UGT1A10 by 95.2 % , 76.1 % , 78.9 % , 87.2 % , 67.2 % , 94.8 % , and 91.7 % , respectively .	2 3 3 9 9 7 5|6 5 5|6 3 11 9 13 11 13 13 13 13 13 13 13 13 13 13|21 13 13|21 13 13 13 30 30 9 30 33 30 33 36 33 36 39 36 39 42 39 42 45 42 45 45 49 45 49 49 3	INHIBITOR
23237733	CHEMICAL	GENE	T10	T18	True	0	What is [Drugprot] between @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ and @GENETgt$ UGT1A10 @/GENETgt$ ? [SEP] The data fitting using Dixon plot and Lineweaver-Burk plot showed that the inhibition of UGT1A1 , UGT1A9 and UGT1A10 by @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ was all best fit to the competitive inhibition , and the second plot using the slopes from the Lineweaver-Burk plot versus isoliquiritigenin concentrations was used to calculate the inhibition kinetic parameter ( K(i ) ) to be 0.7μM , 0.3μM , and 18.3μM for UGT1A1 , UGT1A9 , and @GENETgt$ UGT1A10 @/GENETgt$ , respectively .	2 10 2 2 6 4 6 9 6 10 26 13 26 15 13 15 15 15 15 21 20|13 13 20|13 26 26 26 10 30 30 30 26 26 26 35 35 47 35 38 36 42 42 42 38 42 45 38 47 26 49 47 53 53 53 49 55 53 55 53 60 60 26 60 60 60 60 60 67 60 67 67 67 67 67|70 67 67|70 60 60 10	None-BC7
23237733	CHEMICAL	GENE	T10	T16	True	0	What is [Drugprot] between @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ and @GENETgt$ UGT1A1 @/GENETgt$ ? [SEP] The data fitting using Dixon plot and Lineweaver-Burk plot showed that the inhibition of UGT1A1 , UGT1A9 and UGT1A10 by @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ was all best fit to the competitive inhibition , and the second plot using the slopes from the Lineweaver-Burk plot versus isoliquiritigenin concentrations was used to calculate the inhibition kinetic parameter ( K(i ) ) to be 0.7μM , 0.3μM , and 18.3μM for @GENETgt$ UGT1A1 @/GENETgt$ , UGT1A9 , and UGT1A10 , respectively .	2 10 2 2 6 4 6 9 6 10 26 13 26 15 13 15 15 15 15 21 20|13 13 20|13 26 26 26 10 30 30 30 26 26 26 35 35 47 35 38 36 42 42 42 38 42 45 38 47 26 49 47 53 53 53 49 55 53 55 53 60 60 26 60 60 60 60 60 67 65|60 60 65|60 67 67 67 67 67 60 60 10	None-BC7
23237733	CHEMICAL	GENE	T9	T27	True	0	What is [Drugprot] between @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ and @GENETgt$ UGT1A6 @/GENETgt$ ? [SEP] The results showed that 100μM of @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ inhibited the activity of UGT1A1 , UGT1A3 , @GENETgt$ UGT1A6 @/GENETgt$ , UGT1A7 , UGT1A8 , UGT1A9 , and UGT1A10 by 95.2 % , 76.1 % , 78.9 % , 87.2 % , 67.2 % , 94.8 % , and 91.7 % , respectively .	2 3 3 9 9 7 5|6 5 5|6 3 11 9 13 11 13 13 13 13|15 13 13|15 13 13 13 13 13 13 13 13 13 30 30 9 30 33 30 33 36 33 36 39 36 39 42 39 42 45 42 45 45 49 45 49 49 3	INHIBITOR
23237733	CHEMICAL	GENE	T4	T21	True	0	What is [Drugprot] between @CHEMICALSrc$ UDP @/CHEMICALSrc$ and @GENETgt$ UGT @/GENETgt$ ? [SEP] Isoliquiritigenin , a herbal ingredient with chalcone structure , has been speculated to be able to inhibit one of the most drug-metabolizing enzymes ( DMEs ) @CHEMICALSrc$ UDP-glucuronosyltransferase @/CHEMICALSrc$ ( @GENETgt$ UGT @/GENETgt$ ) .	12 1 5 5 1 8 8 5 1 12 12 12 15 15 12 17 15 17 27 27 22 23 27 25 27 25 26|18 18 26|18 30 27|28 27 27|28 30 12	None-BC7
23237733	CHEMICAL	GENE	T8	T24	True	0	What is [Drugprot] between @CHEMICALSrc$ 4-MU @/CHEMICALSrc$ and @GENETgt$ UGT @/GENETgt$ ? [SEP] The recombinant @GENETgt$ UGT-catalyzed @/GENETgt$ 4-methylumbelliferone ( @CHEMICALSrc$ 4-MU @/CHEMICALSrc$ ) glucuronidation was used as probe reactions .	10 5 2|5 5 2|5 10 7 5 5 5 7 12 12 12 15 15 12 12	SUBSTRATE
23237733	CHEMICAL	GENE	T10	T17	True	0	What is [Drugprot] between @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ and @GENETgt$ UGT1A9 @/GENETgt$ ? [SEP] The data fitting using Dixon plot and Lineweaver-Burk plot showed that the inhibition of UGT1A1 , UGT1A9 and UGT1A10 by @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ was all best fit to the competitive inhibition , and the second plot using the slopes from the Lineweaver-Burk plot versus isoliquiritigenin concentrations was used to calculate the inhibition kinetic parameter ( K(i ) ) to be 0.7μM , 0.3μM , and 18.3μM for UGT1A1 , @GENETgt$ UGT1A9 @/GENETgt$ , and UGT1A10 , respectively .	2 10 2 2 6 4 6 9 6 10 26 13 26 15 13 15 15 15 15 21 20|13 13 20|13 26 26 26 10 30 30 30 26 26 26 35 35 47 35 38 36 42 42 42 38 42 45 38 47 26 49 47 53 53 53 49 55 53 55 53 60 60 26 60 60 60 60 60 67 60 67 67 67 67 67 67 67 60 60 10	None-BC7
23237733	CHEMICAL	GENE	T9	T28	True	0	What is [Drugprot] between @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ and @GENETgt$ UGT1A7 @/GENETgt$ ? [SEP] The results showed that 100μM of @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ inhibited the activity of UGT1A1 , UGT1A3 , UGT1A6 , @GENETgt$ UGT1A7 @/GENETgt$ , UGT1A8 , UGT1A9 , and UGT1A10 by 95.2 % , 76.1 % , 78.9 % , 87.2 % , 67.2 % , 94.8 % , and 91.7 % , respectively .	2 3 3 9 9 7 5|6 5 5|6 3 11 9 13 11 13 13 13 13 13 17|13 13 17|13 13 13 13 13 13 13 13 30 30 9 30 33 30 33 36 33 36 39 36 39 42 39 42 45 42 45 45 49 45 49 49 3	INHIBITOR
23237733	CHEMICAL	GENE	T9	T29	True	0	What is [Drugprot] between @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ and @GENETgt$ UGT1A8 @/GENETgt$ ? [SEP] The results showed that 100μM of @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ inhibited the activity of UGT1A1 , UGT1A3 , UGT1A6 , UGT1A7 , @GENETgt$ UGT1A8 @/GENETgt$ , UGT1A9 , and UGT1A10 by 95.2 % , 76.1 % , 78.9 % , 87.2 % , 67.2 % , 94.8 % , and 91.7 % , respectively .	2 3 3 9 9 7 5|6 5 5|6 3 11 9 13 11 13 13 13 13 13 13 13 19|13 13 19|13 13 13 13 13 13 30 30 9 30 33 30 33 36 33 36 39 36 39 42 39 42 45 42 45 45 49 45 49 49 3	INHIBITOR
23237733	CHEMICAL	GENE	T15	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ UDP @/CHEMICALSrc$ and @GENETgt$ UGT @/GENETgt$ ? [SEP] Isoliquiritigenin showed strong inhibitory effects towards multiple @CHEMICALSrc$ UDP-glucuronosyltransferase @/CHEMICALSrc$ ( @GENETgt$ UGT @/GENETgt$ ) isoform-catalyzed 4-methylumbelliferone ( 4-MU ) glucuronidation .	2 2 5 5 2 19 8 19|7 19 19|7 19 9|19 19 9|19 15 15 19 17 15 17 5 2	None-BC7
23237733	CHEMICAL	GENE	T11	T16	True	0	What is [Drugprot] between @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ and @GENETgt$ UGT1A1 @/GENETgt$ ? [SEP] The data fitting using Dixon plot and Lineweaver-Burk plot showed that the inhibition of UGT1A1 , UGT1A9 and UGT1A10 by isoliquiritigenin was all best fit to the competitive inhibition , and the second plot using the slopes from the Lineweaver-Burk plot versus @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ concentrations was used to calculate the inhibition kinetic parameter ( K(i ) ) to be 0.7μM , 0.3μM , and 18.3μM for @GENETgt$ UGT1A1 @/GENETgt$ , UGT1A9 , and UGT1A10 , respectively .	2 10 2 2 6 4 6 9 6 10 25 13 25 15 13 15 15 15 15 21 13 25 25 25 10 29 29 29 25 25 25 34 34 47 34 37 35 41 41 41 37 41 42|45 45 42|45 37 47 25 49 47 53 53 53 49 55 53 55 53 60 60 25 60 60 60 60 60 67 65|60 60 65|60 67 67 67 67 67 60 60 10	INHIBITOR
23237733	CHEMICAL	GENE	T9	T26	True	0	What is [Drugprot] between @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ and @GENETgt$ UGT1A3 @/GENETgt$ ? [SEP] The results showed that 100μM of @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ inhibited the activity of UGT1A1 , @GENETgt$ UGT1A3 @/GENETgt$ , UGT1A6 , UGT1A7 , UGT1A8 , UGT1A9 , and UGT1A10 by 95.2 % , 76.1 % , 78.9 % , 87.2 % , 67.2 % , 94.8 % , and 91.7 % , respectively .	2 3 3 9 9 7 5|6 5 5|6 3 11 9 13 11 13 13 13 13 13 13 13 13 13 13 13 13 13 13 13 30 30 9 30 33 30 33 36 33 36 39 36 39 42 39 42 45 42 45 45 49 45 49 49 3	INHIBITOR
23237733	CHEMICAL	GENE	T7	T20	True	0	What is [Drugprot] between @CHEMICALSrc$ chalcone @/CHEMICALSrc$ and @GENETgt$ UDP-glucuronosyltransferase @/GENETgt$ ? [SEP] Isoliquiritigenin , a herbal ingredient with @CHEMICALSrc$ chalcone @/CHEMICALSrc$ structure , has been speculated to be able to inhibit one of the most drug-metabolizing enzymes ( DMEs ) @GENETgt$ UDP-glucuronosyltransferase @/GENETgt$ ( UGT ) .	13 1 5 5 1 9 9|6 9 9|6 5 1 13 13 13 16 16 13 18 16 18 28 28 23 24 28 26 28 26 26|19 19 26|19 31 28 31 13	INHIBITOR
23237733	CHEMICAL	GENE	T1	T20	True	0	What is [Drugprot] between @CHEMICALSrc$ Isoliquiritigenin @/CHEMICALSrc$ and @GENETgt$ UDP-glucuronosyltransferase @/GENETgt$ ? [SEP] @CHEMICALSrc$ Isoliquiritigenin @/CHEMICALSrc$ , a herbal ingredient with chalcone structure , has been speculated to be able to inhibit one of the most drug-metabolizing enzymes ( DMEs ) @GENETgt$ UDP-glucuronosyltransferase @/GENETgt$ ( UGT ) .	0|13 13 0|13 1 6 6 1 9 9 6 1 13 13 13 16 16 13 18 16 18 28 28 23 24 28 26 28 26 26|19 19 26|19 31 28 31 13	INHIBITOR
23237733	CHEMICAL	GENE	T12	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ Isoliquiritigenin @/CHEMICALSrc$ and @GENETgt$ UGT @/GENETgt$ ? [SEP] @CHEMICALSrc$ Isoliquiritigenin @/CHEMICALSrc$ showed strong inhibitory effects towards multiple UDP-glucuronosyltransferase ( @GENETgt$ UGT @/GENETgt$ ) isoform-catalyzed 4-methylumbelliferone ( 4-MU ) glucuronidation .	0|3 3 0|3 3 6 6 3 19 9 19 19 9|19 19 9|19 15 15 19 17 15 17 6 3	INHIBITOR
23237733	CHEMICAL	GENE	T5	T23	True	0	What is [Drugprot] between @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ and @GENETgt$ UGT1A1, 1A3, 1A6, 1A7, 1A8, 1A9 and 1A10 @/GENETgt$ ? [SEP] Therefore , the aim of the present study was to investigate the inhibition of @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ towards important UGT isoforms in the liver and intestine , including @GENETgt$ UGT1A1 , 1A3 , 1A6 , 1A7 , 1A8 , 1A9 and 1A10 @/GENETgt$ .	9 9 4 9 8 8 8 4 9 11 9 13 11 15 13|14 13 13|14 20 20 20 13 23 23 13 23 23 23 28 26|28|23 26|28|23 26|28|23 26|28|23 26|28|23 26|28|23 26|28|23 26|28|23 26|28|23 26|28|23 26|28|23 26|28|23 26|28|23 28|23 26|28|23 9	None-BC7
23237733	CHEMICAL	GENE	T10	T33	True	0	What is [Drugprot] between @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ and @GENETgt$ UGT1A9 @/GENETgt$ ? [SEP] The data fitting using Dixon plot and Lineweaver-Burk plot showed that the inhibition of UGT1A1 , @GENETgt$ UGT1A9 @/GENETgt$ and UGT1A10 by @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ was all best fit to the competitive inhibition , and the second plot using the slopes from the Lineweaver-Burk plot versus isoliquiritigenin concentrations was used to calculate the inhibition kinetic parameter ( K(i ) ) to be 0.7μM , 0.3μM , and 18.3μM for UGT1A1 , UGT1A9 , and UGT1A10 , respectively .	2 10 2 2 6 4 6 9 6 10 27 13 27 15 13 15 16|15 15 16|15 15 15 22 20|13 13 20|13 27 27 27 10 31 31 31 27 27 27 36 36 48 36 39 37 43 43 43 39 43 46 39 48 27 50 48 54 54 54 50 56 54 56 54 61 61 27 61 61 61 61 61 68 61 68 68 68 68 68 61 61 10	INHIBITOR
23237733	CHEMICAL	GENE	T2	T19	True	0	What is [Drugprot] between @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ and @GENETgt$ UGT @/GENETgt$ ? [SEP] All these results indicated the risk of clinical application of @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ on the drug-drug interaction and other possible diseases induced by the inhibition of isoliquiritigenin towards these @GENETgt$ UGT @/GENETgt$ isoforms .	3 3 4 4 6 4 9 9 6 11 9|10 9 9|10 16 16 16 6 16 20 20 16 16 24 24 21 26 24 31 31 27|31 31 27|31 24 4	None-BC7
23237733	CHEMICAL	GENE	T9	T31	True	0	What is [Drugprot] between @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ and @GENETgt$ UGT1A10 @/GENETgt$ ? [SEP] The results showed that 100μM of @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ inhibited the activity of UGT1A1 , UGT1A3 , UGT1A6 , UGT1A7 , UGT1A8 , UGT1A9 , and @GENETgt$ UGT1A10 @/GENETgt$ by 95.2 % , 76.1 % , 78.9 % , 87.2 % , 67.2 % , 94.8 % , and 91.7 % , respectively .	2 3 3 9 9 7 5|6 5 5|6 3 11 9 13 11 13 13 13 13 13 13 13 13 13 13 13 13 24|13 13 24|13 30 30 9 30 33 30 33 36 33 36 39 36 39 42 39 42 45 42 45 45 49 45 49 49 3	INHIBITOR
23237733	CHEMICAL	GENE	T13	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ 4-methylumbelliferone @/CHEMICALSrc$ and @GENETgt$ UGT @/GENETgt$ ? [SEP] Isoliquiritigenin showed strong inhibitory effects towards multiple UDP-glucuronosyltransferase ( @GENETgt$ UGT @/GENETgt$ ) isoform-catalyzed @CHEMICALSrc$ 4-methylumbelliferone @/CHEMICALSrc$ ( 4-MU ) glucuronidation .	2 2 5 5 2 19 8 19 19 9|19 19 9|19 14 14 19|12 19 19|12 17 14 17 5 2	SUBSTRATE
23237733	CHEMICAL	GENE	T13	T35	True	0	What is [Drugprot] between @CHEMICALSrc$ 4-methylumbelliferone @/CHEMICALSrc$ and @GENETgt$ UDP-glucuronosyltransferase @/GENETgt$ ? [SEP] Isoliquiritigenin showed strong inhibitory effects towards multiple @GENETgt$ UDP-glucuronosyltransferase @/GENETgt$ ( UGT ) isoform-catalyzed @CHEMICALSrc$ 4-methylumbelliferone @/CHEMICALSrc$ ( 4-MU ) glucuronidation .	2 2 5 5 2 19 8 19|7 19 19|7 19 19 14 14 19|12 19 19|12 17 14 17 5 2	SUBSTRATE
23237733	CHEMICAL	GENE	T3	T19	True	0	What is [Drugprot] between @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ and @GENETgt$ UGT @/GENETgt$ ? [SEP] All these results indicated the risk of clinical application of isoliquiritigenin on the drug-drug interaction and other possible diseases induced by the inhibition of @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ towards these @GENETgt$ UGT @/GENETgt$ isoforms .	3 3 4 4 6 4 9 9 6 11 9 15 15 15 6 15 19 19 15 15 23 23 20 25 24|23 23 24|23 31 31 27|31 31 27|31 23 4	INHIBITOR
23237733	CHEMICAL	GENE	T10	T32	True	0	What is [Drugprot] between @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ and @GENETgt$ UGT1A1 @/GENETgt$ ? [SEP] The data fitting using Dixon plot and Lineweaver-Burk plot showed that the inhibition of @GENETgt$ UGT1A1 @/GENETgt$ , UGT1A9 and UGT1A10 by @CHEMICALSrc$ isoliquiritigenin @/CHEMICALSrc$ was all best fit to the competitive inhibition , and the second plot using the slopes from the Lineweaver-Burk plot versus isoliquiritigenin concentrations was used to calculate the inhibition kinetic parameter ( K(i ) ) to be 0.7μM , 0.3μM , and 18.3μM for UGT1A1 , UGT1A9 , and UGT1A10 , respectively .	2 10 2 2 6 4 6 9 6 10 27 13 27 15 13|14 13 13|14 15 15 15 15 22 20|13 13 20|13 27 27 27 10 31 31 31 27 27 27 36 36 48 36 39 37 43 43 43 39 43 46 39 48 27 50 48 54 54 54 50 56 54 56 54 61 61 27 61 61 61 61 61 68 61 68 68 68 68 68 61 61 10	INHIBITOR
23237733	CHEMICAL	GENE	T1	T21	True	0	What is [Drugprot] between @CHEMICALSrc$ Isoliquiritigenin @/CHEMICALSrc$ and @GENETgt$ UGT @/GENETgt$ ? [SEP] @CHEMICALSrc$ Isoliquiritigenin @/CHEMICALSrc$ , a herbal ingredient with chalcone structure , has been speculated to be able to inhibit one of the most drug-metabolizing enzymes ( DMEs ) UDP-glucuronosyltransferase ( @GENETgt$ UGT @/GENETgt$ ) .	0|13 13 0|13 1 6 6 1 9 9 6 1 13 13 13 16 16 13 18 16 18 28 28 23 24 28 26 28 26 19 30 28 28 28 30 13	INHIBITOR
23361305	CHEMICAL	GENE	T1	T4	True	0	What is [Drugprot] between @CHEMICALSrc$ ATP @/CHEMICALSrc$ and @GENETgt$ mitochondrial ATP synthase @/GENETgt$ ? [SEP] It can be hypothesised that impaired mtΔΨ and @GENETgt$ mitochondrial @/GENETgt$ @CHEMICALSrc$ ATP synthase @/CHEMICALSrc$ activity may contribute to episodes of cardiac arrhythmia that occurred unexpectedly in BTHS patients .	4 4 4 4 16 7 16 7 8|14 14 8|14 9|14 9|14 14 9|14 7 16 4 18 16 21 21 18 23 21 23 27 27 23 4	None-BC7
9353417	CHEMICAL	GENE	T5	T28	True	0	What is [Drugprot] between @CHEMICALSrc$ olanzapine @/CHEMICALSrc$ and @GENETgt$ D4 receptor @/GENETgt$ ? [SEP] In both the cerebral cortex and striatum , @GENETgt$ D4 receptor @/GENETgt$ mRNA was upregulated by certain typical ( chlorpromazine and haloperidol ) and certain atypical ( clozapine , @CHEMICALSrc$ olanzapine @/CHEMICALSrc$ and risperidone ) antipsychotic agents as well as by tiapride .	5 5 5 5 14 5 5 14 8|12 8|12 12 8|12 14 14 14 17 17 14 19 17 19 19 19 17 25 17 27 25 27 26|27 27 26|27 29 29 35 35 14 35 36 36 40 35 14	INDIRECT-UPREGULATOR
9353417	CHEMICAL	GENE	T24	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ D2 and D4 dopamine receptor @/GENETgt$ ? [SEP] The RNase Protection Assay was used to examine the regulation of @GENETgt$ D2 and D4 @/GENETgt$ @CHEMICALSrc$ dopamine receptor @/CHEMICALSrc$ mRNAs in the cerebral cortex and neostriatum of nonhuman primates after chronic treatment with a wide spectrum of antipsychotic medications ( chlorpromazine , clozapine , haloperidol , molindone , olanzapine , pimozide , remoxipride and risperidone ) .	4 4 4 6 6 6 8 6 10 8 19 19|11|12 19|11|12 19|11|12 19|12 19|11|12 19|12 19|12 19 19|12 10 23 23 23 10 23 23 28 28 23 31 31 8 35 35 35 31 38 38 35 40 38 40 40 40 40 40 40 40 40 40 40 40 40 52 52 40 6	None-BC7
9353417	CHEMICAL	GENE	T19	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ pimozide @/CHEMICALSrc$ and @GENETgt$ D2 and D4 dopamine receptor @/GENETgt$ ? [SEP] The RNase Protection Assay was used to examine the regulation of @GENETgt$ D2 and D4 dopamine receptor @/GENETgt$ mRNAs in the cerebral cortex and neostriatum of nonhuman primates after chronic treatment with a wide spectrum of antipsychotic medications ( chlorpromazine , clozapine , haloperidol , molindone , olanzapine , @CHEMICALSrc$ pimozide @/CHEMICALSrc$ , remoxipride and risperidone ) .	4 4 4 6 6 6 8 6 10 8 18 18|11|12 18|11|12 18|11|12 18|11|12 18|11|12 18|12 18|11|12 10 22 22 22 10 22 22 27 27 22 30 30 8 34 34 34 30 37 37 34 39 37 39 39 39 39 39 39 39 39 39 43|39 39 43|39 39 39 52 52 39 6	None-BC7
9353417	CHEMICAL	GENE	T6	T28	True	0	What is [Drugprot] between @CHEMICALSrc$ risperidone @/CHEMICALSrc$ and @GENETgt$ D4 receptor @/GENETgt$ ? [SEP] In both the cerebral cortex and striatum , @GENETgt$ D4 receptor @/GENETgt$ mRNA was upregulated by certain typical ( chlorpromazine and haloperidol ) and certain atypical ( clozapine , olanzapine and @CHEMICALSrc$ risperidone @/CHEMICALSrc$ ) antipsychotic agents as well as by tiapride .	5 5 5 5 14 5 5 14 8|12 8|12 12 8|12 14 14 14 17 17 14 19 17 19 19 19 17 25 17 27 25 27 27 29 28|29 29 28|29 35 35 14 35 36 36 40 35 14	INDIRECT-UPREGULATOR
9353417	CHEMICAL	GENE	T23	T37	True	0	What is [Drugprot] between @CHEMICALSrc$ Tiapride @/CHEMICALSrc$ and @GENETgt$ D2-long @/GENETgt$ ? [SEP] @CHEMICALSrc$ Tiapride @/CHEMICALSrc$ , in contrast , significantly up-regulated only the level of @GENETgt$ D2-long @/GENETgt$ mRNA in these areas .	0|8 8 0|8 8 5 8 8 8 8 11 11 8 15 11|15 15 11|15 11 18 18 8 8	INDIRECT-UPREGULATOR
9353417	CHEMICAL	GENE	T26	T38	True	0	What is [Drugprot] between @CHEMICALSrc$ olanzapine @/CHEMICALSrc$ and @GENETgt$ D2-long @/GENETgt$ ? [SEP] The same drug treatments produced less uniform effects in the neostriatum than in the cortex : clozapine and @CHEMICALSrc$ olanzapine @/CHEMICALSrc$ failed to significantly elevate either @GENETgt$ D2-long @/GENETgt$ or D2-short receptor messages in this structure unlike all other drugs , including tiapride .	4 4 4 5 5 7 8 5 11 11 5 15 15 15 5 5 5 17 17|18 17 17|18 5 24 24 21 26 24 24 24 26 26 31 24 34 34 24 38 38 38 24 38 41 38 5	None-BC7
9353417	CHEMICAL	GENE	T12	T32	True	0	What is [Drugprot] between @CHEMICALSrc$ tiapride @/CHEMICALSrc$ and @GENETgt$ D2 @/GENETgt$ ? [SEP] The finding that up-regulation of D2 dopamine receptor mRNAs was a consistently observed effect of a wide range of antipsychotic agents in the cerebral cortex but not in the neostriatum , coupled with the fact that the D2-short isoforms in the cortex were not regulated by a nonantipsychotic @GENETgt$ D2 @/GENETgt$ antagonist , @CHEMICALSrc$ tiapride @/CHEMICALSrc$ , draws attention to the importance of the D2 dopamine receptor in the cerebral cortex as a potentially critical , common site of action of antipsychotic medications .	2 56 14 14 9 9 9 9 4 14 14 13 14 2 18 18 18 14 21 21 18 25 25 25 14 25 30 30 30 25 14 2 35 35 32 45 39 39 45 42 42 39 45 45 35 51 51 51 48|51 51 48|51 45 51 51 51 51 51 56 56 60 60 56 65 65 65 65 60 69 69 69 60 76 76 73 76 76 76 56 78 76 81 81 78 56	ANTAGONIST
9353417	CHEMICAL	GENE	T13	T33	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ D2 dopamine receptor @/GENETgt$ ? [SEP] The finding that up-regulation of D2 dopamine receptor mRNAs was a consistently observed effect of a wide range of antipsychotic agents in the cerebral cortex but not in the neostriatum , coupled with the fact that the D2-short isoforms in the cortex were not regulated by a nonantipsychotic D2 antagonist , tiapride , draws attention to the importance of the @GENETgt$ D2 @/GENETgt$ @CHEMICALSrc$ dopamine receptor @/CHEMICALSrc$ in the cerebral cortex as a potentially critical , common site of action of antipsychotic medications .	2 54 14 14 9 9 9 9 4 14 14 13 14 2 18 18 18 14 21 21 18 25 25 25 14 25 30 30 30 25 14 2 35 35 32 45 39 39 45 42 42 39 45 45 35 50 50 50 50 45 50 50 50 54 54 58 58 54 63 63 60|63 63 60|63 58|61|63 58|61|63 58|63 58|61|63 69 69 69 58 76 76 73 76 76 76 54 78 76 81 81 78 54	None-BC7
9353417	CHEMICAL	GENE	T20	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ remoxipride @/CHEMICALSrc$ and @GENETgt$ D2 and D4 dopamine receptor @/GENETgt$ ? [SEP] The RNase Protection Assay was used to examine the regulation of @GENETgt$ D2 and D4 dopamine receptor @/GENETgt$ mRNAs in the cerebral cortex and neostriatum of nonhuman primates after chronic treatment with a wide spectrum of antipsychotic medications ( chlorpromazine , clozapine , haloperidol , molindone , olanzapine , pimozide , @CHEMICALSrc$ remoxipride @/CHEMICALSrc$ and risperidone ) .	4 4 4 6 6 6 8 6 10 8 18 18|11|12 18|11|12 18|11|12 18|11|12 18|11|12 18|12 18|11|12 10 22 22 22 10 22 22 27 27 22 30 30 8 34 34 34 30 37 37 34 39 37 39 39 39 39 39 39 39 39 39 39 39 45|39 39 45|39 51 51 39 6	None-BC7
9353417	CHEMICAL	GENE	T12	T30	True	0	What is [Drugprot] between @CHEMICALSrc$ tiapride @/CHEMICALSrc$ and @GENETgt$ D2 dopamine receptor @/GENETgt$ ? [SEP] The finding that up-regulation of @GENETgt$ D2 dopamine receptor @/GENETgt$ mRNAs was a consistently observed effect of a wide range of antipsychotic agents in the cerebral cortex but not in the neostriatum , coupled with the fact that the D2-short isoforms in the cortex were not regulated by a nonantipsychotic D2 antagonist , @CHEMICALSrc$ tiapride @/CHEMICALSrc$ , draws attention to the importance of the D2 dopamine receptor in the cerebral cortex as a potentially critical , common site of action of antipsychotic medications .	2 56 15 15 10 10|5 10|5 10|5 10 10|5 4 15 15 14 15 2 19 19 19 15 22 22 19 26 26 26 15 26 31 31 31 26 15 2 36 36 33 46 40 40 46 43 43 40 46 46 36 51 51 51 51 46 51 49|51 51 49|51 51 56 56 60 60 56 65 65 65 65 60 69 69 69 60 76 76 73 76 76 76 56 78 76 81 81 78 56	None-BC7
9353417	CHEMICAL	GENE	T21	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ risperidone @/CHEMICALSrc$ and @GENETgt$ D2 and D4 dopamine receptor @/GENETgt$ ? [SEP] The RNase Protection Assay was used to examine the regulation of @GENETgt$ D2 and D4 dopamine receptor @/GENETgt$ mRNAs in the cerebral cortex and neostriatum of nonhuman primates after chronic treatment with a wide spectrum of antipsychotic medications ( chlorpromazine , clozapine , haloperidol , molindone , olanzapine , pimozide , remoxipride and @CHEMICALSrc$ risperidone @/CHEMICALSrc$ ) .	4 4 4 6 6 6 8 6 10 8 18 18|11|12 18|11|12 18|11|12 18|11|12 18|11|12 18|12 18|11|12 10 22 22 22 10 22 22 27 27 22 30 30 8 34 34 34 30 37 37 34 39 37 39 39 39 39 39 39 39 39 39 39 39 39 51 51|47 51 51|47 39 6	None-BC7
9353417	CHEMICAL	GENE	T25	T38	True	0	What is [Drugprot] between @CHEMICALSrc$ clozapine @/CHEMICALSrc$ and @GENETgt$ D2-long @/GENETgt$ ? [SEP] The same drug treatments produced less uniform effects in the neostriatum than in the cortex : @CHEMICALSrc$ clozapine @/CHEMICALSrc$ and olanzapine failed to significantly elevate either @GENETgt$ D2-long @/GENETgt$ or D2-short receptor messages in this structure unlike all other drugs , including tiapride .	4 4 4 5 5 7 8 5 11 11 5 15 15 15 5 5 16|5 5 16|5 17 17 5 24 24 21 26 24 24 24 26 26 31 24 34 34 24 38 38 38 24 38 41 38 5	None-BC7
9353417	CHEMICAL	GENE	T1	T38	True	0	What is [Drugprot] between @CHEMICALSrc$ tiapride @/CHEMICALSrc$ and @GENETgt$ D2-long @/GENETgt$ ? [SEP] The same drug treatments produced less uniform effects in the neostriatum than in the cortex : clozapine and olanzapine failed to significantly elevate either @GENETgt$ D2-long @/GENETgt$ or D2-short receptor messages in this structure unlike all other drugs , including @CHEMICALSrc$ tiapride @/CHEMICALSrc$ .	4 4 4 5 5 7 8 5 11 11 5 15 15 15 5 5 5 17 17 5 23 23 20 25 24|23 23 24|23 25 25 30 23 33 33 23 37 37 37 23 37 40 37|38 37 37|38 5	None-BC7
9353417	CHEMICAL	GENE	T11	T33	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ D2 dopamine receptor @/GENETgt$ ? [SEP] The finding that up-regulation of D2 @CHEMICALSrc$ dopamine @/CHEMICALSrc$ receptor mRNAs was a consistently observed effect of a wide range of antipsychotic agents in the cerebral cortex but not in the neostriatum , coupled with the fact that the D2-short isoforms in the cortex were not regulated by a nonantipsychotic D2 antagonist , tiapride , draws attention to the importance of the @GENETgt$ D2 dopamine receptor @/GENETgt$ in the cerebral cortex as a potentially critical , common site of action of antipsychotic medications .	2 55 15 15 10 10 10|6 10 10|6 10 4 15 15 14 15 2 19 19 19 15 22 22 19 26 26 26 15 26 31 31 31 26 15 2 36 36 33 46 40 40 46 43 43 40 46 46 36 51 51 51 51 46 51 51 51 55 55 59 59 55 62 62 59|60|62 59|60|62 59|60|62 59|62 59|60|62 69 69 69 59 76 76 73 76 76 76 55 78 76 81 81 78 55	None-BC7
9353417	CHEMICAL	GENE	T14	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ chlorpromazine @/CHEMICALSrc$ and @GENETgt$ D2 and D4 dopamine receptor @/GENETgt$ ? [SEP] The RNase Protection Assay was used to examine the regulation of @GENETgt$ D2 and D4 dopamine receptor @/GENETgt$ mRNAs in the cerebral cortex and neostriatum of nonhuman primates after chronic treatment with a wide spectrum of antipsychotic medications ( @CHEMICALSrc$ chlorpromazine @/CHEMICALSrc$ , clozapine , haloperidol , molindone , olanzapine , pimozide , remoxipride and risperidone ) .	4 4 4 6 6 6 8 6 10 8 18 18|11|12 18|11|12 18|11|12 18|11|12 18|11|12 18|12 18|11|12 10 22 22 22 10 22 22 27 27 22 30 30 8 34 34 34 30 37 37 34 39 33|37 37 33|37 39 39 39 39 39 39 39 39 39 39 39 39 52 52 39 6	None-BC7
9353417	CHEMICAL	GENE	T17	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ molindone @/CHEMICALSrc$ and @GENETgt$ D2 and D4 dopamine receptor @/GENETgt$ ? [SEP] The RNase Protection Assay was used to examine the regulation of @GENETgt$ D2 and D4 dopamine receptor @/GENETgt$ mRNAs in the cerebral cortex and neostriatum of nonhuman primates after chronic treatment with a wide spectrum of antipsychotic medications ( chlorpromazine , clozapine , haloperidol , @CHEMICALSrc$ molindone @/CHEMICALSrc$ , olanzapine , pimozide , remoxipride and risperidone ) .	4 4 4 6 6 6 8 6 10 8 18 18|11|12 18|11|12 18|11|12 18|11|12 18|11|12 18|12 18|11|12 10 22 22 22 10 22 22 27 27 22 30 30 8 34 34 34 30 37 37 34 39 37 39 39 39 39 39 39 39 39 39 39 39 39 39 39 52 52 39 6	None-BC7
9353417	CHEMICAL	GENE	T11	T32	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ D2 @/GENETgt$ ? [SEP] The finding that up-regulation of D2 @CHEMICALSrc$ dopamine @/CHEMICALSrc$ receptor mRNAs was a consistently observed effect of a wide range of antipsychotic agents in the cerebral cortex but not in the neostriatum , coupled with the fact that the D2-short isoforms in the cortex were not regulated by a nonantipsychotic @GENETgt$ D2 @/GENETgt$ antagonist , tiapride , draws attention to the importance of the D2 dopamine receptor in the cerebral cortex as a potentially critical , common site of action of antipsychotic medications .	2 56 15 15 10 10 10|6 10 10|6 10 4 15 15 14 15 2 19 19 19 15 22 22 19 26 26 26 15 26 31 31 31 26 15 2 36 36 33 46 40 40 46 43 43 40 46 46 36 52 52 52 48|52 52 48|52 46 52 52 52 56 56 60 60 56 65 65 65 65 60 69 69 69 60 76 76 73 76 76 76 56 78 76 81 81 78 56	None-BC7
9353417	CHEMICAL	GENE	T4	T28	True	0	What is [Drugprot] between @CHEMICALSrc$ clozapine @/CHEMICALSrc$ and @GENETgt$ D4 receptor @/GENETgt$ ? [SEP] In both the cerebral cortex and striatum , @GENETgt$ D4 receptor @/GENETgt$ mRNA was upregulated by certain typical ( chlorpromazine and haloperidol ) and certain atypical ( @CHEMICALSrc$ clozapine @/CHEMICALSrc$ , olanzapine and risperidone ) antipsychotic agents as well as by tiapride .	5 5 5 5 14 5 5 14 8|12 8|12 12 8|12 14 14 14 17 17 14 19 17 19 19 19 17 25 17 27 24|25 25 24|25 27 27 30 30 35 35 14 35 36 36 40 35 14	INDIRECT-UPREGULATOR
9353417	CHEMICAL	GENE	T16	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ haloperidol @/CHEMICALSrc$ and @GENETgt$ D2 and D4 dopamine receptor @/GENETgt$ ? [SEP] The RNase Protection Assay was used to examine the regulation of @GENETgt$ D2 and D4 dopamine receptor @/GENETgt$ mRNAs in the cerebral cortex and neostriatum of nonhuman primates after chronic treatment with a wide spectrum of antipsychotic medications ( chlorpromazine , clozapine , @CHEMICALSrc$ haloperidol @/CHEMICALSrc$ , molindone , olanzapine , pimozide , remoxipride and risperidone ) .	4 4 4 6 6 6 8 6 10 8 18 18|11|12 18|11|12 18|11|12 18|11|12 18|11|12 18|12 18|11|12 10 22 22 22 10 22 22 27 27 22 30 30 8 34 34 34 30 37 37 34 39 37 39 39 39 37|39 39 37|39 39 39 39 39 39 39 39 39 52 52 39 6	None-BC7
9353417	CHEMICAL	GENE	T13	T32	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ D2 @/GENETgt$ ? [SEP] The finding that up-regulation of D2 dopamine receptor mRNAs was a consistently observed effect of a wide range of antipsychotic agents in the cerebral cortex but not in the neostriatum , coupled with the fact that the D2-short isoforms in the cortex were not regulated by a nonantipsychotic @GENETgt$ D2 @/GENETgt$ antagonist , tiapride , draws attention to the importance of the D2 @CHEMICALSrc$ dopamine @/CHEMICALSrc$ receptor in the cerebral cortex as a potentially critical , common site of action of antipsychotic medications .	2 55 14 14 9 9 9 9 4 14 14 13 14 2 18 18 18 14 21 21 18 25 25 25 14 25 30 30 30 25 14 2 35 35 32 45 39 39 45 42 42 39 45 45 35 51 51 51 48|51 51 48|51 45 51 51 51 55 55 59 59 55 65 65 65 65|61 65 65|61 59 69 69 69 59 76 76 73 76 76 76 55 78 76 81 81 78 55	None-BC7
9353417	CHEMICAL	GENE	T18	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ olanzapine @/CHEMICALSrc$ and @GENETgt$ D2 and D4 dopamine receptor @/GENETgt$ ? [SEP] The RNase Protection Assay was used to examine the regulation of @GENETgt$ D2 and D4 dopamine receptor @/GENETgt$ mRNAs in the cerebral cortex and neostriatum of nonhuman primates after chronic treatment with a wide spectrum of antipsychotic medications ( chlorpromazine , clozapine , haloperidol , molindone , @CHEMICALSrc$ olanzapine @/CHEMICALSrc$ , pimozide , remoxipride and risperidone ) .	4 4 4 6 6 6 8 6 10 8 18 18|11|12 18|11|12 18|11|12 18|11|12 18|11|12 18|12 18|11|12 10 22 22 22 10 22 22 27 27 22 30 30 8 34 34 34 30 37 37 34 39 37 39 39 39 39 39 39 39 41|39 39 41|39 39 39 39 39 52 52 39 6	None-BC7
9353417	CHEMICAL	GENE	T7	T28	True	0	What is [Drugprot] between @CHEMICALSrc$ tiapride @/CHEMICALSrc$ and @GENETgt$ D4 receptor @/GENETgt$ ? [SEP] In both the cerebral cortex and striatum , @GENETgt$ D4 receptor @/GENETgt$ mRNA was upregulated by certain typical ( chlorpromazine and haloperidol ) and certain atypical ( clozapine , olanzapine and risperidone ) antipsychotic agents as well as by @CHEMICALSrc$ tiapride @/CHEMICALSrc$ .	5 5 5 5 14 5 5 14 8|12 8|12 12 8|12 14 14 14 17 17 14 19 17 19 19 19 17 25 17 27 25 27 27 29 29 34 34 14 34 35 35 39 34|36 34 34|36 14	INDIRECT-UPREGULATOR
9353417	CHEMICAL	GENE	T13	T30	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ D2 dopamine receptor @/GENETgt$ ? [SEP] The finding that up-regulation of @GENETgt$ D2 dopamine receptor @/GENETgt$ mRNAs was a consistently observed effect of a wide range of antipsychotic agents in the cerebral cortex but not in the neostriatum , coupled with the fact that the D2-short isoforms in the cortex were not regulated by a nonantipsychotic D2 antagonist , tiapride , draws attention to the importance of the D2 @CHEMICALSrc$ dopamine @/CHEMICALSrc$ receptor in the cerebral cortex as a potentially critical , common site of action of antipsychotic medications .	2 55 15 15 10 10|5 10|5 10|5 10 10|5 4 15 15 14 15 2 19 19 19 15 22 22 19 26 26 26 15 26 31 31 31 26 15 2 36 36 33 46 40 40 46 43 43 40 46 46 36 51 51 51 51 46 51 51 51 55 55 59 59 55 65 65 65 65|59 65 65|59 59 69 69 69 59 76 76 73 76 76 76 55 78 76 81 81 78 55	None-BC7
9353417	CHEMICAL	GENE	T3	T28	True	0	What is [Drugprot] between @CHEMICALSrc$ haloperidol @/CHEMICALSrc$ and @GENETgt$ D4 receptor @/GENETgt$ ? [SEP] In both the cerebral cortex and striatum , @GENETgt$ D4 receptor @/GENETgt$ mRNA was upregulated by certain typical ( chlorpromazine and @CHEMICALSrc$ haloperidol @/CHEMICALSrc$ ) and certain atypical ( clozapine , olanzapine and risperidone ) antipsychotic agents as well as by tiapride .	5 5 5 5 14 5 5 14 8|12 8|12 12 8|12 14 14 14 17 17 14 19 17 19 18|19 19 18|19 19 17 26 17 28 26 28 28 30 30 35 35 14 35 36 36 40 35 14	INDIRECT-UPREGULATOR
9353417	CHEMICAL	GENE	T11	T31	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ D2-short @/GENETgt$ ? [SEP] The finding that up-regulation of D2 @CHEMICALSrc$ dopamine @/CHEMICALSrc$ receptor mRNAs was a consistently observed effect of a wide range of antipsychotic agents in the cerebral cortex but not in the neostriatum , coupled with the fact that the @GENETgt$ D2-short @/GENETgt$ isoforms in the cortex were not regulated by a nonantipsychotic D2 antagonist , tiapride , draws attention to the importance of the D2 dopamine receptor in the cerebral cortex as a potentially critical , common site of action of antipsychotic medications .	2 56 15 15 10 10 10|6 10 10|6 10 4 15 15 14 15 2 19 19 19 15 22 22 19 26 26 26 15 26 31 31 31 26 15 2 36 36 33 47 41 41|37 41 41|37 47 44 44 41 47 47 36 52 52 52 52 47 52 52 52 56 56 60 60 56 65 65 65 65 60 69 69 69 60 76 76 73 76 76 76 56 78 76 81 81 78 56	None-BC7
9353417	CHEMICAL	GENE	T27	T40	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ D2 and D4 dopamine receptor @/GENETgt$ ? [SEP] Differential regulation of @GENETgt$ D2 and D4 @/GENETgt$ @CHEMICALSrc$ dopamine receptor @/CHEMICALSrc$ mRNAs in the primate cerebral cortex vs. neostriatum : effects of chronic treatment with typical and atypical antipsychotic drugs .	2 2 11 11|3|4 11|3|4 11|3|4 11|4 11|3|4 11|4 11|4 11 11|4 2 16 16 16 16 2 16 16 2 2 23 23 20 29 29 25 25 29 23 2	None-BC7
9353417	CHEMICAL	GENE	T25	T39	True	0	What is [Drugprot] between @CHEMICALSrc$ clozapine @/CHEMICALSrc$ and @GENETgt$ D2-short @/GENETgt$ ? [SEP] The same drug treatments produced less uniform effects in the neostriatum than in the cortex : @CHEMICALSrc$ clozapine @/CHEMICALSrc$ and olanzapine failed to significantly elevate either D2-long or @GENETgt$ D2-short @/GENETgt$ receptor messages in this structure unlike all other drugs , including tiapride .	4 4 4 5 5 7 8 5 11 11 5 15 15 15 5 5 16|5 5 16|5 17 17 5 24 24 21 26 24 26 26 26 26 31 24 34 34 24 38 38 38 24 38 41 38 5	None-BC7
9353417	CHEMICAL	GENE	T11	T30	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ D2 dopamine receptor @/GENETgt$ ? [SEP] The finding that up-regulation of @GENETgt$ D2 @/GENETgt$ @CHEMICALSrc$ dopamine receptor @/CHEMICALSrc$ mRNAs was a consistently observed effect of a wide range of antipsychotic agents in the cerebral cortex but not in the neostriatum , coupled with the fact that the D2-short isoforms in the cortex were not regulated by a nonantipsychotic D2 antagonist , tiapride , draws attention to the importance of the D2 dopamine receptor in the cerebral cortex as a potentially critical , common site of action of antipsychotic medications .	2 56 16 16 11 11|5 11 11|5 11|6 11|6 11 11|6 4 16 16 15 16 2 20 20 20 16 23 23 20 27 27 27 16 27 32 32 32 27 16 2 37 37 34 47 41 41 47 44 44 41 47 47 37 52 52 52 52 47 52 52 52 56 56 60 60 56 65 65 65 65 60 69 69 69 60 76 76 73 76 76 76 56 78 76 81 81 78 56	None-BC7
9353417	CHEMICAL	GENE	T12	T33	True	0	What is [Drugprot] between @CHEMICALSrc$ tiapride @/CHEMICALSrc$ and @GENETgt$ D2 dopamine receptor @/GENETgt$ ? [SEP] The finding that up-regulation of D2 dopamine receptor mRNAs was a consistently observed effect of a wide range of antipsychotic agents in the cerebral cortex but not in the neostriatum , coupled with the fact that the D2-short isoforms in the cortex were not regulated by a nonantipsychotic D2 antagonist , @CHEMICALSrc$ tiapride @/CHEMICALSrc$ , draws attention to the importance of the @GENETgt$ D2 dopamine receptor @/GENETgt$ in the cerebral cortex as a potentially critical , common site of action of antipsychotic medications .	2 55 14 14 9 9 9 9 4 14 14 13 14 2 18 18 18 14 21 21 18 25 25 25 14 25 30 30 30 25 14 2 35 35 32 45 39 39 45 42 42 39 45 45 35 50 50 50 50 45 50 50|51 50 50|51 50 55 55 59 59 55 62 62 59|60|62 59|60|62 59|60|62 59|62 59|60|62 69 69 69 59 76 76 73 76 76 76 55 78 76 81 81 78 55	None-BC7
9353417	CHEMICAL	GENE	T9	T29	True	0	What is [Drugprot] between @CHEMICALSrc$ pimozide @/CHEMICALSrc$ and @GENETgt$ D4 @/GENETgt$ ? [SEP] Other drugs of the typical ( molindone and @CHEMICALSrc$ pimozide @/CHEMICALSrc$ ) and atypical ( remoxipride ) classes had no effect on @GENETgt$ D4 @/GENETgt$ mRNA levels in either cortical or striatal tissue .	2 18 7 7 7 7 2 7 8|7 7 8|7 7 2 17 15 13 15 2 18 20 18 25 25|20 25 25|20 25 18 28 28 18 28 28 28 18	None-BC7
9353417	CHEMICAL	GENE	T15	T36	True	0	What is [Drugprot] between @CHEMICALSrc$ clozapine @/CHEMICALSrc$ and @GENETgt$ D2 and D4 dopamine receptor @/GENETgt$ ? [SEP] The RNase Protection Assay was used to examine the regulation of @GENETgt$ D2 and D4 dopamine receptor @/GENETgt$ mRNAs in the cerebral cortex and neostriatum of nonhuman primates after chronic treatment with a wide spectrum of antipsychotic medications ( chlorpromazine , @CHEMICALSrc$ clozapine @/CHEMICALSrc$ , haloperidol , molindone , olanzapine , pimozide , remoxipride and risperidone ) .	4 4 4 6 6 6 8 6 10 8 18 18|11|12 18|11|12 18|11|12 18|11|12 18|11|12 18|12 18|11|12 10 22 22 22 10 22 22 27 27 22 30 30 8 34 34 34 30 37 37 34 39 37 39 35|39 39 35|39 39 39 39 39 39 39 39 39 39 39 52 52 39 6	None-BC7
9353417	CHEMICAL	GENE	T8	T29	True	0	What is [Drugprot] between @CHEMICALSrc$ molindone @/CHEMICALSrc$ and @GENETgt$ D4 @/GENETgt$ ? [SEP] Other drugs of the typical ( @CHEMICALSrc$ molindone @/CHEMICALSrc$ and pimozide ) and atypical ( remoxipride ) classes had no effect on @GENETgt$ D4 @/GENETgt$ mRNA levels in either cortical or striatal tissue .	2 18 7 7 7 7 2|6 2 2|6 7 7 7 2 17 15 13 15 2 18 20 18 25 25|20 25 25|20 25 18 28 28 18 28 28 28 18	None-BC7
9353417	CHEMICAL	GENE	T10	T29	True	0	What is [Drugprot] between @CHEMICALSrc$ remoxipride @/CHEMICALSrc$ and @GENETgt$ D4 @/GENETgt$ ? [SEP] Other drugs of the typical ( molindone and pimozide ) and atypical ( @CHEMICALSrc$ remoxipride @/CHEMICALSrc$ ) classes had no effect on @GENETgt$ D4 @/GENETgt$ mRNA levels in either cortical or striatal tissue .	2 18 7 7 7 7 2 7 7 7 2 17 14 12|13 12 12|13 14 2 18 20 18 25 25|20 25 25|20 25 18 28 28 18 28 28 28 18	None-BC7
9353417	CHEMICAL	GENE	T13	T31	True	0	What is [Drugprot] between @CHEMICALSrc$ dopamine @/CHEMICALSrc$ and @GENETgt$ D2-short @/GENETgt$ ? [SEP] The finding that up-regulation of D2 dopamine receptor mRNAs was a consistently observed effect of a wide range of antipsychotic agents in the cerebral cortex but not in the neostriatum , coupled with the fact that the @GENETgt$ D2-short @/GENETgt$ isoforms in the cortex were not regulated by a nonantipsychotic D2 antagonist , tiapride , draws attention to the importance of the D2 @CHEMICALSrc$ dopamine @/CHEMICALSrc$ receptor in the cerebral cortex as a potentially critical , common site of action of antipsychotic medications .	2 55 14 14 9 9 9 9 4 14 14 13 14 2 18 18 18 14 21 21 18 25 25 25 14 25 30 30 30 25 14 2 35 35 32 46 40 40|37 40 40|37 46 43 43 40 46 46 35 51 51 51 51 46 51 51 51 55 55 59 59 55 65 65 65 65|61 65 65|61 59 69 69 69 59 76 76 73 76 76 76 55 78 76 81 81 78 55	None-BC7
9353417	CHEMICAL	GENE	T22	T34	True	0	What is [Drugprot] between @CHEMICALSrc$ Tiapride @/CHEMICALSrc$ and @GENETgt$ D2 @/GENETgt$ ? [SEP] @CHEMICALSrc$ Tiapride @/CHEMICALSrc$ , a @GENETgt$ D2 @/GENETgt$ antagonist that lacks antipsychotic activity , was also included .	0|15 15 0|15 1 7 3|7 7 3|7 1 9 7 11 9 1 15 15 15 15	ANTAGONIST
9353417	CHEMICAL	GENE	T1	T39	True	0	What is [Drugprot] between @CHEMICALSrc$ tiapride @/CHEMICALSrc$ and @GENETgt$ D2-short @/GENETgt$ ? [SEP] The same drug treatments produced less uniform effects in the neostriatum than in the cortex : clozapine and olanzapine failed to significantly elevate either D2-long or @GENETgt$ D2-short @/GENETgt$ receptor messages in this structure unlike all other drugs , including @CHEMICALSrc$ tiapride @/CHEMICALSrc$ .	4 4 4 5 5 7 8 5 11 11 5 15 15 15 5 5 5 17 17 5 23 23 20 25 23 25 25|26 25 25|26 30 23 33 33 23 37 37 37 23 37 40 37|38 37 37|38 5	None-BC7
9353417	CHEMICAL	GENE	T12	T31	True	0	What is [Drugprot] between @CHEMICALSrc$ tiapride @/CHEMICALSrc$ and @GENETgt$ D2-short @/GENETgt$ ? [SEP] The finding that up-regulation of D2 dopamine receptor mRNAs was a consistently observed effect of a wide range of antipsychotic agents in the cerebral cortex but not in the neostriatum , coupled with the fact that the @GENETgt$ D2-short @/GENETgt$ isoforms in the cortex were not regulated by a nonantipsychotic D2 antagonist , @CHEMICALSrc$ tiapride @/CHEMICALSrc$ , draws attention to the importance of the D2 dopamine receptor in the cerebral cortex as a potentially critical , common site of action of antipsychotic medications .	2 56 14 14 9 9 9 9 4 14 14 13 14 2 18 18 18 14 21 21 18 25 25 25 14 25 30 30 30 25 14 2 35 35 32 46 40 40|37 40 40|37 46 43 43 40 46 46 35 51 51 51 51 46 51 51 51 51 51 56 56 60 60 56 65 65 65 65 60 69 69 69 60 76 76 73 76 76 76 56 78 76 81 81 78 56	None-BC7
9353417	CHEMICAL	GENE	T2	T28	True	0	What is [Drugprot] between @CHEMICALSrc$ chlorpromazine @/CHEMICALSrc$ and @GENETgt$ D4 receptor @/GENETgt$ ? [SEP] In both the cerebral cortex and striatum , @GENETgt$ D4 receptor @/GENETgt$ mRNA was upregulated by certain typical ( @CHEMICALSrc$ chlorpromazine @/CHEMICALSrc$ and haloperidol ) and certain atypical ( clozapine , olanzapine and risperidone ) antipsychotic agents as well as by tiapride .	5 5 5 5 14 5 5 14 8|12 8|12 12 8|12 14 14 14 17 17 14 19 16|17 17 16|17 19 19 19 17 26 17 28 26 28 28 30 30 35 35 14 35 36 36 40 35 14	INDIRECT-UPREGULATOR
9353417	CHEMICAL	GENE	T26	T39	True	0	What is [Drugprot] between @CHEMICALSrc$ olanzapine @/CHEMICALSrc$ and @GENETgt$ D2-short @/GENETgt$ ? [SEP] The same drug treatments produced less uniform effects in the neostriatum than in the cortex : clozapine and @CHEMICALSrc$ olanzapine @/CHEMICALSrc$ failed to significantly elevate either D2-long or @GENETgt$ D2-short @/GENETgt$ receptor messages in this structure unlike all other drugs , including tiapride .	4 4 4 5 5 7 8 5 11 11 5 15 15 15 5 5 5 17 17|18 17 17|18 5 24 24 21 26 24 26 26 26 26 31 24 34 34 24 38 38 38 24 38 41 38 5	None-BC7
14585280	CHEMICAL	GENE	T1	T9	True	0	What is [Drugprot] between @CHEMICALSrc$ 5-azacytidine @/CHEMICALSrc$ and @GENETgt$ DNA methyltransferase @/GENETgt$ ? [SEP] For these reasons , the use of irreversible @GENETgt$ DNA methyltransferase @/GENETgt$ inhibitors , such as @CHEMICALSrc$ 5-azacytidine @/CHEMICALSrc$ and Decitabine , appears to be a promising option for the treatment of MDS and acute myeloid leukemia .	3 3 21 21 6 4 12 12 8|12 8|12 12 8|12 6 12 16 14 12|13 12 12|13 16 16 21 21 26 26 26 26 21 29 29 26 31 29 31 35 35 31 21	INHIBITOR
14585280	CHEMICAL	GENE	T7	T11	True	0	What is [Drugprot] between @CHEMICALSrc$ PB @/CHEMICALSrc$ and @GENETgt$ p15 @/GENETgt$ ? [SEP] The synergistic effect of histone deacetylase inhibitors , including phenylbutyrate ( PB ) , in reactivating silenced genes encouraged clinical studies on the combination of @CHEMICALSrc$ PB @/CHEMICALSrc$ and demethylating agents in hematological diseases , characterized by @GENETgt$ p15 @/GENETgt$ silencing .	3 3 19 7 7 7 3 7 10 7 12 10 12 3 16 3 18 16 19 21 19 24 24 21 26 24|25 24 24|25 26 26 26 33 33 24 21 21 39 35|39 39 35|39 35 19	None-BC7
14585280	CHEMICAL	GENE	T2	T9	True	0	What is [Drugprot] between @CHEMICALSrc$ Decitabine @/CHEMICALSrc$ and @GENETgt$ DNA methyltransferase @/GENETgt$ ? [SEP] For these reasons , the use of irreversible @GENETgt$ DNA methyltransferase @/GENETgt$ inhibitors , such as 5-azacytidine and @CHEMICALSrc$ Decitabine @/CHEMICALSrc$ , appears to be a promising option for the treatment of MDS and acute myeloid leukemia .	3 3 21 21 6 4 12 12 8|12 8|12 12 8|12 6 12 16 14 12 16 16|15 16 16|15 21 21 26 26 26 26 21 29 29 26 31 29 31 35 35 31 21	INHIBITOR
14585280	CHEMICAL	GENE	T6	T11	True	0	What is [Drugprot] between @CHEMICALSrc$ PB @/CHEMICALSrc$ and @GENETgt$ p15 @/GENETgt$ ? [SEP] The synergistic effect of histone deacetylase inhibitors , including phenylbutyrate ( @CHEMICALSrc$ PB @/CHEMICALSrc$ ) , in reactivating silenced genes encouraged clinical studies on the combination of PB and demethylating agents in hematological diseases , characterized by @GENETgt$ p15 @/GENETgt$ silencing .	3 3 20 7 7 7 3 7 10 7 12 10|11 10 10|11 12 3 17 3 19 17 20 22 20 25 25 22 27 25 27 27 27 33 33 25 22 22 39 35|39 39 35|39 35 20	None-BC7
14585280	CHEMICAL	GENE	T7	T10	True	0	What is [Drugprot] between @CHEMICALSrc$ PB @/CHEMICALSrc$ and @GENETgt$ histone deacetylase @/GENETgt$ ? [SEP] The synergistic effect of @GENETgt$ histone deacetylase @/GENETgt$ inhibitors , including phenylbutyrate ( PB ) , in reactivating silenced genes encouraged clinical studies on the combination of @CHEMICALSrc$ PB @/CHEMICALSrc$ and demethylating agents in hematological diseases , characterized by p15 silencing .	3 3 20 8 8|4 8|4 8 8|4 3 8 11 8 13 11 13 3 17 3 19 17 20 22 20 25 25 22 27 24|25 25 24|25 27 27 27 34 34 25 22 22 39 39 36 20	None-BC7
14585280	CHEMICAL	GENE	T6	T10	True	0	What is [Drugprot] between @CHEMICALSrc$ PB @/CHEMICALSrc$ and @GENETgt$ histone deacetylase @/GENETgt$ ? [SEP] The synergistic effect of @GENETgt$ histone deacetylase @/GENETgt$ inhibitors , including phenylbutyrate ( @CHEMICALSrc$ PB @/CHEMICALSrc$ ) , in reactivating silenced genes encouraged clinical studies on the combination of PB and demethylating agents in hematological diseases , characterized by p15 silencing .	3 3 21 8 8|4 8|4 8 8|4 3 8 11 8 13 10|11 11 10|11 13 3 18 3 20 18 21 23 21 26 26 23 28 26 28 28 28 34 34 26 23 23 39 39 36 21	INHIBITOR
14585280	CHEMICAL	GENE	T8	T12	True	0	What is [Drugprot] between @CHEMICALSrc$ Decitabine @/CHEMICALSrc$ and @GENETgt$ HDAC @/GENETgt$ ? [SEP] The sequential administration of a " first generation " demethylating agent and @GENETgt$ HDAC @/GENETgt$ inhibitors gave preliminary evidence of a reduced methylation of target genes , as also described with @CHEMICALSrc$ Decitabine @/CHEMICALSrc$ .	3 3 16 11 11 11 8 11 11 11 3 11 12|15 15 12|15 11 16 18 16 22 22 22 18 25 25 22 16 29 29 16 31 29 29 29 16	None-BC7
14585280	CHEMICAL	GENE	T5	T11	True	0	What is [Drugprot] between @CHEMICALSrc$ phenylbutyrate @/CHEMICALSrc$ and @GENETgt$ p15 @/GENETgt$ ? [SEP] The synergistic effect of histone deacetylase inhibitors , including @CHEMICALSrc$ phenylbutyrate @/CHEMICALSrc$ ( PB ) , in reactivating silenced genes encouraged clinical studies on the combination of PB and demethylating agents in hematological diseases , characterized by @GENETgt$ p15 @/GENETgt$ silencing .	3 3 20 7 7 7 3 7 10 9|7 7 9|7 13 10 13 3 17 3 19 17 20 22 20 25 25 22 27 25 27 27 27 33 33 25 22 22 39 35|39 39 35|39 35 20	None-BC7
14585280	CHEMICAL	GENE	T5	T10	True	0	What is [Drugprot] between @CHEMICALSrc$ phenylbutyrate @/CHEMICALSrc$ and @GENETgt$ histone deacetylase @/GENETgt$ ? [SEP] The synergistic effect of @GENETgt$ histone deacetylase @/GENETgt$ inhibitors , including @CHEMICALSrc$ phenylbutyrate @/CHEMICALSrc$ ( PB ) , in reactivating silenced genes encouraged clinical studies on the combination of PB and demethylating agents in hematological diseases , characterized by p15 silencing .	3 3 21 8 8|4 8|4 8 8|4 3 8 11 8 8 8 14 11 14 3 18 3 20 18 21 23 21 26 26 23 28 26 28 28 28 34 34 26 23 23 39 39 36 21	INHIBITOR
23211364	CHEMICAL	GENE	T10	T11	True	0	What is [Drugprot] between @CHEMICALSrc$ candesartan @/CHEMICALSrc$ and @GENETgt$ BDNF @/GENETgt$ ? [SEP] In addition , human cerebromicrovascular endothelial cells were treated with either low-dose ( 1 ƒM ) or high-dose ( 1 µM ) angiotensin II alone or in combination with candesartan ( 0.16 µM ) to assess the effect of @CHEMICALSrc$ candesartan @/CHEMICALSrc$ treatment and @GENETgt$ BDNF @/GENETgt$ involvement in the behavior of endothelial cells .	2 9 9 7 7 7 9 9 9 12 12 9 15 15 12 15 12 23 21 21 23 23 12 23 12 12 28 12 30 28 33 33 30 33 36 9 38 36 42 42|39 42 42|39 38 42 42|46 46 42|46 42 49 49 38 52 52 49 9	None-BC7
23211364	CHEMICAL	GENE	T10	T28	True	0	What is [Drugprot] between @CHEMICALSrc$ candesartan @/CHEMICALSrc$ and @GENETgt$ angiotensin II @/GENETgt$ ? [SEP] In addition , human cerebromicrovascular endothelial cells were treated with either low-dose ( 1 ƒM ) or high-dose ( 1 µM ) @GENETgt$ angiotensin II @/GENETgt$ alone or in combination with candesartan ( 0.16 µM ) to assess the effect of @CHEMICALSrc$ candesartan @/CHEMICALSrc$ treatment and BDNF involvement in the behavior of endothelial cells .	2 9 9 7 7 7 9 9 9 12 12 9 15 15 12 15 12 23 21 21 23 23 12|22|23 12|22|23 12|23 12|22|23 12 12 29 12 31 29 34 34 31 34 37 9 39 37 43 43|38 43 43|38 39 43 46 43 49 49 39 52 52 49 9	None-BC7
23211364	CHEMICAL	GENE	T3	T13	True	0	What is [Drugprot] between @CHEMICALSrc$ candesartan @/CHEMICALSrc$ and @GENETgt$ AngII @/GENETgt$ ? [SEP] In addition , @CHEMICALSrc$ candesartan @/CHEMICALSrc$ reversed the antiangiogenic effect of the 1-µM dose of @GENETgt$ AngII @/GENETgt$ ( P = 0.0001 ) .	2 6 6 3|6 6 3|6 6 9 9 6 13 13 13 9 15 13 13 13 18 19 6 19 19 6	None-BC7
23211364	CHEMICAL	GENE	T9	T11	True	0	What is [Drugprot] between @CHEMICALSrc$ candesartan @/CHEMICALSrc$ and @GENETgt$ BDNF @/GENETgt$ ? [SEP] In addition , human cerebromicrovascular endothelial cells were treated with either low-dose ( 1 ƒM ) or high-dose ( 1 µM ) angiotensin II alone or in combination with @CHEMICALSrc$ candesartan @/CHEMICALSrc$ ( 0.16 µM ) to assess the effect of candesartan treatment and @GENETgt$ BDNF @/GENETgt$ involvement in the behavior of endothelial cells .	2 9 9 7 7 7 9 9 9 12 12 9 15 15 12 15 12 23 21 21 23 23 12 23 12 12 28 12 30 28|29 28 28|29 34 34 30 34 37 9 39 37 42 42 39 42 42|46 46 42|46 42 49 49 39 52 52 49 9	None-BC7
23211364	CHEMICAL	GENE	T8	T27	True	0	What is [Drugprot] between @CHEMICALSrc$ candesartan @/CHEMICALSrc$ and @GENETgt$ BDNF @/GENETgt$ ? [SEP] Accordingly , spontaneously hypertensive rats were treated with @CHEMICALSrc$ candesartan @/CHEMICALSrc$ , and brain tissue samples were collected for quantification of @GENETgt$ BDNF @/GENETgt$ expression .	7 7 4 5 7 7 7 9 8|7 7 8|7 7 7 15 15 17 17 7 19 17 23 19|23 23 19|23 19 17	None-BC7
23211364	CHEMICAL	GENE	T4	T14	True	0	What is [Drugprot] between @CHEMICALSrc$ candesartan @/CHEMICALSrc$ and @GENETgt$ BDNF @/GENETgt$ ? [SEP] The observed effects of @CHEMICALSrc$ candesartan @/CHEMICALSrc$ were ablated by neutralizing the effects of @GENETgt$ BDNF @/GENETgt$ .	3 3 8 5 3|4 3 3|4 8 8 10 8 12 10 14 12 12 12 8	None-BC7
23211364	CHEMICAL	GENE	T9	T28	True	0	What is [Drugprot] between @CHEMICALSrc$ candesartan @/CHEMICALSrc$ and @GENETgt$ angiotensin II @/GENETgt$ ? [SEP] In addition , human cerebromicrovascular endothelial cells were treated with either low-dose ( 1 ƒM ) or high-dose ( 1 µM ) @GENETgt$ angiotensin II @/GENETgt$ alone or in combination with @CHEMICALSrc$ candesartan @/CHEMICALSrc$ ( 0.16 µM ) to assess the effect of candesartan treatment and BDNF involvement in the behavior of endothelial cells .	2 9 9 7 7 7 9 9 9 12 12 9 15 15 12 15 12 23 21 21 23 23 12|22|23 12|22|23 12|23 12|22|23 12 12 29 12 31 28|29 29 28|29 35 35 31 35 38 9 40 38 43 43 40 43 46 43 49 49 40 52 52 49 9	None-BC7
23211364	CHEMICAL	GENE	T5	T15	True	0	What is [Drugprot] between @CHEMICALSrc$ PD-123319 @/CHEMICALSrc$ and @GENETgt$ AT2 @/GENETgt$ ? [SEP] Treatment with the @GENETgt$ AT2 @/GENETgt$ antagonist @CHEMICALSrc$ PD-123319 @/CHEMICALSrc$ significantly reduced tube-like formation in endothelial cells .	10 7 7 3|7 7 3|7 7 1|5 1 1|5 10 10 12 10 15 15 12 10	ANTAGONIST
23211364	CHEMICAL	GENE	T2	T12	True	0	What is [Drugprot] between @CHEMICALSrc$ Candesartan @/CHEMICALSrc$ and @GENETgt$ BDNF @/GENETgt$ ? [SEP] @CHEMICALSrc$ Candesartan @/CHEMICALSrc$ significantly increased the expression of @GENETgt$ BDNF @/GENETgt$ in the SHR ( P < 0.05 ) .	0|4 4 0|4 4 4 6 4 8 6 6 6 12 12 4 14 12 14 14 14 4	INDIRECT-UPREGULATOR
23211364	CHEMICAL	GENE	T7	T22	True	0	What is [Drugprot] between @CHEMICALSrc$ candesartan @/CHEMICALSrc$ and @GENETgt$ vascular endothelial growth factor @/GENETgt$ ? [SEP] In experimental stroke , @CHEMICALSrc$ candesartan @/CHEMICALSrc$ induces a proangiogenic effect that is partly attributable to @GENETgt$ vascular endothelial growth factor @/GENETgt$ .	3 3 7 7 4|7 7 4|7 7 10 10 7 14 14 14 10 16 16|14 16|14 16|14 16|14 16|14 16|14 7	None-BC7
23211364	CHEMICAL	GENE	T1	T21	True	0	What is [Drugprot] between @CHEMICALSrc$ Candesartan @/CHEMICALSrc$ and @GENETgt$ angiotensin II type 1 receptor @/GENETgt$ ? [SEP] @CHEMICALSrc$ Candesartan @/CHEMICALSrc$ is an @GENETgt$ angiotensin II type 1 receptor @/GENETgt$ blocker ( ARB ) that has been to shown to limit ischemic stroke and improve stroke outcome .	0|11 11 0|11 11 11 11|3 11|3 11|3 11|3 11|3 11 11|3 11 13 11 13 19 19 19 19 11 21 19 23 21 21 21 27 25 11	INHIBITOR
23211364	CHEMICAL	GENE	T6	T18	True	0	What is [Drugprot] between @CHEMICALSrc$ candesartan @/CHEMICALSrc$ and @GENETgt$ angiotensin II @/GENETgt$ ? [SEP] In conclusion , @CHEMICALSrc$ candesartan @/CHEMICALSrc$ exerts a proangiogenic effect on brain microvascular endothelial cells treated with @GENETgt$ angiotensin II @/GENETgt$ .	2 6 6 3|6 6 3|6 6 9 9 6 14 14 14 14 9 14 17 17|15 17|15 17|15 17|15 6	None-BC7
23624810	CHEMICAL	GENE	T5	T16	True	0	What is [Drugprot] between @CHEMICALSrc$ oxytocin @/CHEMICALSrc$ and @GENETgt$ oxytocin receptor @/GENETgt$ ? [SEP] METHODS : Resident animals were intracerebroventricularly ( icv ) administered with different doses of synthetic @CHEMICALSrc$ oxytocin @/CHEMICALSrc$ and @GENETgt$ oxytocin receptor @/GENETgt$ antagonist , alone and in combination , in order to manipulate brain oxytocin functioning and to assess their behavioral response to an intruder .	1 1 4 10 10 10 8 6 8 1 13 13 10 16 16 13|15 13 13|15 16 17|22 17|22 22 17|22 16 10 10 24 27 10 10 30 10 32 30 34 35 32 32 38 32 41 41 38 44 44 38 10	None-BC7
23624810	CHEMICAL	GENE	T5	T18	True	0	What is [Drugprot] between @CHEMICALSrc$ oxytocin @/CHEMICALSrc$ and @GENETgt$ oxytocin @/GENETgt$ ? [SEP] METHODS : Resident animals were intracerebroventricularly ( icv ) administered with different doses of synthetic @CHEMICALSrc$ oxytocin @/CHEMICALSrc$ and oxytocin receptor antagonist , alone and in combination , in order to manipulate brain @GENETgt$ oxytocin @/GENETgt$ functioning and to assess their behavioral response to an intruder .	1 1 4 10 10 10 8 6 8 1 13 13 10 16 16 13|15 13 13|15 16 21 21 16 10 10 23 26 10 10 29 10 31 29 33 35|31 35 35|31 31 31 38 31 41 41 38 44 44 38 10	None-BC7
23624810	CHEMICAL	GENE	T6	T15	True	0	What is [Drugprot] between @CHEMICALSrc$ oxytocin @/CHEMICALSrc$ and @GENETgt$ oxytocin @/GENETgt$ ? [SEP] METHODS : Resident animals were intracerebroventricularly ( icv ) administered with different doses of synthetic @GENETgt$ oxytocin @/GENETgt$ and @CHEMICALSrc$ oxytocin @/CHEMICALSrc$ receptor antagonist , alone and in combination , in order to manipulate brain oxytocin functioning and to assess their behavioral response to an intruder .	1 1 4 10 10 10 8 6 8 1 13 13 10 16 16 13|15 13 13|15 16 17|22 22 17|22 22 16 10 10 24 27 10 10 30 10 32 30 34 35 32 32 38 32 41 41 38 44 44 38 10	None-BC7
23624810	CHEMICAL	GENE	T8	T15	True	0	What is [Drugprot] between @CHEMICALSrc$ oxytocin @/CHEMICALSrc$ and @GENETgt$ oxytocin @/GENETgt$ ? [SEP] METHODS : Resident animals were intracerebroventricularly ( icv ) administered with different doses of synthetic @GENETgt$ oxytocin @/GENETgt$ and oxytocin receptor antagonist , alone and in combination , in order to manipulate brain @CHEMICALSrc$ oxytocin @/CHEMICALSrc$ functioning and to assess their behavioral response to an intruder .	1 1 4 10 10 10 8 6 8 1 13 13 10 16 16 13|15 13 13|15 16 21 21 16 10 10 23 26 10 10 29 10 31 29 33 35|31 35 35|31 31 31 38 31 41 41 38 44 44 38 10	None-BC7
23624810	CHEMICAL	GENE	T8	T16	True	0	What is [Drugprot] between @CHEMICALSrc$ oxytocin @/CHEMICALSrc$ and @GENETgt$ oxytocin receptor @/GENETgt$ ? [SEP] METHODS : Resident animals were intracerebroventricularly ( icv ) administered with different doses of synthetic oxytocin and @GENETgt$ oxytocin receptor @/GENETgt$ antagonist , alone and in combination , in order to manipulate brain @CHEMICALSrc$ oxytocin @/CHEMICALSrc$ functioning and to assess their behavioral response to an intruder .	1 1 4 10 10 10 8 6 8 1 13 13 10 16 16 13 16 17|21 17|21 21 17|21 16 10 10 23 26 10 10 29 10 31 29 33 35|30 35 35|30 31 31 38 31 41 41 38 44 44 38 10	None-BC7
23624810	CHEMICAL	GENE	T6	T18	True	0	What is [Drugprot] between @CHEMICALSrc$ oxytocin @/CHEMICALSrc$ and @GENETgt$ oxytocin @/GENETgt$ ? [SEP] METHODS : Resident animals were intracerebroventricularly ( icv ) administered with different doses of synthetic oxytocin and @CHEMICALSrc$ oxytocin @/CHEMICALSrc$ receptor antagonist , alone and in combination , in order to manipulate brain @GENETgt$ oxytocin @/GENETgt$ functioning and to assess their behavioral response to an intruder .	1 1 4 10 10 10 8 6 8 1 13 13 10 16 16 13 16 17|21 21 17|21 21 16 10 10 23 26 10 10 29 10 31 29 33 35|31 35 35|31 31 31 38 31 41 41 38 44 44 38 10	None-BC7
10626836	CHEMICAL	GENE	T5	T21	True	0	What is [Drugprot] between @CHEMICALSrc$ aniracetam @/CHEMICALSrc$ and @GENETgt$ GluR3 @/GENETgt$ ? [SEP] Specifically , @CHEMICALSrc$ aniracetam @/CHEMICALSrc$ , which potentiates wild-type AMPA receptors , is ineffective on the non-desensitizing @GENETgt$ GluR3(L507Y @/GENETgt$ ) mutant , but has synergistic effects with lithium on wild-type receptors .	13 13 2|13 13 2|13 3 7 3 10 10 7 3 13 13 20 20 20 20|15 20 20|15 20 13 13 13 13 25 23 27 25 30 30 25 13	None-BC7
10626836	CHEMICAL	GENE	T11	T24	True	0	What is [Drugprot] between @CHEMICALSrc$ AMPA @/CHEMICALSrc$ and @GENETgt$ glutamate receptor @/GENETgt$ ? [SEP] Analysis of splice variants and site-directed mutants of the @CHEMICALSrc$ AMPA @/CHEMICALSrc$ receptor GluR3 expressed in Xenopus oocytes has shown that lithium produces a large potentiation of the GluR3 flop splice variant and suggested that lithium might inhibit rapid desensitization , which is characteristic of this receptor ( Karkanias , N. and Papke , R. , Subtype-specific effects of lithium on @GENETgt$ glutamate receptor @/GENETgt$ function .	19 4 4 1 4 7 4 13 13 9|13 13 9|13 13 7 4 17 17 14 19 19 22 22 19 25 25 22 31 31 31 31 31 25 22 22 37 37 37 33 39 37 39 43 43 39 46 46 43 48 46 48 48 50 50 48 48 48 57 48 59 57 64 64|59 64|59 64 64|59 57 19	None-BC7
10626836	CHEMICAL	GENE	T7	T21	True	0	What is [Drugprot] between @CHEMICALSrc$ lithium @/CHEMICALSrc$ and @GENETgt$ GluR3 @/GENETgt$ ? [SEP] Specifically , aniracetam , which potentiates wild-type AMPA receptors , is ineffective on the non-desensitizing @GENETgt$ GluR3(L507Y @/GENETgt$ ) mutant , but has synergistic effects with @CHEMICALSrc$ lithium @/CHEMICALSrc$ on wild-type receptors .	12 12 12 3 6 3 9 9 6 3 12 12 19 19 19 19|15 19 19|15 19 12 12 12 12 24 22 26 24 24 24 30 30 24 12	ACTIVATOR
10626836	CHEMICAL	GENE	T9	T23	True	0	What is [Drugprot] between @CHEMICALSrc$ lithium @/CHEMICALSrc$ and @GENETgt$ GluR3 flop @/GENETgt$ ? [SEP] Analysis of splice variants and site-directed mutants of the AMPA receptor GluR3 expressed in Xenopus oocytes has shown that lithium produces a large potentiation of the @GENETgt$ GluR3 flop @/GENETgt$ splice variant and suggested that lithium might inhibit rapid desensitization , which is characteristic of this receptor ( Karkanias , N. and Papke , R. , Subtype-specific effects of @CHEMICALSrc$ lithium @/CHEMICALSrc$ on glutamate receptor function .	18 4 4 1 4 7 4 12 12 12 12 7 4 16 16 13 18 18 21 21 18 24 24 21 31 31 26|31 26|31 31 26|31 31 24 21 21 37 37 37 33 39 37 39 43 43 39 46 46 43 48 46 48 48 50 50 48 48 48 57 48 59 56|57 57 56|57 64 64 64 57 18	None-BC7
10626836	CHEMICAL	GENE	T5	T22	True	0	What is [Drugprot] between @CHEMICALSrc$ aniracetam @/CHEMICALSrc$ and @GENETgt$ L507Y @/GENETgt$ ? [SEP] Specifically , @CHEMICALSrc$ aniracetam @/CHEMICALSrc$ , which potentiates wild-type AMPA receptors , is ineffective on the non-desensitizing @GENETgt$ GluR3(L507Y @/GENETgt$ ) mutant , but has synergistic effects with lithium on wild-type receptors .	13 13 2|13 13 2|13 3 7 3 10 10 7 3 13 13 20 20 20 20|15 20 20|15 20 13 13 13 13 25 23 27 25 30 30 25 13	None-BC7
10626836	CHEMICAL	GENE	T15	T32	True	0	What is [Drugprot] between @CHEMICALSrc$ Lithium @/CHEMICALSrc$ and @GENETgt$ gluR3 @/GENETgt$ ? [SEP] @CHEMICALSrc$ Lithium @/CHEMICALSrc$ modulates desensitization of the glutamate receptor subtype @GENETgt$ gluR3 @/GENETgt$ in Xenopus oocytes .	0|3 3 0|3 3 3 10 10 10 10 10 8|4 4 8|4 14 14 4 3	None-BC7
10626836	CHEMICAL	GENE	T3	T23	True	0	What is [Drugprot] between @CHEMICALSrc$ lithium @/CHEMICALSrc$ and @GENETgt$ GluR3 flop @/GENETgt$ ? [SEP] Analysis of splice variants and site-directed mutants of the AMPA receptor GluR3 expressed in Xenopus oocytes has shown that @CHEMICALSrc$ lithium @/CHEMICALSrc$ produces a large potentiation of the @GENETgt$ GluR3 flop @/GENETgt$ splice variant and suggested that lithium might inhibit rapid desensitization , which is characteristic of this receptor ( Karkanias , N. and Papke , R. , Subtype-specific effects of lithium on glutamate receptor function .	18 4 4 1 4 7 4 12 12 12 12 7 4 16 16 13 18 18 22 19|22 22 19|22 18 25 25 22 32 32 32|26 32|26 32 32|26 32 25 22 22 38 38 38 34 40 38 40 44 44 40 47 47 44 49 47 49 49 51 51 49 49 49 58 49 60 58 64 64 64 58 18	ACTIVATOR
10626836	CHEMICAL	GENE	T6	T21	True	0	What is [Drugprot] between @CHEMICALSrc$ AMPA @/CHEMICALSrc$ and @GENETgt$ GluR3 @/GENETgt$ ? [SEP] Specifically , aniracetam , which potentiates wild-type @CHEMICALSrc$ AMPA @/CHEMICALSrc$ receptors , is ineffective on the non-desensitizing @GENETgt$ GluR3(L507Y @/GENETgt$ ) mutant , but has synergistic effects with lithium on wild-type receptors .	13 13 13 3 6 3 10 10|7 10 10|7 6 3 13 13 20 20 20 20|15 20 20|15 20 13 13 13 13 25 23 27 25 30 30 25 13	None-BC7
10626836	CHEMICAL	GENE	T11	T23	True	0	What is [Drugprot] between @CHEMICALSrc$ AMPA @/CHEMICALSrc$ and @GENETgt$ GluR3 flop @/GENETgt$ ? [SEP] Analysis of splice variants and site-directed mutants of the @CHEMICALSrc$ AMPA @/CHEMICALSrc$ receptor GluR3 expressed in Xenopus oocytes has shown that lithium produces a large potentiation of the @GENETgt$ GluR3 flop @/GENETgt$ splice variant and suggested that lithium might inhibit rapid desensitization , which is characteristic of this receptor ( Karkanias , N. and Papke , R. , Subtype-specific effects of lithium on glutamate receptor function .	19 4 4 1 4 7 4 13 13 9|13 13 9|13 13 7 4 17 17 14 19 19 22 22 19 25 25 22 32 32 32|26 32|26 32 32|26 32 25 22 22 38 38 38 34 40 38 40 44 44 40 47 47 44 49 47 49 49 51 51 49 49 49 58 49 60 58 64 64 64 58 19	None-BC7
10626836	CHEMICAL	GENE	T5	T20	True	0	What is [Drugprot] between @CHEMICALSrc$ aniracetam @/CHEMICALSrc$ and @GENETgt$ AMPA receptors @/GENETgt$ ? [SEP] Specifically , @CHEMICALSrc$ aniracetam @/CHEMICALSrc$ , which potentiates wild-type @GENETgt$ AMPA receptors @/GENETgt$ , is ineffective on the non-desensitizing GluR3(L507Y ) mutant , but has synergistic effects with lithium on wild-type receptors .	14 14 2|14 14 2|14 3 7 3 9 9|7 9|7 9|7 9|7 3 14 14 20 20 20 20 20 14 14 14 14 25 23 27 25 30 30 25 14	ACTIVATOR
10626836	CHEMICAL	GENE	T1	T29	True	0	What is [Drugprot] between @CHEMICALSrc$ AMPA @/CHEMICALSrc$ and @GENETgt$ GluR3 @/GENETgt$ ? [SEP] Additionally , experiments with the non-desensitizing site-directed mutant @GENETgt$ GluR3(L507Y @/GENETgt$ ) ( Stern-Bach , Y. , Russo , S. , Neuman , M. and Rosenmund , C. , A point mutation in the glutamate binding site blocks desensitization of @CHEMICALSrc$ AMPA @/CHEMICALSrc$ receptors .	37 37 37 8 8 8 8 3 8 8 8 8 15 15 15 8 15 19 19 15 15 15 15 15 15 27 27 15 15 31 31 37 36 36 36 36 31 37 37 42 42|38 42 42|38 38 37	None-BC7
10626836	CHEMICAL	GENE	T12	T28	True	0	What is [Drugprot] between @CHEMICALSrc$ AMPA @/CHEMICALSrc$ and @GENETgt$ GluR3 @/GENETgt$ ? [SEP] We now show that mutation of the 769R/ G desensitization site ( Lomeli , H.M.J. , Melcher , T. , Hoger , T. , Geiger , J.R. , Kuner , T. , Monyer , H. , Higuchi , M.B.A. and Seeburg , P.H , Control of kinetic properties of @CHEMICALSrc$ AMPA @/CHEMICALSrc$ receptor channels by nuclear RNA editing . Science , 9(266 ) ( 1994 ) 1709 - 1713 ) greatly attenuates the lithium-induced potentiation of @GENETgt$ GluR3 @/GENETgt$ .	3 3 3 71 4 11 11 11 11 11 5 13 11 13 13 13 13 13 13 13 13 13 13 13 27 27 13 13 31 31 13 13 35 35 13 13 13 13 13 13 13 13 13 13 13 48 48 45 53 49|53 53 49|53 53 48 57 57 57 5 5 71 59 59 59 68 68 68 68 68 59 59 71 3 74 74 71 76 74 74 74 3	None-BC7
10626836	CHEMICAL	GENE	T8	T23	True	0	What is [Drugprot] between @CHEMICALSrc$ lithium @/CHEMICALSrc$ and @GENETgt$ GluR3 flop @/GENETgt$ ? [SEP] Analysis of splice variants and site-directed mutants of the AMPA receptor GluR3 expressed in Xenopus oocytes has shown that lithium produces a large potentiation of the @GENETgt$ GluR3 flop @/GENETgt$ splice variant and suggested that @CHEMICALSrc$ lithium @/CHEMICALSrc$ might inhibit rapid desensitization , which is characteristic of this receptor ( Karkanias , N. and Papke , R. , Subtype-specific effects of lithium on glutamate receptor function .	18 4 4 1 4 7 4 12 12 12 12 7 4 16 16 13 18 18 21 21 18 24 24 21 31 31 26|31 26|31 31 26|31 31 24 21 21 38 32|38 38 32|38 38 33 40 38 40 44 44 40 47 47 44 49 47 49 49 51 51 49 49 49 58 49 60 58 64 64 64 58 18	None-BC7
10626836	CHEMICAL	GENE	T3	T27	True	0	What is [Drugprot] between @CHEMICALSrc$ lithium @/CHEMICALSrc$ and @GENETgt$ GluR3 @/GENETgt$ ? [SEP] Analysis of splice variants and site-directed mutants of the AMPA receptor @GENETgt$ GluR3 @/GENETgt$ expressed in Xenopus oocytes has shown that @CHEMICALSrc$ lithium @/CHEMICALSrc$ produces a large potentiation of the GluR3 flop splice variant and suggested that lithium might inhibit rapid desensitization , which is characteristic of this receptor ( Karkanias , N. and Papke , R. , Subtype-specific effects of lithium on glutamate receptor function .	19 4 4 1 4 7 4 12 12 12 12 11|7 7 11|7 4 17 17 14 19 19 23 19|23 23 19|23 19 26 26 23 32 32 32 32 32 26 23 23 38 38 38 34 40 38 40 44 44 40 47 47 44 49 47 49 49 51 51 49 49 49 58 49 60 58 64 64 64 58 19	None-BC7
10626836	CHEMICAL	GENE	T9	T25	True	0	What is [Drugprot] between @CHEMICALSrc$ lithium @/CHEMICALSrc$ and @GENETgt$ AMPA receptor @/GENETgt$ ? [SEP] Analysis of splice variants and site-directed mutants of the @GENETgt$ AMPA receptor @/GENETgt$ GluR3 expressed in Xenopus oocytes has shown that lithium produces a large potentiation of the GluR3 flop splice variant and suggested that lithium might inhibit rapid desensitization , which is characteristic of this receptor ( Karkanias , N. and Papke , R. , Subtype-specific effects of @CHEMICALSrc$ lithium @/CHEMICALSrc$ on glutamate receptor function .	19 4 4 1 4 7 4 13 13 9|13 9|13 13 9|13 7 4 17 17 14 19 19 22 22 19 25 25 22 31 31 31 31 31 25 22 22 37 37 37 33 39 37 39 43 43 39 46 46 43 48 46 48 48 50 50 48 48 48 57 48 59 56|57 57 56|57 64 64 64 57 19	None-BC7
10626836	CHEMICAL	GENE	T6	T22	True	0	What is [Drugprot] between @CHEMICALSrc$ AMPA @/CHEMICALSrc$ and @GENETgt$ L507Y @/GENETgt$ ? [SEP] Specifically , aniracetam , which potentiates wild-type @CHEMICALSrc$ AMPA @/CHEMICALSrc$ receptors , is ineffective on the non-desensitizing @GENETgt$ GluR3(L507Y @/GENETgt$ ) mutant , but has synergistic effects with lithium on wild-type receptors .	13 13 13 3 6 3 10 10|7 10 10|7 6 3 13 13 20 20 20 20|15 20 20|15 20 13 13 13 13 25 23 27 25 30 30 25 13	None-BC7
10626836	CHEMICAL	GENE	T9	T27	True	0	What is [Drugprot] between @CHEMICALSrc$ lithium @/CHEMICALSrc$ and @GENETgt$ GluR3 @/GENETgt$ ? [SEP] Analysis of splice variants and site-directed mutants of the AMPA receptor @GENETgt$ GluR3 @/GENETgt$ expressed in Xenopus oocytes has shown that lithium produces a large potentiation of the GluR3 flop splice variant and suggested that lithium might inhibit rapid desensitization , which is characteristic of this receptor ( Karkanias , N. and Papke , R. , Subtype-specific effects of @CHEMICALSrc$ lithium @/CHEMICALSrc$ on glutamate receptor function .	19 4 4 1 4 7 4 12 12 12 12 11|7 7 11|7 4 17 17 14 19 19 22 22 19 25 25 22 31 31 31 31 31 25 22 22 37 37 37 33 39 37 39 43 43 39 46 46 43 48 46 48 48 50 50 48 48 48 57 48 59 57 57 57 64 64 64 57 19	None-BC7
10626836	CHEMICAL	GENE	T14	T17	True	0	What is [Drugprot] between @CHEMICALSrc$ glutamate @/CHEMICALSrc$ and @GENETgt$ AMPA receptors @/GENETgt$ ? [SEP] Additionally , experiments with the non-desensitizing site-directed mutant GluR3(L507Y ) ( Stern-Bach , Y. , Russo , S. , Neuman , M. and Rosenmund , C. , A point mutation in the @CHEMICALSrc$ glutamate @/CHEMICALSrc$ binding site blocks desensitization of @GENETgt$ AMPA receptors @/GENETgt$ .	37 37 37 8 8 8 8 3 8 8 14 14 14 8 14 18 18 14 14 14 14 14 14 26 26 14 14 30 30 37 36 36 32|36 36 32|36 36 30 37 37 40 40|38 40|38 40|38 40|38 37	None-BC7
10626836	CHEMICAL	GENE	T10	T25	True	0	What is [Drugprot] between @CHEMICALSrc$ glutamate @/CHEMICALSrc$ and @GENETgt$ AMPA receptor @/GENETgt$ ? [SEP] Analysis of splice variants and site-directed mutants of the @GENETgt$ AMPA receptor @/GENETgt$ GluR3 expressed in Xenopus oocytes has shown that lithium produces a large potentiation of the GluR3 flop splice variant and suggested that lithium might inhibit rapid desensitization , which is characteristic of this receptor ( Karkanias , N. and Papke , R. , Subtype-specific effects of lithium on @CHEMICALSrc$ glutamate @/CHEMICALSrc$ receptor function .	19 4 4 1 4 7 4 13 13 9|13 9|13 13 9|13 7 4 17 17 14 19 19 22 22 19 25 25 22 31 31 31 31 31 25 22 22 37 37 37 33 39 37 39 43 43 39 46 46 43 48 46 48 48 50 50 48 48 48 57 48 59 57 64 64|58 64 64|58 64 57 19	None-BC7
10626836	CHEMICAL	GENE	T8	T24	True	0	What is [Drugprot] between @CHEMICALSrc$ lithium @/CHEMICALSrc$ and @GENETgt$ glutamate receptor @/GENETgt$ ? [SEP] Analysis of splice variants and site-directed mutants of the AMPA receptor GluR3 expressed in Xenopus oocytes has shown that lithium produces a large potentiation of the GluR3 flop splice variant and suggested that @CHEMICALSrc$ lithium @/CHEMICALSrc$ might inhibit rapid desensitization , which is characteristic of this receptor ( Karkanias , N. and Papke , R. , Subtype-specific effects of lithium on @GENETgt$ glutamate receptor @/GENETgt$ function .	18 4 4 1 4 7 4 12 12 12 12 7 4 16 16 13 18 18 21 21 18 24 24 21 30 30 30 30 30 24 21 21 37 33|37 37 33|37 37 32 39 37 39 43 43 39 46 46 43 48 46 48 48 50 50 48 48 48 57 48 59 57 64 64|59 64|59 64 64|59 57 18	None-BC7
10626836	CHEMICAL	GENE	T8	T27	True	0	What is [Drugprot] between @CHEMICALSrc$ lithium @/CHEMICALSrc$ and @GENETgt$ GluR3 @/GENETgt$ ? [SEP] Analysis of splice variants and site-directed mutants of the AMPA receptor @GENETgt$ GluR3 @/GENETgt$ expressed in Xenopus oocytes has shown that lithium produces a large potentiation of the GluR3 flop splice variant and suggested that @CHEMICALSrc$ lithium @/CHEMICALSrc$ might inhibit rapid desensitization , which is characteristic of this receptor ( Karkanias , N. and Papke , R. , Subtype-specific effects of lithium on glutamate receptor function .	19 4 4 1 4 7 4 12 12 12 12 11|7 7 11|7 4 17 17 14 19 19 22 22 19 25 25 22 31 31 31 31 31 25 22 22 38 33|38 38 33|38 38 33 40 38 40 44 44 40 47 47 44 49 47 49 49 51 51 49 49 49 58 49 60 58 64 64 64 58 19	None-BC7
10626836	CHEMICAL	GENE	T1	T30	True	0	What is [Drugprot] between @CHEMICALSrc$ AMPA @/CHEMICALSrc$ and @GENETgt$ L507Y @/GENETgt$ ? [SEP] Additionally , experiments with the non-desensitizing site-directed mutant @GENETgt$ GluR3(L507Y @/GENETgt$ ) ( Stern-Bach , Y. , Russo , S. , Neuman , M. and Rosenmund , C. , A point mutation in the glutamate binding site blocks desensitization of @CHEMICALSrc$ AMPA @/CHEMICALSrc$ receptors .	37 37 37 8 8 8 8 3 8 8 8 8 15 15 15 8 15 19 19 15 15 15 15 15 15 27 27 15 15 31 31 37 36 36 36 36 31 37 37 42 42|38 42 42|38 38 37	None-BC7
10626836	CHEMICAL	GENE	T8	T25	True	0	What is [Drugprot] between @CHEMICALSrc$ lithium @/CHEMICALSrc$ and @GENETgt$ AMPA receptor @/GENETgt$ ? [SEP] Analysis of splice variants and site-directed mutants of the @GENETgt$ AMPA receptor @/GENETgt$ GluR3 expressed in Xenopus oocytes has shown that lithium produces a large potentiation of the GluR3 flop splice variant and suggested that @CHEMICALSrc$ lithium @/CHEMICALSrc$ might inhibit rapid desensitization , which is characteristic of this receptor ( Karkanias , N. and Papke , R. , Subtype-specific effects of lithium on glutamate receptor function .	19 4 4 1 4 7 4 13 13 9|13 9|13 13 9|13 7 4 17 17 14 19 19 22 22 19 25 25 22 31 31 31 31 31 25 22 22 38 32|38 38 32|38 38 33 40 38 40 44 44 40 47 47 44 49 47 49 49 51 51 49 49 49 58 49 60 58 64 64 64 58 19	None-BC7
10626836	CHEMICAL	GENE	T13	T28	True	0	What is [Drugprot] between @CHEMICALSrc$ lithium @/CHEMICALSrc$ and @GENETgt$ GluR3 @/GENETgt$ ? [SEP] We now show that mutation of the 769R/ G desensitization site ( Lomeli , H.M.J. , Melcher , T. , Hoger , T. , Geiger , J.R. , Kuner , T. , Monyer , H. , Higuchi , M.B.A. and Seeburg , P.H , Control of kinetic properties of AMPA receptor channels by nuclear RNA editing . Science , 9(266 ) ( 1994 ) 1709 - 1713 ) greatly attenuates the @CHEMICALSrc$ lithium-induced @/CHEMICALSrc$ potentiation of @GENETgt$ GluR3 @/GENETgt$ .	3 3 3 70 4 11 11 11 11 11 5 13 11 13 13 13 13 13 13 13 13 13 13 13 27 27 13 13 31 31 13 13 35 35 13 13 13 13 13 13 13 13 13 13 13 48 48 45 52 52 52 48 56 56 56 5 5 70 58 58 58 67 67 67 67 67 58 58 70 3 74 74|71 74 74|71 70 76 74 74 74 3	ACTIVATOR
10626836	CHEMICAL	GENE	T13	T26	True	0	What is [Drugprot] between @CHEMICALSrc$ lithium @/CHEMICALSrc$ and @GENETgt$ AMPA receptor @/GENETgt$ ? [SEP] We now show that mutation of the 769R/ G desensitization site ( Lomeli , H.M.J. , Melcher , T. , Hoger , T. , Geiger , J.R. , Kuner , T. , Monyer , H. , Higuchi , M.B.A. and Seeburg , P.H , Control of kinetic properties of @GENETgt$ AMPA receptor @/GENETgt$ channels by nuclear RNA editing . Science , 9(266 ) ( 1994 ) 1709 - 1713 ) greatly attenuates the @CHEMICALSrc$ lithium-induced @/CHEMICALSrc$ potentiation of GluR3 .	3 3 3 71 4 11 11 11 11 11 5 13 11 13 13 13 13 13 13 13 13 13 13 13 27 27 13 13 31 31 13 13 35 35 13 13 13 13 13 13 13 13 13 13 13 48 48 45 53 49|53 49|53 53 49|53 48 57 57 57 5 5 71 59 59 59 68 68 68 68 68 59 59 71 3 75 75|70 75 75|70 71 77 75 3	None-BC7
10626836	CHEMICAL	GENE	T2	T18	True	0	What is [Drugprot] between @CHEMICALSrc$ lithium @/CHEMICALSrc$ and @GENETgt$ GluR3 @/GENETgt$ ? [SEP] Neuron , 21 ( 1998 ) 907 - 918 ) further confirms that @CHEMICALSrc$ lithium @/CHEMICALSrc$ enhances @GENETgt$ GluR3 @/GENETgt$ responses by reducing desensitization , since lithium 's effects are reversed in this mutant .	12 1 1 5 9 9 9 9 3 1 12 12 16 16|13 16 16|13 12 19|15 19 19|15 16 21 16 21 16 29 27 25 29 29 16 32 32 29 12	ACTIVATOR
10626836	CHEMICAL	GENE	T7	T20	True	0	What is [Drugprot] between @CHEMICALSrc$ lithium @/CHEMICALSrc$ and @GENETgt$ AMPA receptors @/GENETgt$ ? [SEP] Specifically , aniracetam , which potentiates wild-type @GENETgt$ AMPA receptors @/GENETgt$ , is ineffective on the non-desensitizing GluR3(L507Y ) mutant , but has synergistic effects with @CHEMICALSrc$ lithium @/CHEMICALSrc$ on wild-type receptors .	13 13 13 3 6 3 8 8|6|7 8|6|7 8|6 8|6|7 3 13 13 19 19 19 19 19 13 13 13 13 24 22 26 24|23 24 24|23 30 30 24 13	None-BC7
10626836	CHEMICAL	GENE	T11	T27	True	0	What is [Drugprot] between @CHEMICALSrc$ AMPA @/CHEMICALSrc$ and @GENETgt$ GluR3 @/GENETgt$ ? [SEP] Analysis of splice variants and site-directed mutants of the @CHEMICALSrc$ AMPA @/CHEMICALSrc$ receptor @GENETgt$ GluR3 @/GENETgt$ expressed in Xenopus oocytes has shown that lithium produces a large potentiation of the GluR3 flop splice variant and suggested that lithium might inhibit rapid desensitization , which is characteristic of this receptor ( Karkanias , N. and Papke , R. , Subtype-specific effects of lithium on glutamate receptor function .	20 4 4 1 4 7 4 13 13 9|13 13 9|13 13 11|7 7 11|7 4 18 18 15 20 20 23 23 20 26 26 23 32 32 32 32 32 26 23 23 38 38 38 34 40 38 40 44 44 40 47 47 44 49 47 49 49 51 51 49 49 49 58 49 60 58 64 64 64 58 20	None-BC7
10626836	CHEMICAL	GENE	T15	T31	True	0	What is [Drugprot] between @CHEMICALSrc$ Lithium @/CHEMICALSrc$ and @GENETgt$ glutamate receptor @/GENETgt$ ? [SEP] @CHEMICALSrc$ Lithium @/CHEMICALSrc$ modulates desensitization of the @GENETgt$ glutamate receptor @/GENETgt$ subtype gluR3 in Xenopus oocytes .	0|3 3 0|3 3 3 11 11 11|5 11|5 11 11|5 11 4 14 14 4 3	None-BC7
10626836	CHEMICAL	GENE	T16	T32	True	0	What is [Drugprot] between @CHEMICALSrc$ glutamate @/CHEMICALSrc$ and @GENETgt$ gluR3 @/GENETgt$ ? [SEP] Lithium modulates desensitization of the @CHEMICALSrc$ glutamate @/CHEMICALSrc$ receptor subtype @GENETgt$ gluR3 @/GENETgt$ in Xenopus oocytes .	2 2 2 10 10 10|5 10 10|5 10 10 8|3 3 8|3 14 14 3 2	None-BC7
10626836	CHEMICAL	GENE	T9	T24	True	0	What is [Drugprot] between @CHEMICALSrc$ lithium @/CHEMICALSrc$ and @GENETgt$ glutamate receptor @/GENETgt$ ? [SEP] Analysis of splice variants and site-directed mutants of the AMPA receptor GluR3 expressed in Xenopus oocytes has shown that lithium produces a large potentiation of the GluR3 flop splice variant and suggested that lithium might inhibit rapid desensitization , which is characteristic of this receptor ( Karkanias , N. and Papke , R. , Subtype-specific effects of @CHEMICALSrc$ lithium @/CHEMICALSrc$ on @GENETgt$ glutamate receptor @/GENETgt$ function .	18 4 4 1 4 7 4 12 12 12 12 7 4 16 16 13 18 18 21 21 18 24 24 21 30 30 30 30 30 24 21 21 36 36 36 32 38 36 38 42 42 38 45 45 42 47 45 47 47 49 49 47 47 47 56 47 58 56|57 56 56|57 64 64|59 64|59 64 64|59 56 18	None-BC7
10626836	CHEMICAL	GENE	T10	T23	True	0	What is [Drugprot] between @CHEMICALSrc$ glutamate @/CHEMICALSrc$ and @GENETgt$ GluR3 flop @/GENETgt$ ? [SEP] Analysis of splice variants and site-directed mutants of the AMPA receptor GluR3 expressed in Xenopus oocytes has shown that lithium produces a large potentiation of the @GENETgt$ GluR3 flop @/GENETgt$ splice variant and suggested that lithium might inhibit rapid desensitization , which is characteristic of this receptor ( Karkanias , N. and Papke , R. , Subtype-specific effects of lithium on @CHEMICALSrc$ glutamate @/CHEMICALSrc$ receptor function .	18 4 4 1 4 7 4 12 12 12 12 7 4 16 16 13 18 18 21 21 18 24 24 21 31 31 26|31 26|31 31 26|31 31 24 21 21 37 37 37 33 39 37 39 43 43 39 46 46 43 48 46 48 48 50 50 48 48 48 57 48 59 57 64 64|58 64 64|58 64 57 18	None-BC7
10626836	CHEMICAL	GENE	T14	T29	True	0	What is [Drugprot] between @CHEMICALSrc$ glutamate @/CHEMICALSrc$ and @GENETgt$ GluR3 @/GENETgt$ ? [SEP] Additionally , experiments with the non-desensitizing site-directed mutant @GENETgt$ GluR3(L507Y @/GENETgt$ ) ( Stern-Bach , Y. , Russo , S. , Neuman , M. and Rosenmund , C. , A point mutation in the @CHEMICALSrc$ glutamate @/CHEMICALSrc$ binding site blocks desensitization of AMPA receptors .	38 38 38 8 8 8 8 3 8 8 8 8 15 15 15 8 15 19 19 15 15 15 15 15 15 27 27 15 15 31 31 38 37 37 32|37 37 32|37 37 31 38 38 42 42 39 38	None-BC7
10626836	CHEMICAL	GENE	T3	T24	True	0	What is [Drugprot] between @CHEMICALSrc$ lithium @/CHEMICALSrc$ and @GENETgt$ glutamate receptor @/GENETgt$ ? [SEP] Analysis of splice variants and site-directed mutants of the AMPA receptor GluR3 expressed in Xenopus oocytes has shown that @CHEMICALSrc$ lithium @/CHEMICALSrc$ produces a large potentiation of the GluR3 flop splice variant and suggested that lithium might inhibit rapid desensitization , which is characteristic of this receptor ( Karkanias , N. and Papke , R. , Subtype-specific effects of lithium on @GENETgt$ glutamate receptor @/GENETgt$ function .	18 4 4 1 4 7 4 12 12 12 12 7 4 16 16 13 18 18 22 19|22 22 19|22 18 25 25 22 31 31 31 31 31 25 22 22 37 37 37 33 39 37 39 43 43 39 46 46 43 48 46 48 48 50 50 48 48 48 57 48 59 57 64 64|59 64|59 64 64|59 57 18	None-BC7
10626836	CHEMICAL	GENE	T4	T19	True	0	What is [Drugprot] between @CHEMICALSrc$ aniracetam @/CHEMICALSrc$ and @GENETgt$ GluR3 @/GENETgt$ ? [SEP] Lithium 's effects on @GENETgt$ GluR3 @/GENETgt$ desensitization are distinct from the effects of @CHEMICALSrc$ aniracetam @/CHEMICALSrc$ on desensitization .	3 1 9 7 4|7 7 4|7 3 9 9 12 12 9 14 12 12 12 17 12 9	None-BC7
10626836	CHEMICAL	GENE	T14	T30	True	0	What is [Drugprot] between @CHEMICALSrc$ glutamate @/CHEMICALSrc$ and @GENETgt$ L507Y @/GENETgt$ ? [SEP] Additionally , experiments with the non-desensitizing site-directed mutant @GENETgt$ GluR3(L507Y @/GENETgt$ ) ( Stern-Bach , Y. , Russo , S. , Neuman , M. and Rosenmund , C. , A point mutation in the @CHEMICALSrc$ glutamate @/CHEMICALSrc$ binding site blocks desensitization of AMPA receptors .	38 38 38 8 8 8 8 3 8 8 8 8 15 15 15 8 15 19 19 15 15 15 15 15 15 27 27 15 15 31 31 38 37 37 32|37 37 32|37 37 31 38 38 42 42 39 38	None-BC7
10626836	CHEMICAL	GENE	T3	T25	True	0	What is [Drugprot] between @CHEMICALSrc$ lithium @/CHEMICALSrc$ and @GENETgt$ AMPA receptor @/GENETgt$ ? [SEP] Analysis of splice variants and site-directed mutants of the @GENETgt$ AMPA receptor @/GENETgt$ GluR3 expressed in Xenopus oocytes has shown that @CHEMICALSrc$ lithium @/CHEMICALSrc$ produces a large potentiation of the GluR3 flop splice variant and suggested that lithium might inhibit rapid desensitization , which is characteristic of this receptor ( Karkanias , N. and Papke , R. , Subtype-specific effects of lithium on glutamate receptor function .	19 4 4 1 4 7 4 13 13 9|13 9|13 13 9|13 7 4 17 17 14 19 19 23 18|23 23 18|23 19 26 26 23 32 32 32 32 32 26 23 23 38 38 38 34 40 38 40 44 44 40 47 47 44 49 47 49 49 51 51 49 49 49 58 49 60 58 64 64 64 58 19	None-BC7
10626836	CHEMICAL	GENE	T7	T22	True	0	What is [Drugprot] between @CHEMICALSrc$ lithium @/CHEMICALSrc$ and @GENETgt$ L507Y @/GENETgt$ ? [SEP] Specifically , aniracetam , which potentiates wild-type AMPA receptors , is ineffective on the non-desensitizing @GENETgt$ GluR3(L507Y @/GENETgt$ ) mutant , but has synergistic effects with @CHEMICALSrc$ lithium @/CHEMICALSrc$ on wild-type receptors .	12 12 12 3 6 3 9 9 6 3 12 12 19 19 19 19|15 19 19|15 19 12 12 12 12 24 22 26 24 24 24 30 30 24 12	ACTIVATOR
10626836	CHEMICAL	GENE	T10	T27	True	0	What is [Drugprot] between @CHEMICALSrc$ glutamate @/CHEMICALSrc$ and @GENETgt$ GluR3 @/GENETgt$ ? [SEP] Analysis of splice variants and site-directed mutants of the AMPA receptor @GENETgt$ GluR3 @/GENETgt$ expressed in Xenopus oocytes has shown that lithium produces a large potentiation of the GluR3 flop splice variant and suggested that lithium might inhibit rapid desensitization , which is characteristic of this receptor ( Karkanias , N. and Papke , R. , Subtype-specific effects of lithium on @CHEMICALSrc$ glutamate @/CHEMICALSrc$ receptor function .	19 4 4 1 4 7 4 12 12 12 12 11|7 7 11|7 4 17 17 14 19 19 22 22 19 25 25 22 31 31 31 31 31 25 22 22 37 37 37 33 39 37 39 43 43 39 46 46 43 48 46 48 48 50 50 48 48 48 57 48 59 57 64 64|59 64 64|59 64 57 19	None-BC7
23536522	CHEMICAL	GENE	T7	T21	True	0	What is [Drugprot] between @CHEMICALSrc$ glutathione @/CHEMICALSrc$ and @GENETgt$ catalase @/GENETgt$ ? [SEP] For this purpose , the right ventricular pressures ( RVPs ) and right ventricular/heart weight ( HW ) ratios were compared between groups and the @CHEMICALSrc$ glutathione @/CHEMICALSrc$ ( GSH ) level and superoxide dismutase ( SOD ) , @GENETgt$ catalase @/GENETgt$ ( CAT ) and glutathione-S-transferase ( GST ) activities were determined in lung and liver tissue samples of rats .	3 3 21 21 8 8 8 21 10 8 10 8 15 15 8 17 15 17 8 21 21 23 21 23 31 25|31 31 25|31 31 31 31 23 31 34 31 36 34 36 23 37|23 23 37|23 42 39 42 39 39 47 45 47 51 51 21 53 57 53 53 57 51 59 57 21	None-BC7
23536522	CHEMICAL	GENE	T11	T19	True	0	What is [Drugprot] between @CHEMICALSrc$ S @/CHEMICALSrc$ and @GENETgt$ superoxide dismutase @/GENETgt$ ? [SEP] For this purpose , the right ventricular pressures ( RVPs ) and right ventricular/heart weight ( HW ) ratios were compared between groups and the glutathione ( GSH ) level and @GENETgt$ superoxide dismutase @/GENETgt$ ( SOD ) , catalase ( CAT ) and @CHEMICALSrc$ glutathione-S-transferase @/CHEMICALSrc$ ( GST ) activities were determined in lung and liver tissue samples of rats .	3 3 21 21 8 8 8 21 10 8 10 8 15 15 8 17 15 17 8 21 21 23 21 23 30 30 30 30 30 23 30 32|30|31 32|30|31 32|30 32|30|31 36 32 36 23 23 41 39 41 39 41|39 39 41|39 47 44 47 51 51 21 53 57 53 53 57 51 59 57 21	None-BC7
23536522	CHEMICAL	GENE	T11	T24	True	0	What is [Drugprot] between @CHEMICALSrc$ S @/CHEMICALSrc$ and @GENETgt$ GST @/GENETgt$ ? [SEP] For this purpose , the right ventricular pressures ( RVPs ) and right ventricular/heart weight ( HW ) ratios were compared between groups and the glutathione ( GSH ) level and superoxide dismutase ( SOD ) , catalase ( CAT ) and @CHEMICALSrc$ glutathione-S-transferase @/CHEMICALSrc$ ( @GENETgt$ GST @/GENETgt$ ) activities were determined in lung and liver tissue samples of rats .	3 3 21 21 8 8 8 21 10 8 10 8 15 15 8 17 15 17 8 21 21 23 21 23 30 30 30 30 30 23 30 33 30 35 33 35 23 23 40 38 40 38 42|38 38 42|38 46 43|44 43 43|44 46 51 51 21 53 57 53 53 57 51 59 57 21	None-BC7
23536522	CHEMICAL	GENE	T9	T23	True	0	What is [Drugprot] between @CHEMICALSrc$ superoxide @/CHEMICALSrc$ and @GENETgt$ glutathione-S-transferase @/GENETgt$ ? [SEP] For this purpose , the right ventricular pressures ( RVPs ) and right ventricular/heart weight ( HW ) ratios were compared between groups and the glutathione ( GSH ) level and @CHEMICALSrc$ superoxide @/CHEMICALSrc$ dismutase ( SOD ) , catalase ( CAT ) and @GENETgt$ glutathione-S-transferase @/GENETgt$ ( GST ) activities were determined in lung and liver tissue samples of rats .	3 3 21 21 8 8 8 21 10 8 10 8 15 15 8 17 15 17 8 21 21 23 21 23 30 30 30 30 30 23 30 34|31 34 34|31 30 36 34 36 23 23 41 39 41 39 42|39 39 42|39 47 44 47 51 51 21 53 57 53 53 57 51 59 57 21	None-BC7
23536522	CHEMICAL	GENE	T1	T17	True	0	What is [Drugprot] between @CHEMICALSrc$ GSH @/CHEMICALSrc$ and @GENETgt$ GST @/GENETgt$ ? [SEP] In addition , the lung and liver @CHEMICALSrc$ GSH @/CHEMICALSrc$ level and @GENETgt$ GST @/GENETgt$ and SOD levels were higher in female control rats compared to male control rats .	2 18 18 5 10 5 5 10|7 10 10|7 18 10 10 10 10 12 12 10 18 18 22 22 22 18 27 27 27 27 18 18	None-BC7
23536522	CHEMICAL	GENE	T1	T18	True	0	What is [Drugprot] between @CHEMICALSrc$ GSH @/CHEMICALSrc$ and @GENETgt$ SOD @/GENETgt$ ? [SEP] In addition , the lung and liver @CHEMICALSrc$ GSH @/CHEMICALSrc$ level and GST and @GENETgt$ SOD @/GENETgt$ levels were higher in female control rats compared to male control rats .	2 18 18 5 10 5 5 10|7 10 10|7 18 10 10 12 12 12 12 10 18 18 22 22 22 18 27 27 27 27 18 18	None-BC7
23536522	CHEMICAL	GENE	T14	T27	True	0	What is [Drugprot] between @CHEMICALSrc$ MCT @/CHEMICALSrc$ and @GENETgt$ CAT @/GENETgt$ ? [SEP] @CHEMICALSrc$ MCT-induced @/CHEMICALSrc$ pulmonary hypertension resulted in decreased GSH level , decreased GST and SOD activities and increased @GENETgt$ CAT @/GENETgt$ activity in lung and liver tissues of both male and female rats .	0|4 4 0|4 4 5 5 9 9 9 5 9 12 5 12 12 12 12 20 16|20 20 16|20 12 22 25 22 22 12 31 28 31 28 28 12 5	ACTIVATOR
23536522	CHEMICAL	GENE	T8	T22	True	0	What is [Drugprot] between @CHEMICALSrc$ GSH @/CHEMICALSrc$ and @GENETgt$ CAT @/GENETgt$ ? [SEP] For this purpose , the right ventricular pressures ( RVPs ) and right ventricular/heart weight ( HW ) ratios were compared between groups and the glutathione ( @CHEMICALSrc$ GSH @/CHEMICALSrc$ ) level and superoxide dismutase ( SOD ) , catalase ( @GENETgt$ CAT @/GENETgt$ ) and glutathione-S-transferase ( GST ) activities were determined in lung and liver tissue samples of rats .	3 3 21 21 8 8 8 21 10 8 10 8 15 15 8 17 15 17 8 21 21 23 21 23 31 31 31 27|31 31 27|31 31 23 31 34 31 36 34 36 23 23 41 39 39 39 41 39 39 47 45 47 51 51 21 53 57 53 53 57 51 59 57 21	None-BC7
23536522	CHEMICAL	GENE	T9	T21	True	0	What is [Drugprot] between @CHEMICALSrc$ superoxide @/CHEMICALSrc$ and @GENETgt$ catalase @/GENETgt$ ? [SEP] For this purpose , the right ventricular pressures ( RVPs ) and right ventricular/heart weight ( HW ) ratios were compared between groups and the glutathione ( GSH ) level and @CHEMICALSrc$ superoxide @/CHEMICALSrc$ dismutase ( SOD ) , @GENETgt$ catalase @/GENETgt$ ( CAT ) and glutathione-S-transferase ( GST ) activities were determined in lung and liver tissue samples of rats .	3 3 21 21 8 8 8 21 10 8 10 8 15 15 8 17 15 17 8 21 21 23 21 23 30 30 30 30 30 23 30 34|31 34 34|31 30 36 34 36 23 37|23 23 37|23 42 39 42 39 39 47 45 47 51 51 21 53 57 53 53 57 51 59 57 21	None-BC7
23536522	CHEMICAL	GENE	T10	T22	True	0	What is [Drugprot] between @CHEMICALSrc$ glutathione @/CHEMICALSrc$ and @GENETgt$ CAT @/GENETgt$ ? [SEP] For this purpose , the right ventricular pressures ( RVPs ) and right ventricular/heart weight ( HW ) ratios were compared between groups and the glutathione ( GSH ) level and superoxide dismutase ( SOD ) , catalase ( @GENETgt$ CAT @/GENETgt$ ) and @CHEMICALSrc$ glutathione-S-transferase @/CHEMICALSrc$ ( GST ) activities were determined in lung and liver tissue samples of rats .	3 3 21 21 8 8 8 21 10 8 10 8 15 15 8 17 15 17 8 21 21 23 21 23 30 30 30 30 30 23 30 33 30 35 33 35 23 23 40 38|39 38 38|39 40 38 42|38 38 42|38 47 44 47 51 51 21 53 57 53 53 57 51 59 57 21	None-BC7
23536522	CHEMICAL	GENE	T14	T26	True	0	What is [Drugprot] between @CHEMICALSrc$ MCT @/CHEMICALSrc$ and @GENETgt$ SOD @/GENETgt$ ? [SEP] @CHEMICALSrc$ MCT-induced @/CHEMICALSrc$ pulmonary hypertension resulted in decreased GSH level , decreased GST and @GENETgt$ SOD @/GENETgt$ activities and increased CAT activity in lung and liver tissues of both male and female rats .	0|4 4 0|4 4 5 5 9 9 9 5 9 12 5 12 12 12 12 12 12 20 20 12 22 25 22 22 12 31 28 31 28 28 12 5	INHIBITOR
23536522	CHEMICAL	GENE	T8	T20	True	0	What is [Drugprot] between @CHEMICALSrc$ GSH @/CHEMICALSrc$ and @GENETgt$ SOD @/GENETgt$ ? [SEP] For this purpose , the right ventricular pressures ( RVPs ) and right ventricular/heart weight ( HW ) ratios were compared between groups and the glutathione ( @CHEMICALSrc$ GSH @/CHEMICALSrc$ ) level and superoxide dismutase ( @GENETgt$ SOD @/GENETgt$ ) , catalase ( CAT ) and glutathione-S-transferase ( GST ) activities were determined in lung and liver tissue samples of rats .	3 3 21 21 8 8 8 21 10 8 10 8 15 15 8 17 15 17 8 21 21 23 21 23 31 31 31 27|31 31 27|31 31 23 31 34 31 36 34 34 34 36 23 23 42 40 42 40 40 47 45 47 51 51 21 53 57 53 53 57 51 59 57 21	None-BC7
23536522	CHEMICAL	GENE	T8	T23	True	0	What is [Drugprot] between @CHEMICALSrc$ GSH @/CHEMICALSrc$ and @GENETgt$ glutathione-S-transferase @/GENETgt$ ? [SEP] For this purpose , the right ventricular pressures ( RVPs ) and right ventricular/heart weight ( HW ) ratios were compared between groups and the glutathione ( @CHEMICALSrc$ GSH @/CHEMICALSrc$ ) level and superoxide dismutase ( SOD ) , catalase ( CAT ) and @GENETgt$ glutathione-S-transferase @/GENETgt$ ( GST ) activities were determined in lung and liver tissue samples of rats .	3 3 21 21 8 8 8 21 10 8 10 8 15 15 8 17 15 17 8 21 21 23 21 23 31 31 31 27|31 31 27|31 31 23 31 34 31 36 34 36 23 23 41 39 41 39 42|39 39 42|39 47 44 47 51 51 21 53 57 53 53 57 51 59 57 21	None-BC7
23536522	CHEMICAL	GENE	T15	T25	True	0	What is [Drugprot] between @CHEMICALSrc$ GSH @/CHEMICALSrc$ and @GENETgt$ GST @/GENETgt$ ? [SEP] MCT-induced pulmonary hypertension resulted in decreased @CHEMICALSrc$ GSH @/CHEMICALSrc$ level , decreased @GENETgt$ GST @/GENETgt$ and SOD activities and increased CAT activity in lung and liver tissues of both male and female rats .	3 3 4 4 9 9 9|6 9 9|6 4 9 12 10|4 4 10|4 12 12 12 12 20 20 12 22 25 22 22 12 31 28 31 28 28 12 4	None-BC7
23536522	CHEMICAL	GENE	T11	T21	True	0	What is [Drugprot] between @CHEMICALSrc$ S @/CHEMICALSrc$ and @GENETgt$ catalase @/GENETgt$ ? [SEP] For this purpose , the right ventricular pressures ( RVPs ) and right ventricular/heart weight ( HW ) ratios were compared between groups and the glutathione ( GSH ) level and superoxide dismutase ( SOD ) , @GENETgt$ catalase @/GENETgt$ ( CAT ) and @CHEMICALSrc$ glutathione-S-transferase @/CHEMICALSrc$ ( GST ) activities were determined in lung and liver tissue samples of rats .	3 3 21 21 8 8 8 21 10 8 10 8 15 15 8 17 15 17 8 21 21 23 21 23 30 30 30 30 30 23 30 33 30 35 33 35 23 37|23 23 37|23 41 38 41 38 42|38 38 42|38 47 44 47 51 51 21 53 57 53 53 57 51 59 57 21	None-BC7
23536522	CHEMICAL	GENE	T10	T20	True	0	What is [Drugprot] between @CHEMICALSrc$ glutathione @/CHEMICALSrc$ and @GENETgt$ SOD @/GENETgt$ ? [SEP] For this purpose , the right ventricular pressures ( RVPs ) and right ventricular/heart weight ( HW ) ratios were compared between groups and the glutathione ( GSH ) level and superoxide dismutase ( @GENETgt$ SOD @/GENETgt$ ) , catalase ( CAT ) and @CHEMICALSrc$ glutathione-S-transferase @/CHEMICALSrc$ ( GST ) activities were determined in lung and liver tissue samples of rats .	3 3 21 21 8 8 8 21 10 8 10 8 15 15 8 17 15 17 8 21 21 23 21 23 30 30 30 30 30 23 30 33 30 35 33|34 33 33|34 35 23 23 41 39 41 39 42|39 39 42|39 47 44 47 51 51 21 53 57 53 53 57 51 59 57 21	None-BC7
23536522	CHEMICAL	GENE	T11	T22	True	0	What is [Drugprot] between @CHEMICALSrc$ S @/CHEMICALSrc$ and @GENETgt$ CAT @/GENETgt$ ? [SEP] For this purpose , the right ventricular pressures ( RVPs ) and right ventricular/heart weight ( HW ) ratios were compared between groups and the glutathione ( GSH ) level and superoxide dismutase ( SOD ) , catalase ( @GENETgt$ CAT @/GENETgt$ ) and @CHEMICALSrc$ glutathione-S-transferase @/CHEMICALSrc$ ( GST ) activities were determined in lung and liver tissue samples of rats .	3 3 21 21 8 8 8 21 10 8 10 8 15 15 8 17 15 17 8 21 21 23 21 23 30 30 30 30 30 23 30 33 30 35 33 35 23 23 40 38|39 38 38|39 40 38 42|38 38 42|38 47 44 47 51 51 21 53 57 53 53 57 51 59 57 21	None-BC7
23536522	CHEMICAL	GENE	T15	T27	True	0	What is [Drugprot] between @CHEMICALSrc$ GSH @/CHEMICALSrc$ and @GENETgt$ CAT @/GENETgt$ ? [SEP] MCT-induced pulmonary hypertension resulted in decreased @CHEMICALSrc$ GSH @/CHEMICALSrc$ level , decreased GST and SOD activities and increased @GENETgt$ CAT @/GENETgt$ activity in lung and liver tissues of both male and female rats .	3 3 4 4 9 9 9|6 9 9|6 4 9 12 4 12 12 12 12 20 16|20 20 16|20 12 22 25 22 22 12 31 28 31 28 28 12 4	None-BC7
